data_2n24_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2n24 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.2 t90 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.632 0.253 . . . . 0.0 110.335 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.9 m -119.7 151.56 38.54 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.471 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.51 169.75 14.29 Favored Pre-proline 0 N--CA 1.452 -0.369 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.742 -179.519 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_exo -58.94 139.24 90.0 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 122.109 1.873 . . . . 0.0 111.795 179.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.52 -0.02 88.53 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 179.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -122.21 165.64 15.84 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.139 0.495 . . . . 0.0 110.542 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -146.01 138.44 25.45 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.078 179.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.3 t80 -50.09 137.36 17.64 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.557 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.43 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -118.83 88.84 36.7 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.455 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -66.82 -0.06 4.21 Favored 'Trans proline' 0 N--CA 1.496 1.623 0 C-N-CA 122.732 2.288 . . . . 0.0 112.103 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 19.3 t -103.05 -19.01 6.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.874 0.369 . . . . 0.0 110.471 -179.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -110.03 -41.36 4.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.902 179.416 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.79 -2.92 11.96 Favored Glycine 0 CA--C 1.535 1.288 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.42 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.43 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.2 pt -147.21 -169.55 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 117.5 0.65 . . . . 0.0 110.342 179.599 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 23.6 m -91.76 142.08 27.98 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 121.197 0.523 . . . . 0.0 109.85 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.8 p -129.24 154.73 46.52 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.573 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 tt -57.81 132.1 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-O 121.189 0.519 . . . . 0.0 110.572 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -85.04 152.9 23.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.574 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 11.2 mp . . . . . 0 N--CA 1.452 -0.338 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.878 179.956 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.645 0.26 . . . . 0.0 110.6 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 77.0 m -120.88 151.58 39.48 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.841 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -88.04 167.04 21.15 Favored Pre-proline 0 N--CA 1.45 -0.474 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.635 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -58.04 139.13 89.31 Favored 'Trans proline' 0 N--CA 1.493 1.482 0 C-N-CA 122.573 2.182 . . . . 0.0 111.87 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 85.66 -4.38 85.85 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -119.63 164.53 15.74 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.067 0.461 . . . . 0.0 110.632 179.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -140.51 132.83 28.29 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.298 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.48 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -48.38 134.5 14.95 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.707 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.48 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.8 t30 -118.01 94.57 46.73 Favored Pre-proline 0 CA--C 1.545 0.752 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.951 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -74.39 0.45 8.56 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.963 2.442 . . . . 0.0 112.33 -179.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.8 t -102.74 -19.05 6.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.924 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.408 ' CD1' ' C ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER -108.65 -43.9 4.17 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.511 179.435 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.77 1.8 9.67 Favored Glycine 0 CA--C 1.534 1.269 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.719 179.328 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.465 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -153.81 -173.49 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.235 0 CA-C-N 117.061 0.431 . . . . 0.0 110.408 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.5 m -89.43 140.97 28.99 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-O 120.884 0.373 . . . . 0.0 110.287 179.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.2 p -127.91 152.45 47.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.531 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 tt -58.42 133.06 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.262 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -84.04 142.88 30.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.63 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 6.8 mp . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.89 180.0 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.1 t90 . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.674 0.274 . . . . 0.0 110.454 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.42 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 74.1 m -122.28 153.58 38.72 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.245 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -89.05 168.3 15.84 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.902 -179.488 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -57.64 138.11 84.52 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.678 2.252 . . . . 0.0 111.654 179.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.13 1.47 90.35 Favored Glycine 0 CA--C 1.528 0.857 0 N-CA-C 111.206 -0.758 . . . . 0.0 111.206 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.8 m-85 -125.22 163.23 22.94 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.13 0.49 . . . . 0.0 110.602 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -143.17 135.82 27.56 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.134 179.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.42 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 16.1 t80 -48.36 136.96 11.79 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.601 -179.594 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.457 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -118.58 89.25 36.56 Favored Pre-proline 0 CA--C 1.54 0.568 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.637 -179.605 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -67.02 -0.02 4.3 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 122.907 2.405 . . . . 0.0 112.051 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.0 t -103.49 -17.94 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 CA-C-O 120.94 0.4 . . . . 0.0 110.317 -179.316 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -111.09 -42.65 3.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.4 179.566 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.57 -2.1 10.26 Favored Glycine 0 CA--C 1.534 1.224 0 CA-C-N 116.113 -0.494 . . . . 0.0 112.432 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.457 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.0 pt -149.92 -173.07 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.917 0.358 . . . . 0.0 110.592 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.9 m -89.27 142.34 27.74 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 120.946 0.403 . . . . 0.0 110.332 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 65.0 p -129.6 150.9 50.73 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.515 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 tt -51.83 137.72 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.149 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.414 ' OG1' ' N ' ' A' ' 20' ' ' LEU . 0.0 OUTLIER -101.06 169.66 8.79 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.062 -179.328 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.414 ' N ' ' OG1' ' A' ' 19' ' ' THR . 4.8 tt . . . . . 0 N--CA 1.451 -0.396 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.17 179.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.6 t90 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.645 0.26 . . . . 0.0 110.452 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.414 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 73.4 m -119.44 151.12 39.07 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.566 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.34 169.02 16.36 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.822 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.93 138.92 88.45 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.539 2.159 . . . . 0.0 111.879 179.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.98 0.06 89.09 Favored Glycine 0 CA--C 1.529 0.912 0 N-CA-C 111.359 -0.697 . . . . 0.0 111.359 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -123.9 164.36 19.43 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.073 0.463 . . . . 0.0 110.601 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.89 136.25 25.22 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.235 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.414 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 17.7 t80 -48.6 136.91 12.56 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.553 -179.6 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.421 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -119.1 89.22 38.81 Favored Pre-proline 0 CA--C 1.54 0.59 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.539 -179.541 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -66.67 -0.08 4.12 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 122.915 2.41 . . . . 0.0 112.08 -179.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.4 t -103.53 -19.89 5.99 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 120.895 0.379 . . . . 0.0 110.303 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -108.4 -42.04 4.69 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.624 179.413 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.92 -1.72 11.87 Favored Glycine 0 CA--C 1.534 1.28 0 CA-C-N 116.035 -0.529 . . . . 0.0 112.543 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.421 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 4.7 pt -149.66 -172.9 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 117.094 0.447 . . . . 0.0 110.556 179.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.5 m -88.94 141.77 28.21 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.061 0.458 . . . . 0.0 110.404 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.6 p -128.69 152.69 48.11 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.542 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.7 tt -55.25 132.3 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.348 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.01 166.76 11.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.903 -179.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.0 mt . . . . . 0 N--CA 1.449 -0.516 0 CA-C-O 121.192 0.52 . . . . 0.0 110.861 179.708 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.8 t90 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.694 0.283 . . . . 0.0 110.555 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 93.3 m -123.45 148.93 45.69 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.986 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -69.95 161.97 71.61 Favored Pre-proline 0 N--CA 1.446 -0.67 0 CA-C-N 115.549 -0.751 . . . . 0.0 109.979 179.77 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -64.42 139.63 65.89 Favored 'Trans proline' 0 C--N 1.3 -2.001 0 C-N-CA 122.212 1.941 . . . . 0.0 111.904 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.88 -2.83 87.98 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 -179.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -119.29 166.71 12.66 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 121.006 0.432 . . . . 0.0 110.497 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.69 137.45 31.74 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.097 179.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 19.2 t80 -52.04 137.04 28.19 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.412 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.403 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -118.57 89.44 37.03 Favored Pre-proline 0 CA--C 1.539 0.53 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.38 -179.165 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -67.57 -0.02 4.69 Favored 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 122.721 2.28 . . . . 0.0 112.039 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 23.0 t -102.68 -18.69 6.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.507 -179.125 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -110.65 -41.37 4.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.79 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 119.97 -1.57 13.32 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-N 116.085 -0.507 . . . . 0.0 112.403 179.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.403 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -148.17 -172.72 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 117.484 0.642 . . . . 0.0 110.252 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.9 m -90.5 140.56 29.62 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.106 0.479 . . . . 0.0 109.956 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.0 p -127.36 152.53 47.36 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.315 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.2 tt -57.65 135.05 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 CA-C-O 121.139 0.495 . . . . 0.0 110.539 -179.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.93 141.75 28.49 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.319 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 3.3 tt . . . . . 0 N--CA 1.448 -0.526 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.248 -179.755 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.8 t90 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.596 0.236 . . . . 0.0 110.527 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.4 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 76.1 m -118.92 153.08 35.16 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 121.184 0.516 . . . . 0.0 110.926 -179.716 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.79 168.51 15.56 Favored Pre-proline 0 N--CA 1.452 -0.364 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.995 179.158 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -58.8 138.55 86.35 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 C-N-CA 122.675 2.25 . . . . 0.0 111.78 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.02 -0.81 88.16 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.451 -0.66 . . . . 0.0 111.451 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -121.2 166.07 14.51 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-O 120.916 0.388 . . . . 0.0 110.679 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.21 136.59 26.64 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.899 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.486 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 8.4 t80 -49.46 135.48 17.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.755 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.486 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -119.38 94.92 48.93 Favored Pre-proline 0 CA--C 1.547 0.83 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.882 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -73.63 0.02 8.72 Favored 'Trans proline' 0 N--CA 1.492 1.441 0 C-N-CA 123.182 2.588 . . . . 0.0 112.427 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.5 t -103.29 -17.75 6.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.449 . . . . 0.0 109.985 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.97 -42.47 4.21 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.44 -0.18 11.3 Favored Glycine 0 CA--C 1.536 1.383 0 CA-C-N 116.253 -0.431 . . . . 0.0 113.185 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.474 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.8 pt -152.4 -170.77 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 O-C-N 122.493 -0.416 . . . . 0.0 110.387 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.9 m -90.89 142.67 27.52 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 120.979 0.418 . . . . 0.0 110.322 179.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.4 p -128.0 157.37 40.8 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.654 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.1 tt -59.75 131.68 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.362 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.48 156.15 19.68 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.562 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.419 ' CD2' ' N ' ' A' ' 20' ' ' LEU . 4.3 mm? . . . . . 0 C--N 1.326 -0.439 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.641 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.1 t90 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.6 0.238 . . . . 0.0 110.418 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.6 m -120.28 154.4 35.01 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.899 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.3 168.94 13.15 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.78 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -59.14 139.05 88.69 Favored 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 122.521 2.147 . . . . 0.0 111.73 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.07 0.07 89.2 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.427 -0.669 . . . . 0.0 111.427 179.426 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -122.17 165.11 16.65 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-O 121.168 0.508 . . . . 0.0 110.662 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -142.74 135.29 27.77 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.113 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.462 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 9.1 t80 -49.0 135.04 16.41 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.744 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.485 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.9 t30 -118.38 94.79 47.74 Favored Pre-proline 0 CA--C 1.544 0.747 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.995 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -74.42 0.3 8.77 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 C-N-CA 122.807 2.338 . . . . 0.0 112.41 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.4 t -102.19 -18.43 6.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.838 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.422 ' CD1' ' C ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.72 -43.77 3.97 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.73 179.478 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 123.23 0.96 9.5 Favored Glycine 0 CA--C 1.535 1.309 0 CA-C-N 116.081 -0.509 . . . . 0.0 112.61 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.485 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -152.92 -170.61 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.274 0 CA-C-N 117.113 0.457 . . . . 0.0 110.298 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 15.2 m -91.03 141.53 28.74 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 120.916 0.389 . . . . 0.0 110.196 179.6 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 79.7 p -127.71 152.68 47.41 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.679 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.2 tt -56.76 133.83 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.582 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.349 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.88 147.56 25.04 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.683 -179.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.3 tt . . . . . 0 N--CA 1.45 -0.437 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.468 -179.874 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.6 t90 . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.607 0.241 . . . . 0.0 110.406 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.404 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 73.5 m -120.3 150.59 40.47 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.479 0.657 . . . . 0.0 110.805 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.66 168.1 23.0 Favored Pre-proline 0 CA--C 1.533 0.3 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.601 -179.504 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -59.03 137.87 82.18 Favored 'Trans proline' 0 N--CA 1.492 1.422 0 C-N-CA 122.513 2.142 . . . . 0.0 111.828 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.51 1.31 90.07 Favored Glycine 0 CA--C 1.528 0.879 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 179.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -121.58 165.78 15.18 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-O 121.111 0.481 . . . . 0.0 110.546 179.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -143.66 135.64 26.58 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.149 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.476 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 8.4 t80 -48.22 134.69 14.22 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.752 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.491 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.9 t30 -118.48 94.84 47.99 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.906 -179.667 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -74.25 -0.61 9.85 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.849 2.366 . . . . 0.0 112.348 -179.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.6 t -101.43 -18.0 6.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.946 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.404 ' CD1' ' C ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.85 -43.31 4.04 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.384 179.515 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.98 0.19 9.78 Favored Glycine 0 CA--C 1.533 1.172 0 CA-C-N 116.109 -0.496 . . . . 0.0 112.725 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.491 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.6 pt -152.67 -169.86 0.1 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.263 0 CA-C-N 117.096 0.448 . . . . 0.0 110.234 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 21.6 m -91.55 142.16 27.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.891 0.377 . . . . 0.0 110.219 179.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.6 p -127.2 154.48 44.76 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.63 -179.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt -56.84 132.66 21.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.379 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -92.51 160.18 15.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.692 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 38.7 tp . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.418 179.81 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.0 t90 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.586 0.231 . . . . 0.0 110.431 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.408 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.3 m -120.27 153.35 36.5 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.972 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -89.66 168.1 15.77 Favored Pre-proline 0 C--N 1.327 -0.4 0 O-C-N 123.107 0.255 . . . . 0.0 110.874 -179.529 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_exo -57.75 139.06 89.02 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.47 2.113 . . . . 0.0 111.722 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.76 0.32 89.21 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 179.579 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -124.06 165.24 17.84 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.107 0.479 . . . . 0.0 110.66 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.63 137.07 26.42 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.231 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.408 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 17.7 t80 -49.82 137.57 16.18 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.657 -179.543 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.445 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -119.42 89.01 39.57 Favored Pre-proline 0 CA--C 1.541 0.634 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.414 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_exo -66.37 -0.56 4.41 Favored 'Trans proline' 0 N--CA 1.496 1.623 0 C-N-CA 122.932 2.421 . . . . 0.0 112.132 -179.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.0 t -103.08 -19.71 6.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.952 0.406 . . . . 0.0 110.416 -179.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -108.53 -41.68 4.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.664 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.62 -3.2 11.07 Favored Glycine 0 CA--C 1.533 1.216 0 CA-C-N 116.029 -0.532 . . . . 0.0 112.415 179.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.445 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -148.35 -171.28 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-N 117.042 0.421 . . . . 0.0 110.556 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 15.7 m -90.88 143.12 27.05 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.109 0.481 . . . . 0.0 110.392 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -129.69 152.96 48.62 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.583 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.5 tt -55.17 134.26 18.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.187 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -90.22 167.96 12.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.068 -179.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.489 ' CD2' ' N ' ' A' ' 20' ' ' LEU . 4.1 mm? . . . . . 0 N--CA 1.451 -0.393 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.521 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.6 t90 . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.717 0.294 . . . . 0.0 110.492 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.402 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.2 m -120.03 148.83 43.08 Favored 'General case' 0 CA--C 1.516 -0.329 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.708 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.44 168.0 26.4 Favored Pre-proline 0 N--CA 1.452 -0.327 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.901 179.809 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo -58.65 138.89 88.28 Favored 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 122.485 2.124 . . . . 0.0 111.739 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.44 0.61 89.36 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -122.57 166.28 15.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.097 0.475 . . . . 0.0 110.484 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.65 138.39 25.89 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.172 179.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.402 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 17.4 t80 -50.43 136.76 20.04 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.508 -179.619 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.43 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -118.76 89.24 37.37 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.592 -179.473 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -66.44 -0.04 3.93 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 C-N-CA 122.83 2.353 . . . . 0.0 112.375 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 t -103.8 -19.1 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.02 0.438 . . . . 0.0 110.363 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -109.54 -40.71 4.78 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.697 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.41 -3.38 12.41 Favored Glycine 0 CA--C 1.534 1.26 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.424 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.43 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -147.54 -171.25 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-N 117.149 0.474 . . . . 0.0 110.42 179.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 23.7 m -90.38 142.3 27.87 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-O 121.179 0.514 . . . . 0.0 110.136 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -129.17 155.21 45.87 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.588 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.9 tt -56.82 132.35 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.726 0 CA-C-O 121.076 0.465 . . . . 0.0 110.681 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.06 160.56 18.55 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.724 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.3 tt . . . . . 0 C--N 1.327 -0.404 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.821 179.779 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.3 t90 . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.71 0.29 . . . . 0.0 110.508 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.42 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 78.0 m -123.31 153.52 40.15 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.671 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.68 168.12 16.81 Favored Pre-proline 0 N--CA 1.452 -0.344 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.788 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_exo -56.64 138.86 86.57 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.075 1.85 . . . . 0.0 111.792 179.539 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.35 0.01 89.41 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 179.328 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -123.95 163.84 20.51 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.297 0.57 . . . . 0.0 110.56 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.39 136.94 26.7 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.086 179.438 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.42 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.6 t80 -50.29 137.22 18.7 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.615 -179.281 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.401 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -118.74 88.41 35.13 Favored Pre-proline 0 CA--C 1.539 0.545 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.555 -179.199 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -66.39 0.15 3.7 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 122.753 2.302 . . . . 0.0 112.252 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.3 t -103.49 -18.78 6.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.976 0.417 . . . . 0.0 110.281 -179.349 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -109.82 -41.44 4.51 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.794 179.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.47 -3.03 12.4 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-N 116.118 -0.492 . . . . 0.0 112.525 179.156 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.401 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.1 pt -147.69 -172.82 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 117.52 0.66 . . . . 0.0 110.327 179.634 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 25.4 m -90.23 141.14 29.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-O 121.135 0.493 . . . . 0.0 109.922 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.7 p -127.97 153.95 46.14 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.635 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.9 tt -57.31 131.93 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.504 -179.764 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -90.58 164.76 14.08 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.726 -179.691 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 94.1 mt . . . . . 0 N--CA 1.449 -0.492 0 CA-C-O 121.071 0.462 . . . . 0.0 111.106 179.793 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.8 t90 . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.648 0.261 . . . . 0.0 110.507 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.438 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 71.7 m -121.88 153.14 38.82 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.141 0.496 . . . . 0.0 110.568 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.13 167.77 22.23 Favored Pre-proline 0 N--CA 1.451 -0.405 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.85 179.45 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -58.15 138.61 86.83 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.513 2.142 . . . . 0.0 111.85 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.18 -0.99 88.2 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.468 -0.653 . . . . 0.0 111.468 179.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.1 m-85 -121.91 165.32 16.12 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.024 0.44 . . . . 0.0 110.54 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.84 135.91 24.95 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.214 179.615 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.438 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.0 t80 -48.96 137.28 13.09 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.518 -179.668 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.425 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -119.04 88.79 37.58 Favored Pre-proline 0 CA--C 1.543 0.7 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.468 -179.484 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_exo -66.11 -0.16 3.83 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.835 2.357 . . . . 0.0 112.213 -179.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.7 t -103.78 -19.72 6.1 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.318 0 CA-C-O 120.908 0.385 . . . . 0.0 110.246 -179.101 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -108.53 -41.99 4.67 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.371 179.458 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.0 -3.05 11.65 Favored Glycine 0 CA--C 1.537 1.412 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.779 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.425 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -148.34 -173.5 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 117.126 0.463 . . . . 0.0 110.588 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 21.2 m -89.46 141.28 28.71 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.002 0.429 . . . . 0.0 110.35 179.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -128.64 153.89 46.81 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.574 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.3 tt -56.38 132.61 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.345 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.76 153.75 20.83 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.18 -179.782 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.4 tt . . . . . 0 C--N 1.325 -0.458 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.34 179.549 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.4 t90 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.594 0.235 . . . . 0.0 110.38 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 79.7 m -120.15 150.73 40.15 Favored 'General case' 0 CA--C 1.519 -0.224 0 CA-C-O 121.216 0.531 . . . . 0.0 110.805 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.23 166.35 28.94 Favored Pre-proline 0 N--CA 1.448 -0.557 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.574 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -58.96 139.73 92.17 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 122.478 2.118 . . . . 0.0 111.841 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.47 0.01 89.53 Favored Glycine 0 CA--C 1.53 0.997 0 N-CA-C 111.697 -0.561 . . . . 0.0 111.697 179.4 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -121.71 166.47 14.25 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.97 0.414 . . . . 0.0 110.38 179.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.5 135.15 29.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.215 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.49 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -50.2 134.73 22.21 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.657 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.49 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -118.05 94.98 47.59 Favored Pre-proline 0 CA--C 1.546 0.813 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.923 -179.621 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -74.6 0.63 8.45 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 C-N-CA 122.911 2.407 . . . . 0.0 112.443 -179.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 26.9 t -102.85 -18.87 6.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.926 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -108.75 -43.54 4.23 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.469 179.452 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.98 -0.0 9.79 Favored Glycine 0 CA--C 1.535 1.342 0 CA-C-N 116.065 -0.516 . . . . 0.0 112.853 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.477 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -152.38 -170.53 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.165 0 CA-C-N 117.069 0.435 . . . . 0.0 110.339 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.6 m -91.03 142.13 28.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.954 0.406 . . . . 0.0 110.28 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.4 p -128.88 151.99 49.01 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.605 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.7 tt -52.83 139.42 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.477 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.406 ' OG1' ' N ' ' A' ' 20' ' ' LEU . 0.0 OUTLIER -95.5 169.66 9.89 Favored 'General case' 0 C--O 1.241 0.635 0 CA-C-O 121.246 0.546 . . . . 0.0 111.036 -179.944 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.406 ' N ' ' OG1' ' A' ' 19' ' ' THR . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.841 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.1 t90 . . . . . 0 C--O 1.231 0.091 0 N-CA-C 110.21 -0.293 . . . . 0.0 110.21 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.44 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.5 m -119.01 150.56 39.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.671 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.4 168.55 18.33 Favored Pre-proline 0 N--CA 1.451 -0.381 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.668 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -57.94 138.56 86.63 Favored 'Trans proline' 0 N--CA 1.496 1.643 0 C-N-CA 122.115 1.877 . . . . 0.0 111.8 179.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.87 1.31 90.21 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 179.195 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 20.0 m-85 -123.75 165.54 17.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.272 0.558 . . . . 0.0 110.568 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.29 138.2 26.23 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.076 179.325 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.44 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.8 t80 -50.81 137.31 20.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.509 -179.339 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.415 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -118.77 88.3 34.99 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.311 -179.134 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_exo -66.2 0.27 3.46 Favored 'Trans proline' 0 N--CA 1.495 1.562 0 C-N-CA 122.771 2.314 . . . . 0.0 112.305 -179.626 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.8 t -103.08 -19.84 5.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.917 0.389 . . . . 0.0 110.441 -179.478 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.402 ' CD1' ' C ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.24 -41.23 4.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.136 179.464 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.04 -3.0 11.62 Favored Glycine 0 CA--C 1.533 1.188 0 CA-C-N 116.208 -0.451 . . . . 0.0 112.228 178.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.415 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -147.61 -171.95 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 117.469 0.634 . . . . 0.0 110.262 179.7 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 24.0 m -90.85 142.41 27.79 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.259 0.552 . . . . 0.0 109.845 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.7 p -128.68 154.35 46.38 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.692 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.4 tt -57.31 131.11 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.805 -179.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.27 154.45 20.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.85 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 2.7 mm? . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.407 179.868 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.1 t90 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.651 0.262 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.414 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 75.4 m -120.34 153.08 36.96 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.363 -179.815 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -87.55 170.67 11.3 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.487 -179.681 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_exo -59.18 139.25 89.45 Favored 'Trans proline' 0 C--N 1.311 -1.406 0 C-N-CA 121.946 1.764 . . . . 0.0 111.855 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.43 -0.05 88.39 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 179.098 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -122.3 164.88 17.13 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.008 0.432 . . . . 0.0 110.448 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.54 139.5 28.23 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.648 179.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.414 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 20.3 t80 -52.24 137.99 27.29 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.973 0.416 . . . . 0.0 110.575 -179.422 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.412 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -119.16 87.91 35.91 Favored Pre-proline 0 CA--C 1.54 0.578 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.357 -179.035 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -66.28 0.71 3.06 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.892 2.395 . . . . 0.0 112.105 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.1 t -103.36 -19.27 6.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.069 0.462 . . . . 0.0 110.35 -179.263 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -110.52 -41.35 4.36 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.949 179.647 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.04 -3.38 11.56 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 121.302 -0.475 . . . . 0.0 112.45 179.01 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.412 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.1 pt -146.02 -170.9 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-N 117.14 0.47 . . . . 0.0 110.617 179.597 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 28.0 m -92.14 142.09 27.88 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 120.959 0.409 . . . . 0.0 110.078 179.755 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.1 p -128.33 154.41 45.98 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.109 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 15.7 tt -57.34 133.06 22.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.668 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -92.84 163.93 13.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.727 -179.455 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.0 mt . . . . . 0 N--CA 1.449 -0.51 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.843 179.894 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.3 t90 . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.568 0.223 . . . . 0.0 110.451 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.6 m -120.31 152.25 38.08 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.817 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -88.27 168.33 16.73 Favored Pre-proline 0 N--CA 1.45 -0.455 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.733 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -58.15 138.79 87.78 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 C-N-CA 122.526 2.151 . . . . 0.0 111.755 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.38 0.27 89.68 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.551 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.7 m-85 -123.27 164.43 18.79 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 121.168 0.508 . . . . 0.0 110.745 179.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -142.93 135.43 27.57 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.249 179.394 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.483 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 9.0 t80 -48.34 135.47 13.69 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.848 -179.634 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.483 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -119.13 94.81 48.76 Favored Pre-proline 0 CA--C 1.545 0.753 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.054 -179.597 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -74.22 -0.12 9.2 Favored 'Trans proline' 0 N--CA 1.493 1.452 0 C-N-CA 122.715 2.277 . . . . 0.0 112.503 -179.554 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 t -101.58 -18.62 6.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.885 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.422 ' CD1' ' C ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.34 -43.35 4.14 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.006 179.421 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.78 0.21 9.96 Favored Glycine 0 CA--C 1.535 1.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 112.56 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.483 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.7 pt -152.38 -170.48 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.281 0 CA-C-N 117.215 0.507 . . . . 0.0 110.258 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 18.7 m -91.13 141.93 28.28 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 120.999 0.428 . . . . 0.0 110.13 179.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.7 p -127.36 153.78 45.79 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.529 -0.76 . . . . 0.0 110.858 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.5 tt -57.23 131.81 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.422 -179.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -90.39 160.99 15.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.722 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.475 ' CD2' ' N ' ' A' ' 20' ' ' LEU . 4.2 mm? . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.702 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.607 0.241 . . . . 0.0 110.515 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.441 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.3 m -119.94 151.98 38.12 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.586 -179.855 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.43 168.81 17.14 Favored Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.845 179.302 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -58.45 138.92 88.43 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 122.624 2.216 . . . . 0.0 111.833 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.48 -0.24 88.18 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -122.33 166.33 14.86 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.043 0.449 . . . . 0.0 110.503 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.88 137.5 25.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.0 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.441 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 16.1 t80 -50.36 136.79 19.73 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.64 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.419 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -119.16 89.27 39.15 Favored Pre-proline 0 CA--C 1.543 0.699 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.524 -179.655 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -66.66 -0.14 4.19 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 122.964 2.443 . . . . 0.0 112.135 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.8 t -103.95 -18.89 6.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.9 0.381 . . . . 0.0 110.383 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.08 -42.12 4.51 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.629 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.25 -2.35 11.47 Favored Glycine 0 CA--C 1.536 1.367 0 CA-C-N 116.214 -0.448 . . . . 0.0 112.914 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.419 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.7 pt -149.33 -171.5 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 122.641 -0.329 . . . . 0.0 110.543 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.2 m -91.62 142.84 27.19 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-O 121.091 0.472 . . . . 0.0 110.297 179.782 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 66.4 p -129.1 154.84 46.3 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.444 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.3 tt -57.08 131.1 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.586 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.47 159.74 18.54 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.793 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.4 mt . . . . . 0 N--CA 1.447 -0.607 0 CA-C-O 121.111 0.482 . . . . 0.0 110.998 179.651 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.0 t90 . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.595 0.236 . . . . 0.0 110.445 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.9 m -123.04 155.16 37.42 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.292 0.568 . . . . 0.0 111.107 -179.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.69 166.59 18.77 Favored Pre-proline 0 N--CA 1.449 -0.516 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.797 179.208 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -57.79 139.16 89.38 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 122.494 2.129 . . . . 0.0 111.911 179.573 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.78 1.67 90.29 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.748 -0.541 . . . . 0.0 111.748 179.481 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 18.9 m-85 -123.61 165.63 16.85 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.062 0.458 . . . . 0.0 110.415 179.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.68 134.59 28.84 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.225 179.614 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.498 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -49.1 135.31 16.5 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.639 -179.764 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.498 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -118.93 94.64 48.38 Favored Pre-proline 0 CA--C 1.546 0.794 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.807 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -74.25 -0.33 9.49 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.851 2.367 . . . . 0.0 112.249 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.7 t -101.99 -18.14 6.61 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.965 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.408 ' CD1' ' C ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.61 -43.65 4.02 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.376 179.455 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.69 1.12 9.94 Favored Glycine 0 CA--C 1.535 1.322 0 CA-C-N 116.049 -0.523 . . . . 0.0 112.908 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.476 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -153.07 -170.85 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.163 0 CA-C-N 117.055 0.427 . . . . 0.0 110.354 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 16.7 m -91.86 141.34 28.77 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-O 120.945 0.402 . . . . 0.0 110.24 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.0 p -127.99 153.0 47.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.615 -179.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.8 tt -53.66 141.03 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.799 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.346 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -97.16 163.22 13.01 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.847 -179.78 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 3.8 mm? . . . . . 0 N--CA 1.454 -0.271 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.52 -179.707 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.68 0.276 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.8 m -118.08 152.26 35.92 Favored 'General case' 0 CA--C 1.52 -0.202 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.568 -179.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -89.53 169.27 13.07 Favored Pre-proline 0 N--CA 1.451 -0.404 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 -179.436 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -57.79 139.23 89.6 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 121.939 1.759 . . . . 0.0 111.779 179.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.88 1.18 90.18 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.416 -0.674 . . . . 0.0 111.416 179.267 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.8 m-85 -124.23 164.28 19.85 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.273 0.559 . . . . 0.0 110.525 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.68 137.37 26.55 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.164 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.8 t80 -50.8 137.86 19.66 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 120.478 -0.489 . . . . 0.0 110.681 -179.321 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.405 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -119.37 88.39 37.98 Favored Pre-proline 0 CA--C 1.538 0.511 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.504 -179.209 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -66.62 0.52 3.45 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.705 2.27 . . . . 0.0 112.189 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.0 t -103.3 -19.24 6.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.952 0.406 . . . . 0.0 110.282 -179.294 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.56 -41.66 4.52 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.143 179.491 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.49 -2.38 12.44 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-N 116.068 -0.515 . . . . 0.0 112.312 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.405 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -147.87 -172.45 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 117.707 0.753 . . . . 0.0 110.25 179.58 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.5 m -90.63 142.48 27.71 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.254 0.549 . . . . 0.0 109.592 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.7 p -128.96 154.1 46.91 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.641 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.9 tt -57.22 131.82 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-O 120.991 0.424 . . . . 0.0 110.547 -179.489 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -89.55 160.98 16.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.78 -179.613 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 8.8 mp . . . . . 0 C--N 1.331 -0.233 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.892 179.751 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.2 t90 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.647 0.26 . . . . 0.0 110.453 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 97.5 m -123.56 149.39 45.34 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-O 121.403 0.62 . . . . 0.0 111.109 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.78 160.73 81.33 Favored Pre-proline 0 N--CA 1.442 -0.846 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.252 179.306 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -64.46 138.51 60.33 Favored 'Trans proline' 0 C--N 1.302 -1.883 0 C-N-CA 122.429 2.086 . . . . 0.0 111.929 -179.665 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.61 -7.89 80.95 Favored Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 -179.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 15.6 m-85 -115.19 167.91 10.41 Favored 'General case' 0 CA--C 1.522 -0.129 0 CA-C-O 121.131 0.491 . . . . 0.0 110.5 179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -139.04 134.08 32.52 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.171 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.456 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 9.3 t80 -50.87 135.39 24.31 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.692 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.456 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -119.12 95.52 49.4 Favored Pre-proline 0 CA--C 1.545 0.777 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.927 -179.573 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -75.04 0.71 8.6 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.857 2.371 . . . . 0.0 112.35 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 36.3 t -103.0 -17.82 6.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.995 -179.762 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -110.32 -43.18 3.96 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.598 179.411 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.05 2.29 11.16 Favored Glycine 0 CA--C 1.535 1.333 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.882 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.446 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.2 pt -153.65 -174.21 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.232 0 CA-C-N 117.314 0.557 . . . . 0.0 110.121 179.67 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 3.9 m -88.29 139.99 29.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.04 0.447 . . . . 0.0 110.535 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.8 p -126.21 152.95 45.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.521 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.5 tt -58.0 133.59 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.433 -179.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -85.19 152.24 23.5 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.788 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 8.0 mp . . . . . 0 C--N 1.327 -0.37 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.601 179.965 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . 0.475 ' HG3' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.148 0 CA-C-O 118.224 -0.893 . . . . 0.0 111.044 . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.2 t90 -67.28 133.07 48.98 Favored 'General case' 0 C--N 1.329 -0.317 0 O-C-N 124.262 0.976 . . . . 0.0 110.335 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.9 m -119.7 151.56 38.54 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.471 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.51 169.75 14.29 Favored Pre-proline 0 N--CA 1.452 -0.369 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.742 -179.519 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_exo -58.94 139.24 90.0 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 122.109 1.873 . . . . 0.0 111.795 179.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.52 -0.02 88.53 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 179.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -122.21 165.64 15.84 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.139 0.495 . . . . 0.0 110.542 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -146.01 138.44 25.45 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.078 179.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.475 ' CD2' ' HG3' ' A' ' 1' ' ' PCA . 18.3 t80 -50.09 137.36 17.64 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.557 -179.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.43 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -118.83 88.84 36.7 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.455 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -66.82 -0.06 4.21 Favored 'Trans proline' 0 N--CA 1.496 1.623 0 C-N-CA 122.732 2.288 . . . . 0.0 112.103 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 19.3 t -103.05 -19.01 6.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.874 0.369 . . . . 0.0 110.471 -179.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -110.03 -41.36 4.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.902 179.416 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.79 -2.92 11.96 Favored Glycine 0 CA--C 1.535 1.288 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.42 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.43 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.2 pt -147.21 -169.55 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 117.5 0.65 . . . . 0.0 110.342 179.599 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 23.6 m -91.76 142.08 27.98 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 121.197 0.523 . . . . 0.0 109.85 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.8 p -129.24 154.73 46.52 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.573 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 tt -57.81 132.1 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-O 121.189 0.519 . . . . 0.0 110.572 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -85.04 152.9 23.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.574 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.491 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 11.2 mp -61.34 -25.83 67.41 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.878 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 88.4 p -56.62 -34.37 67.17 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.508 -179.39 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.426 ' O ' ' O ' ' A' ' 23' ' ' ILE . 21.5 ttm180 -62.45 -40.25 96.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.52 -0.309 . . . . 0.0 111.051 179.489 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' A' ' 22' ' ' ARG . 92.6 mt -46.27 -99.19 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.963 -179.269 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.448 ' C ' ' CD2' ' A' ' 25' ' ' HIS . 99.4 mt-10 -127.04 89.72 3.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.77 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.491 ' CD2' ' O ' ' A' ' 20' ' ' LEU . 49.1 m-70 -149.44 69.44 9.55 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.452 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.557 ' O ' ' N ' ' A' ' 30' ' ' ASP . 52.2 Cg_exo -53.98 -37.38 86.1 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.423 2.082 . . . . 0.0 111.82 -179.439 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.66 -40.38 98.67 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.959 -0.856 . . . . 0.0 110.959 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 37.7 t-20 -62.1 -44.34 96.86 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.72 0.295 . . . . 0.0 110.988 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.573 ' CD2' ' O ' ' A' ' 29' ' ' TYR . 24.7 p90 -126.17 47.17 2.3 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.934 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.557 ' N ' ' O ' ' A' ' 26' ' ' PRO . 67.7 t0 -59.3 -43.0 92.65 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.717 -179.57 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 66.9 t80 . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.661 179.916 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . 0.457 ' HG3' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.392 -5.127 0 CA-C-O 118.133 -0.937 . . . . 0.0 111.076 . . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 -66.15 131.88 47.19 Favored 'General case' 0 C--N 1.329 -0.324 0 O-C-N 124.286 0.991 . . . . 0.0 110.6 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 77.0 m -120.88 151.58 39.48 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.841 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -88.04 167.04 21.15 Favored Pre-proline 0 N--CA 1.45 -0.474 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.635 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -58.04 139.13 89.31 Favored 'Trans proline' 0 N--CA 1.493 1.482 0 C-N-CA 122.573 2.182 . . . . 0.0 111.87 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 85.66 -4.38 85.85 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -119.63 164.53 15.74 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.067 0.461 . . . . 0.0 110.632 179.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -140.51 132.83 28.29 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.298 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.48 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -48.38 134.5 14.95 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.707 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.48 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.8 t30 -118.01 94.57 46.73 Favored Pre-proline 0 CA--C 1.545 0.752 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.951 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -74.39 0.45 8.56 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.963 2.442 . . . . 0.0 112.33 -179.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.8 t -102.74 -19.05 6.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.924 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.408 ' CD1' ' C ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER -108.65 -43.9 4.17 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.511 179.435 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.77 1.8 9.67 Favored Glycine 0 CA--C 1.534 1.269 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.719 179.328 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.465 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -153.81 -173.49 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.235 0 CA-C-N 117.061 0.431 . . . . 0.0 110.408 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.5 m -89.43 140.97 28.99 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-O 120.884 0.373 . . . . 0.0 110.287 179.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.2 p -127.91 152.45 47.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.531 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 tt -58.42 133.06 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.262 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -84.04 142.88 30.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.63 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 6.8 mp -57.44 -27.96 62.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.89 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.0 t -57.37 -38.48 74.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.417 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 75.7 ttt180 -58.84 -38.85 79.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.399 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 34.4 mm -63.72 -102.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.818 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -149.93 74.06 1.19 Allowed 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.692 0.282 . . . . 0.0 111.05 -179.554 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -144.71 67.51 14.06 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.816 179.356 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -61.79 -37.07 69.98 Favored 'Trans proline' 0 N--CA 1.494 1.554 0 C-N-CA 122.767 2.311 . . . . 0.0 112.19 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.38 -44.81 97.56 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -64.3 -39.97 94.99 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.806 0.336 . . . . 0.0 110.654 179.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -132.84 71.52 1.47 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.612 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -61.32 -43.63 98.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.542 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.598 179.975 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.391 -5.152 0 CA-C-O 118.271 -0.871 . . . . 0.0 111.067 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.1 t90 -65.1 132.14 48.4 Favored 'General case' 0 C--N 1.33 -0.261 0 O-C-N 124.167 0.917 . . . . 0.0 110.454 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.42 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 74.1 m -122.28 153.58 38.72 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.245 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -89.05 168.3 15.84 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.902 -179.488 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -57.64 138.11 84.52 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.678 2.252 . . . . 0.0 111.654 179.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.13 1.47 90.35 Favored Glycine 0 CA--C 1.528 0.857 0 N-CA-C 111.206 -0.758 . . . . 0.0 111.206 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.8 m-85 -125.22 163.23 22.94 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.13 0.49 . . . . 0.0 110.602 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -143.17 135.82 27.56 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.134 179.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.42 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 16.1 t80 -48.36 136.96 11.79 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.601 -179.594 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.457 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -118.58 89.25 36.56 Favored Pre-proline 0 CA--C 1.54 0.568 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.637 -179.605 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -67.02 -0.02 4.3 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 122.907 2.405 . . . . 0.0 112.051 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.0 t -103.49 -17.94 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 CA-C-O 120.94 0.4 . . . . 0.0 110.317 -179.316 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -111.09 -42.65 3.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.4 179.566 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.57 -2.1 10.26 Favored Glycine 0 CA--C 1.534 1.224 0 CA-C-N 116.113 -0.494 . . . . 0.0 112.432 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.457 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.0 pt -149.92 -173.07 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.917 0.358 . . . . 0.0 110.592 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.9 m -89.27 142.34 27.74 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 120.946 0.403 . . . . 0.0 110.332 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 65.0 p -129.6 150.9 50.73 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.515 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 tt -51.83 137.72 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.149 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.414 ' OG1' ' N ' ' A' ' 20' ' ' LEU . 0.0 OUTLIER -101.06 169.66 8.79 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.062 -179.328 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.414 ' N ' ' OG1' ' A' ' 19' ' ' THR . 4.8 tt -60.43 -32.53 71.45 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.17 179.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.444 ' OG ' ' O ' ' A' ' 25' ' ' HIS . 42.0 t -43.78 -29.73 0.57 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.458 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 9.8 ttp-105 -53.37 -33.16 52.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.261 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.419 ' CG2' ' N ' ' A' ' 24' ' ' GLU . 36.4 mm -50.38 -95.34 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.47 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.419 ' N ' ' CG2' ' A' ' 23' ' ' ILE . 99.4 mt-10 -141.15 30.99 1.76 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.641 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.444 ' O ' ' OG ' ' A' ' 21' ' ' SER . 91.3 m-70 -132.0 59.5 44.9 Favored Pre-proline 0 C--N 1.332 -0.182 0 C-N-CA 120.814 -0.354 . . . . 0.0 110.075 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.65 -23.5 74.68 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.876 2.384 . . . . 0.0 111.97 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.7 -37.24 93.93 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 11.8 t-20 54.84 43.11 30.51 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.844 0.354 . . . . 0.0 110.514 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 12.1 m-85 56.1 23.23 6.68 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.513 179.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 50.8 t0 52.79 41.02 31.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.426 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 85.8 t80 . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.557 179.972 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . 0.485 ' HG3' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.158 0 CA-C-O 118.242 -0.885 . . . . 0.0 111.114 . . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.6 t90 -66.22 130.2 42.43 Favored 'General case' 0 C--N 1.329 -0.318 0 O-C-N 124.21 0.944 . . . . 0.0 110.452 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.414 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 73.4 m -119.44 151.12 39.07 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.566 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.34 169.02 16.36 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.822 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.93 138.92 88.45 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.539 2.159 . . . . 0.0 111.879 179.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.98 0.06 89.09 Favored Glycine 0 CA--C 1.529 0.912 0 N-CA-C 111.359 -0.697 . . . . 0.0 111.359 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -123.9 164.36 19.43 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.073 0.463 . . . . 0.0 110.601 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.89 136.25 25.22 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.235 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.485 ' CD2' ' HG3' ' A' ' 1' ' ' PCA . 17.7 t80 -48.6 136.91 12.56 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.553 -179.6 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.421 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -119.1 89.22 38.81 Favored Pre-proline 0 CA--C 1.54 0.59 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.539 -179.541 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -66.67 -0.08 4.12 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 122.915 2.41 . . . . 0.0 112.08 -179.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.4 t -103.53 -19.89 5.99 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 120.895 0.379 . . . . 0.0 110.303 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -108.4 -42.04 4.69 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.624 179.413 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.92 -1.72 11.87 Favored Glycine 0 CA--C 1.534 1.28 0 CA-C-N 116.035 -0.529 . . . . 0.0 112.543 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.421 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 4.7 pt -149.66 -172.9 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 117.094 0.447 . . . . 0.0 110.556 179.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.5 m -88.94 141.77 28.21 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.061 0.458 . . . . 0.0 110.404 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.6 p -128.69 152.69 48.11 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.542 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.497 ' CD1' ' HE ' ' A' ' 22' ' ' ARG . 10.7 tt -55.25 132.3 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.348 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.01 166.76 11.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.903 -179.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.0 mt -65.04 -26.09 68.11 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-O 121.192 0.52 . . . . 0.0 110.861 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 89.1 p -61.28 -17.55 54.08 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.197 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.497 ' HE ' ' CD1' ' A' ' 18' ' ' ILE . 0.1 OUTLIER -53.79 -21.15 6.8 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.576 -179.882 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 95.8 mt -58.34 -95.03 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.617 -179.802 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -133.31 41.68 3.08 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.864 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 81.5 m-70 -132.23 59.35 43.42 Favored Pre-proline 0 C--N 1.331 -0.197 0 C-N-CA 120.792 -0.363 . . . . 0.0 110.866 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -76.15 -11.85 19.39 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.865 2.377 . . . . 0.0 112.238 178.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.07 -40.0 96.49 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.236 -0.745 . . . . 0.0 111.236 -179.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -62.99 -37.31 86.67 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.846 0.355 . . . . 0.0 110.983 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -103.45 17.53 23.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.361 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -81.86 74.73 8.83 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.238 179.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.462 ' CD2' ' O ' ' A' ' 31' ' ' TYR . 74.9 t80 . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.563 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.391 -5.138 0 CA-C-O 118.21 -0.9 . . . . 0.0 111.107 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.8 t90 -67.03 131.47 45.91 Favored 'General case' 0 C--N 1.329 -0.297 0 O-C-N 124.332 1.02 . . . . 0.0 110.555 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 93.3 m -123.45 148.93 45.69 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.986 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -69.95 161.97 71.61 Favored Pre-proline 0 N--CA 1.446 -0.67 0 CA-C-N 115.549 -0.751 . . . . 0.0 109.979 179.77 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -64.42 139.63 65.89 Favored 'Trans proline' 0 C--N 1.3 -2.001 0 C-N-CA 122.212 1.941 . . . . 0.0 111.904 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.88 -2.83 87.98 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 -179.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -119.29 166.71 12.66 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 121.006 0.432 . . . . 0.0 110.497 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.69 137.45 31.74 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.097 179.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 19.2 t80 -52.04 137.04 28.19 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.412 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.403 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -118.57 89.44 37.03 Favored Pre-proline 0 CA--C 1.539 0.53 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.38 -179.165 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -67.57 -0.02 4.69 Favored 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 122.721 2.28 . . . . 0.0 112.039 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 23.0 t -102.68 -18.69 6.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.507 -179.125 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -110.65 -41.37 4.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.79 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 119.97 -1.57 13.32 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-N 116.085 -0.507 . . . . 0.0 112.403 179.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.403 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -148.17 -172.72 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 117.484 0.642 . . . . 0.0 110.252 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.9 m -90.5 140.56 29.62 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.106 0.479 . . . . 0.0 109.956 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.0 p -127.36 152.53 47.36 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.315 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.2 tt -57.65 135.05 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 CA-C-O 121.139 0.495 . . . . 0.0 110.539 -179.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.93 141.75 28.49 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.319 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 3.3 tt -59.51 -28.9 67.47 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.248 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.411 ' CB ' HD22 ' A' ' 28' ' ' ASN . 89.0 p -59.06 -30.47 68.07 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.841 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.421 ' O ' ' O ' ' A' ' 23' ' ' ILE . 75.5 ttt180 -57.87 -39.36 77.62 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.261 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.421 ' O ' ' O ' ' A' ' 22' ' ' ARG . 50.7 mm -45.98 -94.96 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.359 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -143.62 35.0 1.29 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.569 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -132.32 61.14 55.63 Favored Pre-proline 0 C--O 1.232 0.142 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.295 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.96 -17.7 55.96 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 C-N-CA 122.574 2.183 . . . . 0.0 112.174 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.94 -29.43 70.65 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.411 HD22 ' CB ' ' A' ' 21' ' ' SER . 33.5 m120 54.8 37.38 28.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.804 0.335 . . . . 0.0 110.654 -179.722 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 46.3 m-85 56.51 23.01 7.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.58 179.502 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 52.6 t0 53.81 41.44 32.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.477 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.965 -1.017 . . . . 0.0 110.527 179.964 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.392 -5.114 0 CA-C-O 118.21 -0.9 . . . . 0.0 111.025 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.8 t90 -65.04 133.07 50.87 Favored 'General case' 0 C--N 1.33 -0.252 0 O-C-N 124.216 0.947 . . . . 0.0 110.527 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.4 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 76.1 m -118.92 153.08 35.16 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 121.184 0.516 . . . . 0.0 110.926 -179.716 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.79 168.51 15.56 Favored Pre-proline 0 N--CA 1.452 -0.364 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.995 179.158 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -58.8 138.55 86.35 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 C-N-CA 122.675 2.25 . . . . 0.0 111.78 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.02 -0.81 88.16 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.451 -0.66 . . . . 0.0 111.451 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -121.2 166.07 14.51 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-O 120.916 0.388 . . . . 0.0 110.679 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.21 136.59 26.64 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.899 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.486 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 8.4 t80 -49.46 135.48 17.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.755 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.486 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -119.38 94.92 48.93 Favored Pre-proline 0 CA--C 1.547 0.83 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.882 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -73.63 0.02 8.72 Favored 'Trans proline' 0 N--CA 1.492 1.441 0 C-N-CA 123.182 2.588 . . . . 0.0 112.427 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.5 t -103.29 -17.75 6.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.449 . . . . 0.0 109.985 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.97 -42.47 4.21 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.44 -0.18 11.3 Favored Glycine 0 CA--C 1.536 1.383 0 CA-C-N 116.253 -0.431 . . . . 0.0 113.185 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.474 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.8 pt -152.4 -170.77 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 O-C-N 122.493 -0.416 . . . . 0.0 110.387 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.9 m -90.89 142.67 27.52 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 120.979 0.418 . . . . 0.0 110.322 179.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.4 p -128.0 157.37 40.8 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.654 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.1 tt -59.75 131.68 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.362 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.451 ' HG1' ' H ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -87.48 156.15 19.68 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.562 179.983 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.419 ' CD2' ' N ' ' A' ' 20' ' ' LEU . 4.3 mm? -63.39 -24.4 67.82 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.641 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.451 ' H ' ' HG1' ' A' ' 19' ' ' THR . 95.8 p -62.42 -22.78 66.44 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.555 -179.699 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.425 ' NH2' ' CE2' ' A' ' 29' ' ' TYR . 2.2 tpm_? -56.67 -33.59 66.55 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.276 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 95.2 mt -40.11 -82.86 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.045 0.45 . . . . 0.0 110.915 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -141.5 -106.11 0.14 Allowed 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.97 179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 82.3 m-70 55.6 66.17 3.95 Favored Pre-proline 0 C--O 1.237 0.399 0 CA-C-O 120.968 0.414 . . . . 0.0 110.758 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.85 -36.21 82.14 Favored 'Trans proline' 0 N--CA 1.493 1.5 0 C-N-CA 122.783 2.322 . . . . 0.0 111.875 -179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.73 -39.24 97.18 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -61.34 -40.31 93.75 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.88 0.371 . . . . 0.0 110.488 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.425 ' CE2' ' NH2' ' A' ' 22' ' ' ARG . 96.9 m-85 -96.07 -0.24 50.59 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.616 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 51.5 t0 50.56 49.98 19.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.604 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.442 ' O ' ' CG ' ' A' ' 31' ' ' TYR . 15.5 p90 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.655 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.39 -5.184 0 CA-C-O 118.342 -0.837 . . . . 0.0 111.127 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.1 t90 -70.47 131.67 44.4 Favored 'General case' 0 C--N 1.33 -0.273 0 O-C-N 124.204 0.94 . . . . 0.0 110.418 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.6 m -120.28 154.4 35.01 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.899 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.3 168.94 13.15 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.78 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -59.14 139.05 88.69 Favored 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 122.521 2.147 . . . . 0.0 111.73 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.07 0.07 89.2 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.427 -0.669 . . . . 0.0 111.427 179.426 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -122.17 165.11 16.65 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-O 121.168 0.508 . . . . 0.0 110.662 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -142.74 135.29 27.77 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.113 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.462 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 9.1 t80 -49.0 135.04 16.41 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.744 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.485 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.9 t30 -118.38 94.79 47.74 Favored Pre-proline 0 CA--C 1.544 0.747 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.995 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -74.42 0.3 8.77 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 C-N-CA 122.807 2.338 . . . . 0.0 112.41 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.4 t -102.19 -18.43 6.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.838 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.422 ' CD1' ' C ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.72 -43.77 3.97 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.73 179.478 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 123.23 0.96 9.5 Favored Glycine 0 CA--C 1.535 1.309 0 CA-C-N 116.081 -0.509 . . . . 0.0 112.61 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.485 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -152.92 -170.61 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.274 0 CA-C-N 117.113 0.457 . . . . 0.0 110.298 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 15.2 m -91.03 141.53 28.74 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 120.916 0.389 . . . . 0.0 110.196 179.6 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 79.7 p -127.71 152.68 47.41 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.679 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.2 tt -56.76 133.83 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.582 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.349 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.486 ' HG1' ' H ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -87.88 147.56 25.04 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.683 -179.83 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.3 tt -58.9 -27.0 64.82 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.468 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.486 ' H ' ' HG1' ' A' ' 19' ' ' THR . 72.7 m -56.34 -36.94 69.32 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.901 -179.121 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.401 ' O ' ' C ' ' A' ' 23' ' ' ILE . 24.3 ttm180 -56.5 -39.42 73.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.721 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.401 ' C ' ' O ' ' A' ' 22' ' ' ARG . 47.8 mm -38.25 -86.41 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.899 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -142.86 58.59 1.42 Allowed 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.065 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 54.6 m-70 -135.08 72.36 67.33 Favored Pre-proline 0 N--CA 1.463 0.176 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.531 179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -54.82 -36.05 90.07 Favored 'Trans proline' 0 N--CA 1.498 1.78 0 C-N-CA 122.869 2.379 . . . . 0.0 112.238 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.49 -39.66 96.65 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 32.6 m120 54.55 36.6 26.21 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.734 0.302 . . . . 0.0 110.528 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 51.9 m-85 57.72 21.77 7.71 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.565 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 51.9 t0 50.4 42.25 25.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.447 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 78.6 t80 . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.06 -0.972 . . . . 0.0 110.516 -179.986 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . 0.47 ' HG3' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.392 -5.106 0 CA-C-O 118.224 -0.893 . . . . 0.0 111.076 . . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.6 t90 -67.33 131.65 46.15 Favored 'General case' 0 C--N 1.332 -0.177 0 O-C-N 124.3 1.0 . . . . 0.0 110.406 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.404 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 73.5 m -120.3 150.59 40.47 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.479 0.657 . . . . 0.0 110.805 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.66 168.1 23.0 Favored Pre-proline 0 CA--C 1.533 0.3 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.601 -179.504 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -59.03 137.87 82.18 Favored 'Trans proline' 0 N--CA 1.492 1.422 0 C-N-CA 122.513 2.142 . . . . 0.0 111.828 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.51 1.31 90.07 Favored Glycine 0 CA--C 1.528 0.879 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 179.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -121.58 165.78 15.18 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-O 121.111 0.481 . . . . 0.0 110.546 179.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -143.66 135.64 26.58 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.149 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.476 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 8.4 t80 -48.22 134.69 14.22 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.752 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.491 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.9 t30 -118.48 94.84 47.99 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.906 -179.667 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -74.25 -0.61 9.85 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.849 2.366 . . . . 0.0 112.348 -179.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.6 t -101.43 -18.0 6.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.946 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.404 ' CD1' ' C ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.85 -43.31 4.04 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.384 179.515 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.98 0.19 9.78 Favored Glycine 0 CA--C 1.533 1.172 0 CA-C-N 116.109 -0.496 . . . . 0.0 112.725 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.491 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.6 pt -152.67 -169.86 0.1 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.263 0 CA-C-N 117.096 0.448 . . . . 0.0 110.234 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 21.6 m -91.55 142.16 27.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.891 0.377 . . . . 0.0 110.219 179.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.6 p -127.2 154.48 44.76 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.63 -179.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt -56.84 132.66 21.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.379 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -92.51 160.18 15.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.692 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 38.7 tp -61.84 -26.83 68.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.418 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.607 ' O ' ' NE2' ' A' ' 25' ' ' HIS . 37.9 t -53.6 -36.74 62.29 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.458 -179.343 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.409 ' C ' ' O ' ' A' ' 21' ' ' SER . 15.4 tpt180 -38.4 -30.17 0.04 OUTLIER 'General case' 0 C--O 1.231 0.11 0 O-C-N 123.287 0.367 . . . . 0.0 110.386 -179.707 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.449 ' N ' ' O ' ' A' ' 21' ' ' SER . 36.2 mt -129.53 66.75 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.783 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -148.15 44.02 1.05 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.602 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.607 ' NE2' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -171.37 54.59 0.21 Allowed Pre-proline 0 C--N 1.325 -0.477 0 CA-C-O 121.454 0.645 . . . . 0.0 110.325 -179.726 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.432 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 32.1 Cg_endo -65.38 -31.71 51.63 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.498 2.132 . . . . 0.0 111.871 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -62.74 -43.48 98.9 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.939 -0.865 . . . . 0.0 110.939 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -69.05 -38.29 79.03 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.704 0.288 . . . . 0.0 110.801 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 84.6 m-85 -114.63 63.04 0.67 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.756 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' A' ' 26' ' ' PRO . 98.6 m-20 -61.27 -39.96 92.34 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.517 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.511 ' CD2' ' OXT' ' A' ' 31' ' ' TYR . 69.1 t80 . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.581 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.392 -5.098 0 CA-C-O 118.233 -0.889 . . . . 0.0 111.155 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.0 t90 -65.53 133.46 51.27 Favored 'General case' 0 C--N 1.33 -0.262 0 O-C-N 124.256 0.973 . . . . 0.0 110.431 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.408 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.3 m -120.27 153.35 36.5 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.972 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -89.66 168.1 15.77 Favored Pre-proline 0 C--N 1.327 -0.4 0 O-C-N 123.107 0.255 . . . . 0.0 110.874 -179.529 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_exo -57.75 139.06 89.02 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.47 2.113 . . . . 0.0 111.722 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.76 0.32 89.21 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 179.579 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -124.06 165.24 17.84 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.107 0.479 . . . . 0.0 110.66 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.63 137.07 26.42 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.231 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.408 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 17.7 t80 -49.82 137.57 16.18 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.657 -179.543 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.445 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -119.42 89.01 39.57 Favored Pre-proline 0 CA--C 1.541 0.634 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.414 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_exo -66.37 -0.56 4.41 Favored 'Trans proline' 0 N--CA 1.496 1.623 0 C-N-CA 122.932 2.421 . . . . 0.0 112.132 -179.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.0 t -103.08 -19.71 6.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.952 0.406 . . . . 0.0 110.416 -179.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -108.53 -41.68 4.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.664 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.62 -3.2 11.07 Favored Glycine 0 CA--C 1.533 1.216 0 CA-C-N 116.029 -0.532 . . . . 0.0 112.415 179.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.445 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -148.35 -171.28 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-N 117.042 0.421 . . . . 0.0 110.556 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 15.7 m -90.88 143.12 27.05 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.109 0.481 . . . . 0.0 110.392 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -129.69 152.96 48.62 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.583 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.5 tt -55.17 134.26 18.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.187 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.468 ' HG1' ' H ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -90.22 167.96 12.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.068 -179.494 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.489 ' CD2' ' N ' ' A' ' 20' ' ' LEU . 4.1 mm? -68.22 -11.66 59.69 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.521 -179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.468 ' H ' ' HG1' ' A' ' 19' ' ' THR . 89.8 p -61.97 -25.74 67.8 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.051 0.453 . . . . 0.0 110.399 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 39.8 tpt85 -60.62 -39.11 87.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.134 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 51.1 mm -40.96 -86.81 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.845 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -143.23 60.61 1.4 Allowed 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.941 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 42.8 m-70 -130.82 63.59 70.62 Favored Pre-proline 0 CA--C 1.529 0.169 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.633 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -61.59 -18.74 61.66 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.886 2.391 . . . . 0.0 112.164 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.97 -40.05 97.89 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -64.08 -39.33 93.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.96 0.41 . . . . 0.0 110.71 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -78.73 -11.88 60.0 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.519 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 53.1 t0 57.84 44.29 20.34 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.357 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 92.4 t80 . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.037 -0.983 . . . . 0.0 110.578 179.896 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . 0.476 ' HG3' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.392 -5.122 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.991 . . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.6 t90 -68.08 130.39 42.81 Favored 'General case' 0 C--N 1.328 -0.331 0 O-C-N 124.273 0.983 . . . . 0.0 110.492 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.402 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.2 m -120.03 148.83 43.08 Favored 'General case' 0 CA--C 1.516 -0.329 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.708 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.44 168.0 26.4 Favored Pre-proline 0 N--CA 1.452 -0.327 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.901 179.809 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo -58.65 138.89 88.28 Favored 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 122.485 2.124 . . . . 0.0 111.739 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.44 0.61 89.36 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -122.57 166.28 15.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.097 0.475 . . . . 0.0 110.484 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.65 138.39 25.89 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.172 179.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.476 ' CD2' ' HG3' ' A' ' 1' ' ' PCA . 17.4 t80 -50.43 136.76 20.04 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.508 -179.619 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.43 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -118.76 89.24 37.37 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.592 -179.473 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -66.44 -0.04 3.93 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 C-N-CA 122.83 2.353 . . . . 0.0 112.375 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 t -103.8 -19.1 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.02 0.438 . . . . 0.0 110.363 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -109.54 -40.71 4.78 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.697 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.41 -3.38 12.41 Favored Glycine 0 CA--C 1.534 1.26 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.424 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.43 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -147.54 -171.25 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-N 117.149 0.474 . . . . 0.0 110.42 179.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 23.7 m -90.38 142.3 27.87 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-O 121.179 0.514 . . . . 0.0 110.136 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -129.17 155.21 45.87 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.588 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.9 tt -56.82 132.35 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.726 0 CA-C-O 121.076 0.465 . . . . 0.0 110.681 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.06 160.56 18.55 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.724 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.3 tt -56.66 -29.98 62.88 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.821 179.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 89.0 p -56.32 -23.12 34.95 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.441 -178.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.602 ' CA ' ' HE2' ' A' ' 25' ' ' HIS . 57.7 ttt-85 -109.4 30.29 6.76 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.905 0.384 . . . . 0.0 110.365 179.524 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.588 ' N ' ' HE2' ' A' ' 25' ' ' HIS . 57.0 mt -131.88 -32.36 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.338 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.642 ' C ' ' CG ' ' A' ' 25' ' ' HIS . 98.6 mt-10 -115.74 112.28 21.81 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.148 -178.78 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.642 ' CG ' ' C ' ' A' ' 24' ' ' GLU . 0.0 OUTLIER -167.43 51.96 0.23 Allowed Pre-proline 0 N--CA 1.466 0.357 0 CA-C-O 121.656 0.741 . . . . 0.0 110.571 -179.533 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.478 ' CD ' ' N ' ' A' ' 25' ' ' HIS . 33.7 Cg_endo -64.89 -28.34 58.58 Favored 'Trans proline' 0 C--N 1.301 -1.966 0 C-N-CA 122.19 1.927 . . . . 0.0 112.339 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -65.43 -12.55 56.27 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 63.4 t30 -58.8 -38.39 78.49 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.499 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.7 p90 -115.6 38.68 3.2 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.927 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.543 ' OD1' ' N ' ' A' ' 31' ' ' TYR . 56.7 p-10 -60.8 -24.8 66.09 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.772 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.543 ' N ' ' OD1' ' A' ' 30' ' ' ASP . 64.8 t80 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.956 -1.021 . . . . 0.0 110.535 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.391 -5.168 0 CA-C-O 118.302 -0.856 . . . . 0.0 111.084 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.3 t90 -64.65 131.32 46.63 Favored 'General case' 0 C--N 1.329 -0.306 0 O-C-N 124.236 0.96 . . . . 0.0 110.508 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.42 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 78.0 m -123.31 153.52 40.15 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.671 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.68 168.12 16.81 Favored Pre-proline 0 N--CA 1.452 -0.344 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.788 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_exo -56.64 138.86 86.57 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.075 1.85 . . . . 0.0 111.792 179.539 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.35 0.01 89.41 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 179.328 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -123.95 163.84 20.51 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.297 0.57 . . . . 0.0 110.56 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.39 136.94 26.7 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.086 179.438 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.42 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.6 t80 -50.29 137.22 18.7 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.615 -179.281 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.401 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -118.74 88.41 35.13 Favored Pre-proline 0 CA--C 1.539 0.545 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.555 -179.199 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -66.39 0.15 3.7 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 122.753 2.302 . . . . 0.0 112.252 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.3 t -103.49 -18.78 6.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.976 0.417 . . . . 0.0 110.281 -179.349 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -109.82 -41.44 4.51 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.794 179.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.47 -3.03 12.4 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-N 116.118 -0.492 . . . . 0.0 112.525 179.156 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.401 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.1 pt -147.69 -172.82 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 117.52 0.66 . . . . 0.0 110.327 179.634 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 25.4 m -90.23 141.14 29.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-O 121.135 0.493 . . . . 0.0 109.922 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.7 p -127.97 153.95 46.14 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.635 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.9 tt -57.31 131.93 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.504 -179.764 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -90.58 164.76 14.08 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.726 -179.691 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 94.1 mt -66.82 -20.56 65.96 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 121.071 0.462 . . . . 0.0 111.106 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 72.8 m -57.01 -25.57 58.78 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.54 -0.754 . . . . 0.0 110.541 -179.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.417 ' O ' ' O ' ' A' ' 23' ' ' ILE . 0.0 OUTLIER -58.0 -35.78 71.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.44 179.679 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.417 ' O ' ' O ' ' A' ' 22' ' ' ARG . 97.3 mt -37.54 -92.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.191 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.942 -179.53 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.4 ' N ' ' CG2' ' A' ' 23' ' ' ILE . 99.9 mt-10 -137.04 33.3 2.61 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.908 179.797 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -130.02 59.13 43.03 Favored Pre-proline 0 C--N 1.33 -0.242 0 CA-C-O 120.8 0.333 . . . . 0.0 110.244 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -64.03 -19.36 66.29 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.806 2.337 . . . . 0.0 112.04 179.68 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.09 -35.48 87.66 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 32.9 m120 55.25 38.11 29.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.774 0.321 . . . . 0.0 110.651 -179.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 53.3 m-85 58.05 18.25 5.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.655 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 52.7 t0 49.98 44.03 25.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.486 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 41.9 p90 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.902 -1.047 . . . . 0.0 110.64 179.984 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.391 -5.138 0 CA-C-O 118.251 -0.881 . . . . 0.0 111.069 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.8 t90 -62.3 131.28 48.81 Favored 'General case' 0 C--N 1.328 -0.34 0 O-C-N 124.268 0.98 . . . . 0.0 110.507 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.438 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 71.7 m -121.88 153.14 38.82 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.141 0.496 . . . . 0.0 110.568 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.13 167.77 22.23 Favored Pre-proline 0 N--CA 1.451 -0.405 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.85 179.45 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -58.15 138.61 86.83 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.513 2.142 . . . . 0.0 111.85 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.18 -0.99 88.2 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.468 -0.653 . . . . 0.0 111.468 179.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.1 m-85 -121.91 165.32 16.12 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.024 0.44 . . . . 0.0 110.54 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.84 135.91 24.95 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.214 179.615 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.438 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.0 t80 -48.96 137.28 13.09 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.518 -179.668 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.425 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -119.04 88.79 37.58 Favored Pre-proline 0 CA--C 1.543 0.7 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.468 -179.484 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_exo -66.11 -0.16 3.83 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.835 2.357 . . . . 0.0 112.213 -179.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.7 t -103.78 -19.72 6.1 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.318 0 CA-C-O 120.908 0.385 . . . . 0.0 110.246 -179.101 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -108.53 -41.99 4.67 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.371 179.458 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.0 -3.05 11.65 Favored Glycine 0 CA--C 1.537 1.412 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.779 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.425 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -148.34 -173.5 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 117.126 0.463 . . . . 0.0 110.588 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 21.2 m -89.46 141.28 28.71 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.002 0.429 . . . . 0.0 110.35 179.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -128.64 153.89 46.81 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.574 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.525 ' CD1' ' HE ' ' A' ' 22' ' ' ARG . 9.3 tt -56.38 132.61 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.345 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.477 ' HG1' ' HG ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -88.76 153.75 20.83 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.18 -179.782 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.4 tt -61.31 -34.08 74.66 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.34 179.549 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.477 ' HG ' ' HG1' ' A' ' 19' ' ' THR . 50.6 p -59.02 -20.47 53.4 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.144 -179.088 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.525 ' HE ' ' CD1' ' A' ' 18' ' ' ILE . 8.2 tmm_? -52.37 -29.92 26.3 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.769 179.459 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 96.9 mt -55.16 -88.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.753 -179.596 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 99.3 mt-10 -141.27 -15.86 0.85 Allowed 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.968 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.6 ' CD2' ' N ' ' A' ' 25' ' ' HIS . 0.1 OUTLIER -169.92 151.4 4.07 Favored Pre-proline 0 N--CA 1.446 -0.662 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.143 -179.718 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -72.79 -43.24 0.89 Allowed 'Trans proline' 0 N--CA 1.494 1.549 0 C-N-CA 122.834 2.356 . . . . 0.0 112.272 179.342 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -63.48 -41.04 99.39 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 59.27 65.23 1.21 Allowed 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.956 0.408 . . . . 0.0 110.865 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.679 ' N ' ' CD1' ' A' ' 29' ' ' TYR . 0.1 OUTLIER -106.25 62.58 0.65 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.22 0.533 . . . . 0.0 110.603 -179.423 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 54.5 p-10 -78.69 -0.11 28.83 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.4 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.491 ' CD2' ' O ' ' A' ' 31' ' ' TYR . 64.1 t80 . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.632 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.391 -5.154 0 CA-C-O 118.222 -0.894 . . . . 0.0 111.212 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.4 t90 -66.35 132.12 47.62 Favored 'General case' 0 C--N 1.33 -0.281 0 O-C-N 124.257 0.973 . . . . 0.0 110.38 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 79.7 m -120.15 150.73 40.15 Favored 'General case' 0 CA--C 1.519 -0.224 0 CA-C-O 121.216 0.531 . . . . 0.0 110.805 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.23 166.35 28.94 Favored Pre-proline 0 N--CA 1.448 -0.557 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.574 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -58.96 139.73 92.17 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 122.478 2.118 . . . . 0.0 111.841 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.47 0.01 89.53 Favored Glycine 0 CA--C 1.53 0.997 0 N-CA-C 111.697 -0.561 . . . . 0.0 111.697 179.4 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -121.71 166.47 14.25 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.97 0.414 . . . . 0.0 110.38 179.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.5 135.15 29.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.215 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.49 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -50.2 134.73 22.21 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.657 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.49 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -118.05 94.98 47.59 Favored Pre-proline 0 CA--C 1.546 0.813 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.923 -179.621 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -74.6 0.63 8.45 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 C-N-CA 122.911 2.407 . . . . 0.0 112.443 -179.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 26.9 t -102.85 -18.87 6.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.926 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -108.75 -43.54 4.23 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.469 179.452 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.98 -0.0 9.79 Favored Glycine 0 CA--C 1.535 1.342 0 CA-C-N 116.065 -0.516 . . . . 0.0 112.853 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.477 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -152.38 -170.53 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.165 0 CA-C-N 117.069 0.435 . . . . 0.0 110.339 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.6 m -91.03 142.13 28.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.954 0.406 . . . . 0.0 110.28 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.4 p -128.88 151.99 49.01 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.605 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.478 ' CD1' HH11 ' A' ' 22' ' ' ARG . 11.7 tt -52.83 139.42 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.477 -179.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.514 ' C ' ' H ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -95.5 169.66 9.89 Favored 'General case' 0 C--O 1.241 0.635 0 CA-C-O 121.246 0.546 . . . . 0.0 111.036 -179.944 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.406 ' N ' ' OG1' ' A' ' 19' ' ' THR . 0.5 OUTLIER -71.7 11.91 0.44 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.841 179.965 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.53 ' C ' ' CE1' ' A' ' 25' ' ' HIS . 68.6 m -107.47 11.13 29.15 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.726 179.568 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.606 ' N ' ' CE1' ' A' ' 25' ' ' HIS . 75.6 ttt-85 -139.16 -30.13 0.74 Allowed 'General case' 0 CA--C 1.533 0.325 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.109 179.606 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 92.6 mt -57.23 -45.18 84.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-O 120.928 0.394 . . . . 0.0 111.337 -179.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.645 ' C ' ' CG ' ' A' ' 25' ' ' HIS . 99.6 mt-10 -103.36 42.24 1.19 Allowed 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.222 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.645 ' CG ' ' C ' ' A' ' 24' ' ' GLU . 0.0 OUTLIER -165.79 74.66 1.29 Allowed Pre-proline 0 CA--C 1.538 0.485 0 CA-C-O 121.35 0.595 . . . . 0.0 110.66 -178.934 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_exo -55.43 -36.97 95.13 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 122.579 2.186 . . . . 0.0 112.14 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.04 -38.5 95.65 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 16.9 t-20 59.85 59.79 2.36 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-O 121.073 0.463 . . . . 0.0 111.036 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.682 ' N ' ' CD1' ' A' ' 29' ' ' TYR . 0.1 OUTLIER -99.59 45.66 0.99 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.559 -179.606 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.439 ' O ' ' OXT' ' A' ' 31' ' ' TYR . 67.0 t0 -59.85 -43.38 94.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.32 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.439 ' OXT' ' O ' ' A' ' 30' ' ' ASP . 69.0 t80 . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 117.956 -1.021 . . . . 0.0 110.577 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.392 -5.112 0 CA-C-O 118.43 -0.795 . . . . 0.0 111.115 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.1 t90 -67.98 131.36 45.32 Favored 'General case' 0 C--N 1.329 -0.313 0 O-C-N 124.065 0.853 . . . . 0.0 110.21 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.44 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.5 m -119.01 150.56 39.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.671 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.4 168.55 18.33 Favored Pre-proline 0 N--CA 1.451 -0.381 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.668 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -57.94 138.56 86.63 Favored 'Trans proline' 0 N--CA 1.496 1.643 0 C-N-CA 122.115 1.877 . . . . 0.0 111.8 179.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.87 1.31 90.21 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 179.195 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 20.0 m-85 -123.75 165.54 17.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.272 0.558 . . . . 0.0 110.568 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.29 138.2 26.23 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.076 179.325 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.44 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.8 t80 -50.81 137.31 20.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.509 -179.339 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.415 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -118.77 88.3 34.99 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.311 -179.134 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_exo -66.2 0.27 3.46 Favored 'Trans proline' 0 N--CA 1.495 1.562 0 C-N-CA 122.771 2.314 . . . . 0.0 112.305 -179.626 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.8 t -103.08 -19.84 5.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.917 0.389 . . . . 0.0 110.441 -179.478 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.402 ' CD1' ' C ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.24 -41.23 4.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.136 179.464 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.04 -3.0 11.62 Favored Glycine 0 CA--C 1.533 1.188 0 CA-C-N 116.208 -0.451 . . . . 0.0 112.228 178.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.415 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -147.61 -171.95 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 117.469 0.634 . . . . 0.0 110.262 179.7 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 24.0 m -90.85 142.41 27.79 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.259 0.552 . . . . 0.0 109.845 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.7 p -128.68 154.35 46.38 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.692 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.4 tt -57.31 131.11 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.805 -179.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.27 154.45 20.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.85 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -62.4 -17.7 59.8 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.407 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.536 ' O ' ' ND2' ' A' ' 28' ' ' ASN . 73.6 m -62.41 -25.38 67.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.401 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.529 ' C ' HD22 ' A' ' 28' ' ' ASN . 4.0 tmt_? -60.65 -39.25 87.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.537 179.84 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.509 ' C ' HD21 ' A' ' 28' ' ' ASN . 34.1 mm -52.5 -87.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.991 -179.039 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.553 ' CA ' HD21 ' A' ' 28' ' ' ASN . 77.9 mm-40 -129.13 -118.83 0.24 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.507 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.442 ' CD2' ' C ' ' A' ' 24' ' ' GLU . 12.4 m-70 68.99 153.2 0.14 Allowed Pre-proline 0 CA--C 1.536 0.418 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.995 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -44.22 -35.8 8.36 Favored 'Trans proline' 0 N--CA 1.5 1.903 0 C-N-CA 122.574 2.183 . . . . 0.0 112.777 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.438 ' O ' ' OD1' ' A' ' 30' ' ' ASP . . . -56.46 -34.48 63.77 Favored Glycine 0 CA--C 1.529 0.965 0 N-CA-C 111.074 -0.811 . . . . 0.0 111.074 -179.576 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.553 HD21 ' CA ' ' A' ' 24' ' ' GLU . 98.7 m-20 -87.21 -34.2 19.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.074 0.464 . . . . 0.0 110.791 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 67.5 m-85 -73.83 -9.46 58.67 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.586 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' A' ' 27' ' ' GLY . 50.9 p-10 -77.8 -0.52 27.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.211 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 1.5 p90 . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 117.917 -1.04 . . . . 0.0 110.539 179.85 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . 0.496 ' HG3' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.16 0 CA-C-O 118.235 -0.888 . . . . 0.0 111.203 . . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.1 t90 -68.88 131.05 44.49 Favored 'General case' 0 C--N 1.33 -0.28 0 O-C-N 124.25 0.969 . . . . 0.0 110.435 179.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.414 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 75.4 m -120.34 153.08 36.96 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.363 -179.815 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -87.55 170.67 11.3 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.487 -179.681 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_exo -59.18 139.25 89.45 Favored 'Trans proline' 0 C--N 1.311 -1.406 0 C-N-CA 121.946 1.764 . . . . 0.0 111.855 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.43 -0.05 88.39 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 179.098 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -122.3 164.88 17.13 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.008 0.432 . . . . 0.0 110.448 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.54 139.5 28.23 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.648 179.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.496 ' CD2' ' HG3' ' A' ' 1' ' ' PCA . 20.3 t80 -52.24 137.99 27.29 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.973 0.416 . . . . 0.0 110.575 -179.422 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.412 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -119.16 87.91 35.91 Favored Pre-proline 0 CA--C 1.54 0.578 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.357 -179.035 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -66.28 0.71 3.06 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.892 2.395 . . . . 0.0 112.105 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.1 t -103.36 -19.27 6.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.069 0.462 . . . . 0.0 110.35 -179.263 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -110.52 -41.35 4.36 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.949 179.647 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.04 -3.38 11.56 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 121.302 -0.475 . . . . 0.0 112.45 179.01 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.412 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.1 pt -146.02 -170.9 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-N 117.14 0.47 . . . . 0.0 110.617 179.597 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 28.0 m -92.14 142.09 27.88 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 120.959 0.409 . . . . 0.0 110.078 179.755 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.1 p -128.33 154.41 45.98 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.109 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 15.7 tt -57.34 133.06 22.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.668 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -92.84 163.93 13.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.727 -179.455 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.0 mt -64.46 -26.05 68.27 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.843 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.596 ' O ' ' NE2' ' A' ' 25' ' ' HIS . 73.6 m -56.38 -35.71 68.02 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.394 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.427 ' C ' ' O ' ' A' ' 21' ' ' SER . 6.3 tpm_? -36.94 -30.24 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.603 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.494 ' N ' ' O ' ' A' ' 21' ' ' SER . 33.8 mt -131.15 67.09 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.814 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -146.12 27.77 1.15 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.784 179.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.596 ' NE2' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -155.25 58.46 1.93 Allowed Pre-proline 0 C--N 1.324 -0.51 0 CA-C-O 121.229 0.538 . . . . 0.0 110.528 -179.369 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.62 -25.31 47.26 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.449 2.1 . . . . 0.0 111.987 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.91 -22.11 61.97 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -60.12 -40.99 91.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.659 0.266 . . . . 0.0 110.547 179.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -118.5 -107.98 0.37 Allowed 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.439 179.734 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 68.0 t0 -143.66 107.26 4.61 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.496 ' CD2' ' OXT' ' A' ' 31' ' ' TYR . 74.2 t80 . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.47 -179.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . 0.502 ' HG3' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.157 0 CA-C-O 118.31 -0.853 . . . . 0.0 111.046 . . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.3 t90 -63.68 132.75 52.04 Favored 'General case' 0 C--N 1.33 -0.282 0 O-C-N 124.24 0.962 . . . . 0.0 110.451 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.6 m -120.31 152.25 38.08 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.817 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -88.27 168.33 16.73 Favored Pre-proline 0 N--CA 1.45 -0.455 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.733 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -58.15 138.79 87.78 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 C-N-CA 122.526 2.151 . . . . 0.0 111.755 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.38 0.27 89.68 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.551 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.7 m-85 -123.27 164.43 18.79 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 121.168 0.508 . . . . 0.0 110.745 179.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -142.93 135.43 27.57 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.249 179.394 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.502 ' CD2' ' HG3' ' A' ' 1' ' ' PCA . 9.0 t80 -48.34 135.47 13.69 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.848 -179.634 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.483 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -119.13 94.81 48.76 Favored Pre-proline 0 CA--C 1.545 0.753 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.054 -179.597 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -74.22 -0.12 9.2 Favored 'Trans proline' 0 N--CA 1.493 1.452 0 C-N-CA 122.715 2.277 . . . . 0.0 112.503 -179.554 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 t -101.58 -18.62 6.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.885 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.422 ' CD1' ' C ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.34 -43.35 4.14 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.006 179.421 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.78 0.21 9.96 Favored Glycine 0 CA--C 1.535 1.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 112.56 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.483 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.7 pt -152.38 -170.48 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.281 0 CA-C-N 117.215 0.507 . . . . 0.0 110.258 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 18.7 m -91.13 141.93 28.28 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 120.999 0.428 . . . . 0.0 110.13 179.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.7 p -127.36 153.78 45.79 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.529 -0.76 . . . . 0.0 110.858 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.5 tt -57.23 131.81 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.422 -179.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -90.39 160.99 15.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.722 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.475 ' CD2' ' N ' ' A' ' 20' ' ' LEU . 4.2 mm? -67.26 -19.71 65.55 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.702 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.497 ' O ' ' ND2' ' A' ' 28' ' ' ASN . 99.0 p -62.62 -21.52 65.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.424 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 4.1 tmt_? -59.23 -36.45 75.47 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.368 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.466 ' CG2' ' N ' ' A' ' 24' ' ' GLU . 78.1 mt -61.77 -111.78 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.019 -179.327 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.568 ' O ' ' CG ' ' A' ' 25' ' ' HIS . 98.7 mt-10 -120.79 108.31 13.8 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.971 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.568 ' CG ' ' O ' ' A' ' 24' ' ' GLU . 63.1 m-70 -158.77 145.66 12.92 Favored Pre-proline 0 C--O 1.245 0.848 0 CA-C-O 120.915 0.388 . . . . 0.0 110.324 -179.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -68.37 -33.26 23.94 Favored 'Trans proline' 0 N--CA 1.492 1.386 0 C-N-CA 122.638 2.225 . . . . 0.0 112.379 179.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.53 -14.35 77.52 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.497 ' ND2' ' O ' ' A' ' 21' ' ' SER . 64.2 t30 -87.37 -48.37 8.03 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.751 0.31 . . . . 0.0 110.863 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -160.57 -33.14 0.05 Allowed 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.714 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 16.2 t0 63.38 72.37 0.48 Allowed 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.029 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.466 ' CD2' ' OXT' ' A' ' 31' ' ' TYR . 89.6 t80 . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.436 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . 0.493 ' HG3' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.171 0 CA-C-O 118.216 -0.897 . . . . 0.0 110.98 . . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 -68.35 131.21 44.93 Favored 'General case' 0 C--N 1.328 -0.367 0 O-C-N 124.237 0.961 . . . . 0.0 110.515 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.441 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.3 m -119.94 151.98 38.12 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.586 -179.855 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.43 168.81 17.14 Favored Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.845 179.302 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -58.45 138.92 88.43 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 122.624 2.216 . . . . 0.0 111.833 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.405 ' HA3' HH11 ' A' ' 22' ' ' ARG . . . 81.48 -0.24 88.18 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 179.602 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -122.33 166.33 14.86 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.043 0.449 . . . . 0.0 110.503 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.88 137.5 25.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.0 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.493 ' CD2' ' HG3' ' A' ' 1' ' ' PCA . 16.1 t80 -50.36 136.79 19.73 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.64 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.419 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -119.16 89.27 39.15 Favored Pre-proline 0 CA--C 1.543 0.699 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.524 -179.655 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -66.66 -0.14 4.19 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 122.964 2.443 . . . . 0.0 112.135 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.8 t -103.95 -18.89 6.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.9 0.381 . . . . 0.0 110.383 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.08 -42.12 4.51 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.629 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.25 -2.35 11.47 Favored Glycine 0 CA--C 1.536 1.367 0 CA-C-N 116.214 -0.448 . . . . 0.0 112.914 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.419 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.7 pt -149.33 -171.5 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 122.641 -0.329 . . . . 0.0 110.543 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.2 m -91.62 142.84 27.19 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-O 121.091 0.472 . . . . 0.0 110.297 179.782 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 66.4 p -129.1 154.84 46.3 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.444 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.3 tt -57.08 131.1 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.586 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.637 ' HG1' ' H ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -87.47 159.74 18.54 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.793 -179.994 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.4 mt -63.11 -27.14 69.18 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-O 121.111 0.482 . . . . 0.0 110.998 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.637 ' H ' ' HG1' ' A' ' 19' ' ' THR . 40.5 t -57.38 -36.96 71.92 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.261 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.405 HH11 ' HA3' ' A' ' 6' ' ' GLY . 11.7 tpt180 -43.19 -31.6 0.62 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.407 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.432 ' CG2' ' N ' ' A' ' 24' ' ' GLU . 96.7 mt -89.56 -98.21 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.742 179.786 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.432 ' N ' ' CG2' ' A' ' 23' ' ' ILE . 94.2 mt-10 -151.47 70.78 0.97 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.146 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -143.03 69.34 18.3 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.779 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.411 ' O ' ' N ' ' A' ' 30' ' ' ASP . 22.9 Cg_exo -63.28 -28.54 72.48 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 123.054 2.503 . . . . 0.0 112.129 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.88 -27.49 68.65 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -60.5 -39.43 87.7 Favored 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 121.049 -0.261 . . . . 0.0 110.988 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 79.1 m-85 -115.52 4.72 14.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.653 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.411 ' N ' ' O ' ' A' ' 26' ' ' PRO . 65.7 m-20 49.4 40.19 18.13 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.374 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 57.8 t80 . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.627 -179.888 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.391 -5.151 0 CA-C-O 118.267 -0.873 . . . . 0.0 111.223 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.0 t90 -62.18 132.36 52.5 Favored 'General case' 0 C--N 1.329 -0.326 0 O-C-N 124.311 1.007 . . . . 0.0 110.445 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.9 m -123.04 155.16 37.42 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.292 0.568 . . . . 0.0 111.107 -179.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.69 166.59 18.77 Favored Pre-proline 0 N--CA 1.449 -0.516 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.797 179.208 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -57.79 139.16 89.38 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 122.494 2.129 . . . . 0.0 111.911 179.573 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.78 1.67 90.29 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.748 -0.541 . . . . 0.0 111.748 179.481 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 18.9 m-85 -123.61 165.63 16.85 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.062 0.458 . . . . 0.0 110.415 179.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.68 134.59 28.84 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.225 179.614 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.498 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -49.1 135.31 16.5 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.639 -179.764 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.498 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -118.93 94.64 48.38 Favored Pre-proline 0 CA--C 1.546 0.794 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.807 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -74.25 -0.33 9.49 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.851 2.367 . . . . 0.0 112.249 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.7 t -101.99 -18.14 6.61 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.965 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.408 ' CD1' ' C ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.61 -43.65 4.02 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.376 179.455 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.69 1.12 9.94 Favored Glycine 0 CA--C 1.535 1.322 0 CA-C-N 116.049 -0.523 . . . . 0.0 112.908 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.476 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -153.07 -170.85 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.163 0 CA-C-N 117.055 0.427 . . . . 0.0 110.354 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 16.7 m -91.86 141.34 28.77 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-O 120.945 0.402 . . . . 0.0 110.24 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.0 p -127.99 153.0 47.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.615 -179.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.8 tt -53.66 141.03 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.799 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.346 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -97.16 163.22 13.01 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.847 -179.78 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -59.2 -19.03 41.85 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.52 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.416 ' O ' ' O ' ' A' ' 24' ' ' GLU . 75.1 m -60.33 -44.26 95.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.434 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 37.7 mtp180 -75.98 -30.91 58.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.623 179.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 47.5 mm -59.61 -46.94 92.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.539 -179.438 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.56 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 98.2 mt-10 -143.58 173.19 11.86 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.9 180.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.56 ' CD2' ' O ' ' A' ' 24' ' ' GLU . 1.9 p-80 35.49 57.08 2.63 Favored Pre-proline 0 CA--C 1.531 0.248 0 CA-C-O 120.992 0.425 . . . . 0.0 110.489 179.798 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -59.92 -28.09 86.37 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 C-N-CA 122.668 2.245 . . . . 0.0 111.885 -178.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -62.28 -39.22 97.43 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 179.67 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 67.0 m-80 51.65 39.81 25.93 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.784 0.326 . . . . 0.0 110.691 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 55.64 24.95 7.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.594 179.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.524 ' O ' ' CD2' ' A' ' 31' ' ' TYR . 67.2 m-20 48.11 37.33 7.8 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.724 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.524 ' CD2' ' O ' ' A' ' 30' ' ' ASP . 9.9 m-85 . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.545 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . 0.479 ' HG3' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.15 0 CA-C-O 118.248 -0.882 . . . . 0.0 111.02 . . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 -65.86 132.87 49.7 Favored 'General case' 0 C--N 1.329 -0.318 0 O-C-N 124.275 0.984 . . . . 0.0 110.394 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.8 m -118.08 152.26 35.92 Favored 'General case' 0 CA--C 1.52 -0.202 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.568 -179.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -89.53 169.27 13.07 Favored Pre-proline 0 N--CA 1.451 -0.404 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 -179.436 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -57.79 139.23 89.6 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 121.939 1.759 . . . . 0.0 111.779 179.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.88 1.18 90.18 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.416 -0.674 . . . . 0.0 111.416 179.267 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.8 m-85 -124.23 164.28 19.85 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.273 0.559 . . . . 0.0 110.525 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.68 137.37 26.55 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.164 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.479 ' CD2' ' HG3' ' A' ' 1' ' ' PCA . 18.8 t80 -50.8 137.86 19.66 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 120.478 -0.489 . . . . 0.0 110.681 -179.321 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.405 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -119.37 88.39 37.98 Favored Pre-proline 0 CA--C 1.538 0.511 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.504 -179.209 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -66.62 0.52 3.45 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.705 2.27 . . . . 0.0 112.189 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.0 t -103.3 -19.24 6.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.952 0.406 . . . . 0.0 110.282 -179.294 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.56 -41.66 4.52 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.143 179.491 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.49 -2.38 12.44 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-N 116.068 -0.515 . . . . 0.0 112.312 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.405 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -147.87 -172.45 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 117.707 0.753 . . . . 0.0 110.25 179.58 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.5 m -90.63 142.48 27.71 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.254 0.549 . . . . 0.0 109.592 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.7 p -128.96 154.1 46.91 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.641 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.9 tt -57.22 131.82 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-O 120.991 0.424 . . . . 0.0 110.547 -179.489 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -89.55 160.98 16.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.78 -179.613 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 8.8 mp -62.45 -23.97 67.18 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.892 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 43.5 t -53.07 -37.17 61.43 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.575 -179.419 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.409 ' O ' ' O ' ' A' ' 23' ' ' ILE . 0.0 OUTLIER -56.07 -39.99 72.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.257 -179.831 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.409 ' O ' ' O ' ' A' ' 22' ' ' ARG . 50.2 mm -45.67 -94.46 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.617 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -145.71 38.87 1.13 Allowed 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.551 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 90.7 m-70 -133.57 59.99 44.01 Favored Pre-proline 0 N--CA 1.461 0.121 0 C-N-CA 120.486 -0.486 . . . . 0.0 110.713 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -75.29 -18.37 18.18 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.745 2.296 . . . . 0.0 112.541 179.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -58.41 -38.53 90.98 Favored Glycine 0 CA--C 1.52 0.395 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.176 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -60.41 -36.93 79.3 Favored 'General case' 0 C--N 1.321 -0.666 0 C-N-CA 121.158 -0.217 . . . . 0.0 110.631 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -113.82 31.4 6.55 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.269 -179.016 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 59.0 p30 -92.88 7.5 43.61 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.936 -0.305 . . . . 0.0 110.575 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.476 ' CD2' ' OXT' ' A' ' 31' ' ' TYR . 55.6 t80 . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.676 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.393 -5.094 0 CA-C-O 118.161 -0.923 . . . . 0.0 111.026 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.2 t90 -65.89 129.98 41.68 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 124.29 0.994 . . . . 0.0 110.453 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 97.5 m -123.56 149.39 45.34 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-O 121.403 0.62 . . . . 0.0 111.109 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.78 160.73 81.33 Favored Pre-proline 0 N--CA 1.442 -0.846 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.252 179.306 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -64.46 138.51 60.33 Favored 'Trans proline' 0 C--N 1.302 -1.883 0 C-N-CA 122.429 2.086 . . . . 0.0 111.929 -179.665 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.61 -7.89 80.95 Favored Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 -179.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 15.6 m-85 -115.19 167.91 10.41 Favored 'General case' 0 CA--C 1.522 -0.129 0 CA-C-O 121.131 0.491 . . . . 0.0 110.5 179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -139.04 134.08 32.52 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.171 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.456 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 9.3 t80 -50.87 135.39 24.31 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.692 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.456 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -119.12 95.52 49.4 Favored Pre-proline 0 CA--C 1.545 0.777 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.927 -179.573 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -75.04 0.71 8.6 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.857 2.371 . . . . 0.0 112.35 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 36.3 t -103.0 -17.82 6.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.995 -179.762 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -110.32 -43.18 3.96 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.598 179.411 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.05 2.29 11.16 Favored Glycine 0 CA--C 1.535 1.333 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.882 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.446 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.2 pt -153.65 -174.21 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.232 0 CA-C-N 117.314 0.557 . . . . 0.0 110.121 179.67 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 3.9 m -88.29 139.99 29.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.04 0.447 . . . . 0.0 110.535 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.8 p -126.21 152.95 45.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.521 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.5 tt -58.0 133.59 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.433 -179.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -85.19 152.24 23.5 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.788 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 8.0 mp -57.43 -27.55 62.51 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.601 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.511 ' OG ' ' CE2' ' A' ' 29' ' ' TYR . 70.5 m -58.49 -44.09 89.25 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.189 -179.385 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 73.3 ttt180 -70.59 -35.85 73.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.057 0.455 . . . . 0.0 110.149 179.168 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 40.0 mm -59.66 -49.55 83.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.053 -178.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.493 ' C ' ' CD2' ' A' ' 25' ' ' HIS . 35.9 mt-10 -157.22 -167.64 2.38 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.701 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.493 ' CD2' ' C ' ' A' ' 24' ' ' GLU . 1.6 m-70 58.87 55.65 5.52 Favored Pre-proline 0 CA--C 1.542 0.659 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.831 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.547 ' O ' ' N ' ' A' ' 30' ' ' ASP . 31.3 Cg_exo -58.94 -40.15 74.36 Favored 'Trans proline' 0 N--CA 1.497 1.698 0 C-N-CA 122.272 1.981 . . . . 0.0 112.166 -179.551 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.33 -39.66 91.83 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 111.774 -0.53 . . . . 0.0 111.774 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -61.05 -40.06 92.22 Favored 'General case' 0 CA--C 1.52 -0.195 0 C-N-CA 121.007 -0.277 . . . . 0.0 111.009 -179.264 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.511 ' CE2' ' OG ' ' A' ' 21' ' ' SER . 82.7 m-85 -112.55 11.33 19.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.829 -179.864 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.547 ' N ' ' O ' ' A' ' 26' ' ' PRO . 54.2 t0 49.37 44.51 23.73 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.552 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.527 ' CD2' ' O ' ' A' ' 31' ' ' TYR . 90.7 t80 . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.577 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.2 t90 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.632 0.253 . . . . 0.0 110.335 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.9 m -119.7 151.56 38.54 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.471 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.51 169.75 14.29 Favored Pre-proline 0 N--CA 1.452 -0.369 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.742 -179.519 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_exo -58.94 139.24 90.0 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 122.109 1.873 . . . . 0.0 111.795 179.68 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.534 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.52 -0.02 88.53 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 179.296 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -122.21 165.64 15.84 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.139 0.495 . . . . 0.0 110.542 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -146.01 138.44 25.45 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.078 179.52 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.3 t80 -50.09 137.36 17.64 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.557 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.43 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.7 t-20 -118.83 88.84 36.7 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.455 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -66.82 -0.06 4.21 Favored 'Trans proline' 0 N--CA 1.496 1.623 0 C-N-CA 122.732 2.288 . . . . 0.0 112.103 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 19.3 t -103.05 -19.01 6.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.874 0.369 . . . . 0.0 110.471 -179.225 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.803 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -110.03 -41.36 4.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.902 179.416 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.79 -2.92 11.96 Favored Glycine 0 CA--C 1.535 1.288 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.42 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.43 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.2 pt -147.21 -169.55 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 117.5 0.65 . . . . 0.0 110.342 179.599 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 23.6 m -91.76 142.08 27.98 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 121.197 0.523 . . . . 0.0 109.85 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.8 p -129.24 154.73 46.52 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.573 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.413 ' O ' HG23 ' A' ' 18' ' ' ILE . 12.6 tt -57.81 132.1 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-O 121.189 0.519 . . . . 0.0 110.572 -179.681 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.534 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -85.04 152.9 23.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.574 -179.803 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.475 ' N ' HD12 ' A' ' 20' ' ' LEU . 11.2 mp . . . . . 0 N--CA 1.452 -0.338 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.645 0.26 . . . . 0.0 110.6 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 77.0 m -120.88 151.58 39.48 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.841 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -88.04 167.04 21.15 Favored Pre-proline 0 N--CA 1.45 -0.474 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.635 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -58.04 139.13 89.31 Favored 'Trans proline' 0 N--CA 1.493 1.482 0 C-N-CA 122.573 2.182 . . . . 0.0 111.87 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.479 ' O ' HG22 ' A' ' 19' ' ' THR . . . 85.66 -4.38 85.85 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -119.63 164.53 15.74 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.067 0.461 . . . . 0.0 110.632 179.734 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -140.51 132.83 28.29 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.298 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.48 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -48.38 134.5 14.95 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.707 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.48 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.5 t-20 -118.01 94.57 46.73 Favored Pre-proline 0 CA--C 1.545 0.752 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.951 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -74.39 0.45 8.56 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.963 2.442 . . . . 0.0 112.33 -179.613 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.8 t -102.74 -19.05 6.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.924 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.8 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -108.65 -43.9 4.17 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.511 179.435 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.77 1.8 9.67 Favored Glycine 0 CA--C 1.534 1.269 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.719 179.328 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.465 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -153.81 -173.49 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.235 0 CA-C-N 117.061 0.431 . . . . 0.0 110.408 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.5 m -89.43 140.97 28.99 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-O 120.884 0.373 . . . . 0.0 110.287 179.613 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.2 p -127.91 152.45 47.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.531 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 tt -58.42 133.06 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.262 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.479 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -84.04 142.88 30.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.63 -179.935 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 6.8 mp . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.89 180.0 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.1 t90 . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.674 0.274 . . . . 0.0 110.454 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.42 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 74.1 m -122.28 153.58 38.72 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.245 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -89.05 168.3 15.84 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.902 -179.488 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -57.64 138.11 84.52 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.678 2.252 . . . . 0.0 111.654 179.697 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.479 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.13 1.47 90.35 Favored Glycine 0 CA--C 1.528 0.857 0 N-CA-C 111.206 -0.758 . . . . 0.0 111.206 179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.8 m-85 -125.22 163.23 22.94 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.13 0.49 . . . . 0.0 110.602 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -143.17 135.82 27.56 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.134 179.528 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.42 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 16.1 t80 -48.36 136.96 11.79 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.601 -179.594 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.457 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.7 t-20 -118.58 89.25 36.56 Favored Pre-proline 0 CA--C 1.54 0.568 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.637 -179.605 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -67.02 -0.02 4.3 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 122.907 2.405 . . . . 0.0 112.051 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.0 t -103.49 -17.94 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 CA-C-O 120.94 0.4 . . . . 0.0 110.317 -179.316 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.808 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -111.09 -42.65 3.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.4 179.566 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.57 -2.1 10.26 Favored Glycine 0 CA--C 1.534 1.224 0 CA-C-N 116.113 -0.494 . . . . 0.0 112.432 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.457 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.0 pt -149.92 -173.07 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.917 0.358 . . . . 0.0 110.592 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.9 m -89.27 142.34 27.74 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 120.946 0.403 . . . . 0.0 110.332 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 65.0 p -129.6 150.9 50.73 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.515 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 tt -51.83 137.72 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.149 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.479 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -101.06 169.66 8.79 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.062 -179.328 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.414 ' N ' ' OG1' ' A' ' 19' ' ' THR . 4.8 tt . . . . . 0 N--CA 1.451 -0.396 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.17 179.444 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.6 t90 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.645 0.26 . . . . 0.0 110.452 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.414 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 73.4 m -119.44 151.12 39.07 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.566 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.34 169.02 16.36 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.822 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.93 138.92 88.45 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.539 2.159 . . . . 0.0 111.879 179.554 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.437 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.98 0.06 89.09 Favored Glycine 0 CA--C 1.529 0.912 0 N-CA-C 111.359 -0.697 . . . . 0.0 111.359 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -123.9 164.36 19.43 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.073 0.463 . . . . 0.0 110.601 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.89 136.25 25.22 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.235 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.414 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 17.7 t80 -48.6 136.91 12.56 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.553 -179.6 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.421 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.6 t-20 -119.1 89.22 38.81 Favored Pre-proline 0 CA--C 1.54 0.59 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.539 -179.541 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -66.67 -0.08 4.12 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 122.915 2.41 . . . . 0.0 112.08 -179.616 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.4 t -103.53 -19.89 5.99 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 120.895 0.379 . . . . 0.0 110.303 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.791 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -108.4 -42.04 4.69 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.624 179.413 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.92 -1.72 11.87 Favored Glycine 0 CA--C 1.534 1.28 0 CA-C-N 116.035 -0.529 . . . . 0.0 112.543 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.421 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 4.7 pt -149.66 -172.9 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 117.094 0.447 . . . . 0.0 110.556 179.797 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.5 m -88.94 141.77 28.21 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.061 0.458 . . . . 0.0 110.404 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.6 p -128.69 152.69 48.11 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.542 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.407 ' O ' HG23 ' A' ' 18' ' ' ILE . 10.7 tt -55.25 132.3 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.348 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.437 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -94.01 166.76 11.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.903 -179.667 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.0 mt . . . . . 0 N--CA 1.449 -0.516 0 CA-C-O 121.192 0.52 . . . . 0.0 110.861 179.708 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.8 t90 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.694 0.283 . . . . 0.0 110.555 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 93.3 m -123.45 148.93 45.69 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.986 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -69.95 161.97 71.61 Favored Pre-proline 0 N--CA 1.446 -0.67 0 CA-C-N 115.549 -0.751 . . . . 0.0 109.979 179.77 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -64.42 139.63 65.89 Favored 'Trans proline' 0 C--N 1.3 -2.001 0 C-N-CA 122.212 1.941 . . . . 0.0 111.904 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.461 ' O ' HG22 ' A' ' 19' ' ' THR . . . 84.88 -2.83 87.98 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 -179.301 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -119.29 166.71 12.66 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 121.006 0.432 . . . . 0.0 110.497 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.69 137.45 31.74 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.097 179.485 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 19.2 t80 -52.04 137.04 28.19 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.412 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.403 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.7 t-20 -118.57 89.44 37.03 Favored Pre-proline 0 CA--C 1.539 0.53 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.38 -179.165 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -67.57 -0.02 4.69 Favored 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 122.721 2.28 . . . . 0.0 112.039 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 23.0 t -102.68 -18.69 6.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.507 -179.125 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.805 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -110.65 -41.37 4.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.79 179.67 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 119.97 -1.57 13.32 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-N 116.085 -0.507 . . . . 0.0 112.403 179.226 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.403 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -148.17 -172.72 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 117.484 0.642 . . . . 0.0 110.252 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.9 m -90.5 140.56 29.62 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.106 0.479 . . . . 0.0 109.956 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.0 p -127.36 152.53 47.36 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.315 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.2 tt -57.65 135.05 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 CA-C-O 121.139 0.495 . . . . 0.0 110.539 -179.646 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.461 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -86.93 141.75 28.49 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.319 -179.788 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.795 HD23 ' O ' ' A' ' 20' ' ' LEU . 3.3 tt . . . . . 0 N--CA 1.448 -0.526 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.248 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.8 t90 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.596 0.236 . . . . 0.0 110.527 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.4 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 76.1 m -118.92 153.08 35.16 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 121.184 0.516 . . . . 0.0 110.926 -179.716 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.79 168.51 15.56 Favored Pre-proline 0 N--CA 1.452 -0.364 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.995 179.158 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -58.8 138.55 86.35 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 C-N-CA 122.675 2.25 . . . . 0.0 111.78 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.559 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.02 -0.81 88.16 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.451 -0.66 . . . . 0.0 111.451 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -121.2 166.07 14.51 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-O 120.916 0.388 . . . . 0.0 110.679 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.21 136.59 26.64 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.899 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.486 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 8.4 t80 -49.46 135.48 17.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.755 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.486 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.6 t-20 -119.38 94.92 48.93 Favored Pre-proline 0 CA--C 1.547 0.83 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.882 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -73.63 0.02 8.72 Favored 'Trans proline' 0 N--CA 1.492 1.441 0 C-N-CA 123.182 2.588 . . . . 0.0 112.427 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.5 t -103.29 -17.75 6.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.449 . . . . 0.0 109.985 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.771 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.97 -42.47 4.21 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 179.769 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.44 -0.18 11.3 Favored Glycine 0 CA--C 1.536 1.383 0 CA-C-N 116.253 -0.431 . . . . 0.0 113.185 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.474 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.8 pt -152.4 -170.77 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 O-C-N 122.493 -0.416 . . . . 0.0 110.387 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.9 m -90.89 142.67 27.52 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 120.979 0.418 . . . . 0.0 110.322 179.57 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.4 p -128.0 157.37 40.8 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.654 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.43 ' O ' HG23 ' A' ' 18' ' ' ILE . 14.1 tt -59.75 131.68 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.362 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.559 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -87.48 156.15 19.68 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.562 179.983 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.446 HD22 ' N ' ' A' ' 20' ' ' LEU . 4.3 mm? . . . . . 0 C--N 1.326 -0.439 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.641 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.1 t90 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.6 0.238 . . . . 0.0 110.418 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.6 m -120.28 154.4 35.01 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.899 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.3 168.94 13.15 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.78 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -59.14 139.05 88.69 Favored 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 122.521 2.147 . . . . 0.0 111.73 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.499 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.07 0.07 89.2 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.427 -0.669 . . . . 0.0 111.427 179.426 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -122.17 165.11 16.65 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-O 121.168 0.508 . . . . 0.0 110.662 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -142.74 135.29 27.77 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.113 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.462 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 9.1 t80 -49.0 135.04 16.41 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.744 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.485 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.6 t-20 -118.38 94.79 47.74 Favored Pre-proline 0 CA--C 1.544 0.747 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.995 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -74.42 0.3 8.77 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 C-N-CA 122.807 2.338 . . . . 0.0 112.41 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.4 t -102.19 -18.43 6.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.838 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.818 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.72 -43.77 3.97 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.73 179.478 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 123.23 0.96 9.5 Favored Glycine 0 CA--C 1.535 1.309 0 CA-C-N 116.081 -0.509 . . . . 0.0 112.61 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.485 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -152.92 -170.61 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.274 0 CA-C-N 117.113 0.457 . . . . 0.0 110.298 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 15.2 m -91.03 141.53 28.74 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 120.916 0.389 . . . . 0.0 110.196 179.6 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 79.7 p -127.71 152.68 47.41 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.679 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.2 tt -56.76 133.83 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.582 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.349 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.499 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -87.88 147.56 25.04 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.683 -179.83 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.863 HD23 ' O ' ' A' ' 20' ' ' LEU . 5.3 tt . . . . . 0 N--CA 1.45 -0.437 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.468 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.6 t90 . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.607 0.241 . . . . 0.0 110.406 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.404 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 73.5 m -120.3 150.59 40.47 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.479 0.657 . . . . 0.0 110.805 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.66 168.1 23.0 Favored Pre-proline 0 CA--C 1.533 0.3 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.601 -179.504 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -59.03 137.87 82.18 Favored 'Trans proline' 0 N--CA 1.492 1.422 0 C-N-CA 122.513 2.142 . . . . 0.0 111.828 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.575 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.51 1.31 90.07 Favored Glycine 0 CA--C 1.528 0.879 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 179.413 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -121.58 165.78 15.18 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-O 121.111 0.481 . . . . 0.0 110.546 179.694 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -143.66 135.64 26.58 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.149 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.476 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 8.4 t80 -48.22 134.69 14.22 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.752 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.491 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.6 t-20 -118.48 94.84 47.99 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.906 -179.667 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -74.25 -0.61 9.85 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.849 2.366 . . . . 0.0 112.348 -179.65 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.6 t -101.43 -18.0 6.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.946 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.796 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.85 -43.31 4.04 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.384 179.515 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.98 0.19 9.78 Favored Glycine 0 CA--C 1.533 1.172 0 CA-C-N 116.109 -0.496 . . . . 0.0 112.725 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.491 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.6 pt -152.67 -169.86 0.1 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.263 0 CA-C-N 117.096 0.448 . . . . 0.0 110.234 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 21.6 m -91.55 142.16 27.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.891 0.377 . . . . 0.0 110.219 179.597 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.6 p -127.2 154.48 44.76 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.63 -179.778 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt -56.84 132.66 21.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.379 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.575 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.1 OUTLIER -92.51 160.18 15.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.692 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 38.7 tp . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.418 179.81 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.0 t90 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.586 0.231 . . . . 0.0 110.431 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.408 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.3 m -120.27 153.35 36.5 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.972 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -89.66 168.1 15.77 Favored Pre-proline 0 C--N 1.327 -0.4 0 O-C-N 123.107 0.255 . . . . 0.0 110.874 -179.529 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_exo -57.75 139.06 89.02 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.47 2.113 . . . . 0.0 111.722 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.463 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.76 0.32 89.21 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 179.579 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -124.06 165.24 17.84 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.107 0.479 . . . . 0.0 110.66 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.63 137.07 26.42 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.231 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.408 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 17.7 t80 -49.82 137.57 16.18 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.657 -179.543 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.445 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.6 t-20 -119.42 89.01 39.57 Favored Pre-proline 0 CA--C 1.541 0.634 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.414 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_exo -66.37 -0.56 4.41 Favored 'Trans proline' 0 N--CA 1.496 1.623 0 C-N-CA 122.932 2.421 . . . . 0.0 112.132 -179.715 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.0 t -103.08 -19.71 6.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.952 0.406 . . . . 0.0 110.416 -179.339 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.808 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -108.53 -41.68 4.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.664 179.349 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.62 -3.2 11.07 Favored Glycine 0 CA--C 1.533 1.216 0 CA-C-N 116.029 -0.532 . . . . 0.0 112.415 179.344 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.445 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -148.35 -171.28 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-N 117.042 0.421 . . . . 0.0 110.556 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 15.7 m -90.88 143.12 27.05 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.109 0.481 . . . . 0.0 110.392 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -129.69 152.96 48.62 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.583 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.5 tt -55.17 134.26 18.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.187 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.463 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -90.22 167.96 12.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.068 -179.494 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.522 HD22 ' N ' ' A' ' 20' ' ' LEU . 4.1 mm? . . . . . 0 N--CA 1.451 -0.393 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.521 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.6 t90 . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.717 0.294 . . . . 0.0 110.492 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.402 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.2 m -120.03 148.83 43.08 Favored 'General case' 0 CA--C 1.516 -0.329 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.708 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.44 168.0 26.4 Favored Pre-proline 0 N--CA 1.452 -0.327 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.901 179.809 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo -58.65 138.89 88.28 Favored 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 122.485 2.124 . . . . 0.0 111.739 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.534 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.44 0.61 89.36 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.398 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -122.57 166.28 15.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.097 0.475 . . . . 0.0 110.484 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.65 138.39 25.89 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.172 179.662 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.402 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 17.4 t80 -50.43 136.76 20.04 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.508 -179.619 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.43 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.6 t-20 -118.76 89.24 37.37 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.592 -179.473 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -66.44 -0.04 3.93 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 C-N-CA 122.83 2.353 . . . . 0.0 112.375 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 t -103.8 -19.1 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.02 0.438 . . . . 0.0 110.363 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.816 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -109.54 -40.71 4.78 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.697 179.531 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.41 -3.38 12.41 Favored Glycine 0 CA--C 1.534 1.26 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.424 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.43 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -147.54 -171.25 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-N 117.149 0.474 . . . . 0.0 110.42 179.799 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 23.7 m -90.38 142.3 27.87 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-O 121.179 0.514 . . . . 0.0 110.136 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -129.17 155.21 45.87 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.588 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.415 ' O ' HG23 ' A' ' 18' ' ' ILE . 10.9 tt -56.82 132.35 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.726 0 CA-C-O 121.076 0.465 . . . . 0.0 110.681 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.534 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -87.06 160.56 18.55 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.724 -179.932 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.3 tt . . . . . 0 C--N 1.327 -0.404 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.821 179.779 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.3 t90 . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.71 0.29 . . . . 0.0 110.508 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.42 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 78.0 m -123.31 153.52 40.15 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.671 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.68 168.12 16.81 Favored Pre-proline 0 N--CA 1.452 -0.344 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.788 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_exo -56.64 138.86 86.57 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.075 1.85 . . . . 0.0 111.792 179.539 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.459 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.35 0.01 89.41 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 179.328 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -123.95 163.84 20.51 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.297 0.57 . . . . 0.0 110.56 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.39 136.94 26.7 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.086 179.438 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.42 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.6 t80 -50.29 137.22 18.7 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.615 -179.281 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.401 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.7 t-20 -118.74 88.41 35.13 Favored Pre-proline 0 CA--C 1.539 0.545 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.555 -179.199 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -66.39 0.15 3.7 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 122.753 2.302 . . . . 0.0 112.252 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.3 t -103.49 -18.78 6.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.976 0.417 . . . . 0.0 110.281 -179.349 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.799 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -109.82 -41.44 4.51 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.794 179.488 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.47 -3.03 12.4 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-N 116.118 -0.492 . . . . 0.0 112.525 179.156 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.401 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.1 pt -147.69 -172.82 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 117.52 0.66 . . . . 0.0 110.327 179.634 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 25.4 m -90.23 141.14 29.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-O 121.135 0.493 . . . . 0.0 109.922 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.7 p -127.97 153.95 46.14 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.635 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.418 ' O ' HG23 ' A' ' 18' ' ' ILE . 9.9 tt -57.31 131.93 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.504 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.459 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -90.58 164.76 14.08 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.726 -179.691 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.415 ' HA ' HD23 ' A' ' 20' ' ' LEU . 94.1 mt . . . . . 0 N--CA 1.449 -0.492 0 CA-C-O 121.071 0.462 . . . . 0.0 111.106 179.793 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.8 t90 . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.648 0.261 . . . . 0.0 110.507 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.438 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 71.7 m -121.88 153.14 38.82 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.141 0.496 . . . . 0.0 110.568 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.13 167.77 22.23 Favored Pre-proline 0 N--CA 1.451 -0.405 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.85 179.45 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -58.15 138.61 86.83 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.513 2.142 . . . . 0.0 111.85 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.536 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.18 -0.99 88.2 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.468 -0.653 . . . . 0.0 111.468 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.1 m-85 -121.91 165.32 16.12 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.024 0.44 . . . . 0.0 110.54 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.84 135.91 24.95 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.214 179.615 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.438 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.0 t80 -48.96 137.28 13.09 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.518 -179.668 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.425 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.7 t-20 -119.04 88.79 37.58 Favored Pre-proline 0 CA--C 1.543 0.7 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.468 -179.484 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_exo -66.11 -0.16 3.83 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.835 2.357 . . . . 0.0 112.213 -179.646 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.7 t -103.78 -19.72 6.1 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.318 0 CA-C-O 120.908 0.385 . . . . 0.0 110.246 -179.101 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.777 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -108.53 -41.99 4.67 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.371 179.458 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.0 -3.05 11.65 Favored Glycine 0 CA--C 1.537 1.412 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.779 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.425 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -148.34 -173.5 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 117.126 0.463 . . . . 0.0 110.588 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 21.2 m -89.46 141.28 28.71 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.002 0.429 . . . . 0.0 110.35 179.722 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -128.64 153.89 46.81 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.574 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.3 tt -56.38 132.61 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.345 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.536 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -88.76 153.75 20.83 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.18 -179.782 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.4 tt . . . . . 0 C--N 1.325 -0.458 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.34 179.549 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.4 t90 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.594 0.235 . . . . 0.0 110.38 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 79.7 m -120.15 150.73 40.15 Favored 'General case' 0 CA--C 1.519 -0.224 0 CA-C-O 121.216 0.531 . . . . 0.0 110.805 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.23 166.35 28.94 Favored Pre-proline 0 N--CA 1.448 -0.557 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.574 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -58.96 139.73 92.17 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 122.478 2.118 . . . . 0.0 111.841 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.574 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.47 0.01 89.53 Favored Glycine 0 CA--C 1.53 0.997 0 N-CA-C 111.697 -0.561 . . . . 0.0 111.697 179.4 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -121.71 166.47 14.25 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.97 0.414 . . . . 0.0 110.38 179.639 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.5 135.15 29.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.215 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.49 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -50.2 134.73 22.21 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.657 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.49 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.5 t-20 -118.05 94.98 47.59 Favored Pre-proline 0 CA--C 1.546 0.813 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.923 -179.621 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -74.6 0.63 8.45 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 C-N-CA 122.911 2.407 . . . . 0.0 112.443 -179.716 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 26.9 t -102.85 -18.87 6.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.926 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.794 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -108.75 -43.54 4.23 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.469 179.452 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.98 -0.0 9.79 Favored Glycine 0 CA--C 1.535 1.342 0 CA-C-N 116.065 -0.516 . . . . 0.0 112.853 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.477 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -152.38 -170.53 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.165 0 CA-C-N 117.069 0.435 . . . . 0.0 110.339 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.6 m -91.03 142.13 28.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.954 0.406 . . . . 0.0 110.28 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.4 p -128.88 151.99 49.01 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.605 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.7 tt -52.83 139.42 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.477 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.574 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -95.5 169.66 9.89 Favored 'General case' 0 C--O 1.241 0.635 0 CA-C-O 121.246 0.546 . . . . 0.0 111.036 -179.944 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.416 HD13 ' HA ' ' A' ' 20' ' ' LEU . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.841 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.1 t90 . . . . . 0 C--O 1.231 0.091 0 N-CA-C 110.21 -0.293 . . . . 0.0 110.21 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.44 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.5 m -119.01 150.56 39.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.671 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.4 168.55 18.33 Favored Pre-proline 0 N--CA 1.451 -0.381 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.668 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -57.94 138.56 86.63 Favored 'Trans proline' 0 N--CA 1.496 1.643 0 C-N-CA 122.115 1.877 . . . . 0.0 111.8 179.665 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.529 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.87 1.31 90.21 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 179.195 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 20.0 m-85 -123.75 165.54 17.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.272 0.558 . . . . 0.0 110.568 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.29 138.2 26.23 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.076 179.325 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.44 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.8 t80 -50.81 137.31 20.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.509 -179.339 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.415 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.7 t-20 -118.77 88.3 34.99 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.311 -179.134 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_exo -66.2 0.27 3.46 Favored 'Trans proline' 0 N--CA 1.495 1.562 0 C-N-CA 122.771 2.314 . . . . 0.0 112.305 -179.626 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.8 t -103.08 -19.84 5.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.917 0.389 . . . . 0.0 110.441 -179.478 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.816 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.24 -41.23 4.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.136 179.464 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.04 -3.0 11.62 Favored Glycine 0 CA--C 1.533 1.188 0 CA-C-N 116.208 -0.451 . . . . 0.0 112.228 178.727 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.415 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -147.61 -171.95 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 117.469 0.634 . . . . 0.0 110.262 179.7 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 24.0 m -90.85 142.41 27.79 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.259 0.552 . . . . 0.0 109.845 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.7 p -128.68 154.35 46.38 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.692 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.443 ' O ' HG23 ' A' ' 18' ' ' ILE . 10.4 tt -57.31 131.11 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.805 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.529 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -88.27 154.45 20.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.85 -179.938 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 2.7 mm? . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.407 179.868 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.1 t90 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.651 0.262 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.414 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 75.4 m -120.34 153.08 36.96 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.363 -179.815 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -87.55 170.67 11.3 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.487 -179.681 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_exo -59.18 139.25 89.45 Favored 'Trans proline' 0 C--N 1.311 -1.406 0 C-N-CA 121.946 1.764 . . . . 0.0 111.855 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.516 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.43 -0.05 88.39 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 179.098 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -122.3 164.88 17.13 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.008 0.432 . . . . 0.0 110.448 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.54 139.5 28.23 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.648 179.385 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.414 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 20.3 t80 -52.24 137.99 27.29 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.973 0.416 . . . . 0.0 110.575 -179.422 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.412 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.8 t-20 -119.16 87.91 35.91 Favored Pre-proline 0 CA--C 1.54 0.578 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.357 -179.035 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -66.28 0.71 3.06 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.892 2.395 . . . . 0.0 112.105 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.1 t -103.36 -19.27 6.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.069 0.462 . . . . 0.0 110.35 -179.263 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.811 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -110.52 -41.35 4.36 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.949 179.647 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.04 -3.38 11.56 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 121.302 -0.475 . . . . 0.0 112.45 179.01 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.412 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.1 pt -146.02 -170.9 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-N 117.14 0.47 . . . . 0.0 110.617 179.597 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 28.0 m -92.14 142.09 27.88 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 120.959 0.409 . . . . 0.0 110.078 179.755 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.1 p -128.33 154.41 45.98 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.109 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 15.7 tt -57.34 133.06 22.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.668 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.516 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -92.84 163.93 13.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.727 -179.455 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.0 mt . . . . . 0 N--CA 1.449 -0.51 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.843 179.894 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.3 t90 . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.568 0.223 . . . . 0.0 110.451 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.6 m -120.31 152.25 38.08 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.817 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -88.27 168.33 16.73 Favored Pre-proline 0 N--CA 1.45 -0.455 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.733 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -58.15 138.79 87.78 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 C-N-CA 122.526 2.151 . . . . 0.0 111.755 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.466 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.38 0.27 89.68 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.7 m-85 -123.27 164.43 18.79 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 121.168 0.508 . . . . 0.0 110.745 179.744 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -142.93 135.43 27.57 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.249 179.394 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.483 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 9.0 t80 -48.34 135.47 13.69 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.848 -179.634 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.483 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.6 t-20 -119.13 94.81 48.76 Favored Pre-proline 0 CA--C 1.545 0.753 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.054 -179.597 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -74.22 -0.12 9.2 Favored 'Trans proline' 0 N--CA 1.493 1.452 0 C-N-CA 122.715 2.277 . . . . 0.0 112.503 -179.554 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 t -101.58 -18.62 6.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.885 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.818 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.34 -43.35 4.14 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.006 179.421 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.78 0.21 9.96 Favored Glycine 0 CA--C 1.535 1.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 112.56 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.483 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.7 pt -152.38 -170.48 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.281 0 CA-C-N 117.215 0.507 . . . . 0.0 110.258 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 18.7 m -91.13 141.93 28.28 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 120.999 0.428 . . . . 0.0 110.13 179.435 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.7 p -127.36 153.78 45.79 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.529 -0.76 . . . . 0.0 110.858 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.411 ' O ' HG23 ' A' ' 18' ' ' ILE . 10.5 tt -57.23 131.81 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.422 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.466 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -90.39 160.99 15.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.722 -179.903 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.514 HD22 ' N ' ' A' ' 20' ' ' LEU . 4.2 mm? . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.702 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.607 0.241 . . . . 0.0 110.515 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.441 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.3 m -119.94 151.98 38.12 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.586 -179.855 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.43 168.81 17.14 Favored Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.845 179.302 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -58.45 138.92 88.43 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 122.624 2.216 . . . . 0.0 111.833 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.537 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.48 -0.24 88.18 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 179.602 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -122.33 166.33 14.86 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.043 0.449 . . . . 0.0 110.503 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.88 137.5 25.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.0 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.441 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 16.1 t80 -50.36 136.79 19.73 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.64 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.419 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.6 t-20 -119.16 89.27 39.15 Favored Pre-proline 0 CA--C 1.543 0.699 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.524 -179.655 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -66.66 -0.14 4.19 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 122.964 2.443 . . . . 0.0 112.135 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.8 t -103.95 -18.89 6.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.9 0.381 . . . . 0.0 110.383 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.775 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.08 -42.12 4.51 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.629 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.25 -2.35 11.47 Favored Glycine 0 CA--C 1.536 1.367 0 CA-C-N 116.214 -0.448 . . . . 0.0 112.914 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.419 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.7 pt -149.33 -171.5 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 122.641 -0.329 . . . . 0.0 110.543 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.2 m -91.62 142.84 27.19 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-O 121.091 0.472 . . . . 0.0 110.297 179.782 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 66.4 p -129.1 154.84 46.3 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.444 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.449 ' O ' HG23 ' A' ' 18' ' ' ILE . 14.3 tt -57.08 131.1 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.586 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.537 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -87.47 159.74 18.54 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.793 -179.994 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.4 mt . . . . . 0 N--CA 1.447 -0.607 0 CA-C-O 121.111 0.482 . . . . 0.0 110.998 179.651 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.0 t90 . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.595 0.236 . . . . 0.0 110.445 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.9 m -123.04 155.16 37.42 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.292 0.568 . . . . 0.0 111.107 -179.694 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.69 166.59 18.77 Favored Pre-proline 0 N--CA 1.449 -0.516 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.797 179.208 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -57.79 139.16 89.38 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 122.494 2.129 . . . . 0.0 111.911 179.573 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.548 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.78 1.67 90.29 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.748 -0.541 . . . . 0.0 111.748 179.481 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 18.9 m-85 -123.61 165.63 16.85 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.062 0.458 . . . . 0.0 110.415 179.731 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.68 134.59 28.84 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.225 179.614 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.498 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -49.1 135.31 16.5 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.639 -179.764 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.498 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.5 t-20 -118.93 94.64 48.38 Favored Pre-proline 0 CA--C 1.546 0.794 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.807 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -74.25 -0.33 9.49 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.851 2.367 . . . . 0.0 112.249 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.7 t -101.99 -18.14 6.61 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.965 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.799 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.61 -43.65 4.02 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.376 179.455 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.69 1.12 9.94 Favored Glycine 0 CA--C 1.535 1.322 0 CA-C-N 116.049 -0.523 . . . . 0.0 112.908 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.476 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -153.07 -170.85 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.163 0 CA-C-N 117.055 0.427 . . . . 0.0 110.354 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 16.7 m -91.86 141.34 28.77 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-O 120.945 0.402 . . . . 0.0 110.24 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.0 p -127.99 153.0 47.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.615 -179.799 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.8 tt -53.66 141.03 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.799 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.346 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.548 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -97.16 163.22 13.01 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.847 -179.78 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 3.8 mm? . . . . . 0 N--CA 1.454 -0.271 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.52 -179.707 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.68 0.276 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.8 m -118.08 152.26 35.92 Favored 'General case' 0 CA--C 1.52 -0.202 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.568 -179.776 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -89.53 169.27 13.07 Favored Pre-proline 0 N--CA 1.451 -0.404 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 -179.436 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -57.79 139.23 89.6 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 121.939 1.759 . . . . 0.0 111.779 179.53 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.513 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.88 1.18 90.18 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.416 -0.674 . . . . 0.0 111.416 179.267 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.8 m-85 -124.23 164.28 19.85 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.273 0.559 . . . . 0.0 110.525 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.68 137.37 26.55 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.164 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.8 t80 -50.8 137.86 19.66 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 120.478 -0.489 . . . . 0.0 110.681 -179.321 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.405 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.7 t-20 -119.37 88.39 37.98 Favored Pre-proline 0 CA--C 1.538 0.511 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.504 -179.209 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -66.62 0.52 3.45 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.705 2.27 . . . . 0.0 112.189 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.0 t -103.3 -19.24 6.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.952 0.406 . . . . 0.0 110.282 -179.294 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.801 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.56 -41.66 4.52 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.143 179.491 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.49 -2.38 12.44 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-N 116.068 -0.515 . . . . 0.0 112.312 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.405 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -147.87 -172.45 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 117.707 0.753 . . . . 0.0 110.25 179.58 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.5 m -90.63 142.48 27.71 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.254 0.549 . . . . 0.0 109.592 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.7 p -128.96 154.1 46.91 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.641 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.418 ' O ' HG23 ' A' ' 18' ' ' ILE . 8.9 tt -57.22 131.82 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-O 120.991 0.424 . . . . 0.0 110.547 -179.489 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.513 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -89.55 160.98 16.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.78 -179.613 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 8.8 mp . . . . . 0 C--N 1.331 -0.233 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.892 179.751 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.2 t90 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.647 0.26 . . . . 0.0 110.453 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 97.5 m -123.56 149.39 45.34 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-O 121.403 0.62 . . . . 0.0 111.109 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.78 160.73 81.33 Favored Pre-proline 0 N--CA 1.442 -0.846 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.252 179.306 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -64.46 138.51 60.33 Favored 'Trans proline' 0 C--N 1.302 -1.883 0 C-N-CA 122.429 2.086 . . . . 0.0 111.929 -179.665 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.587 ' O ' HG22 ' A' ' 19' ' ' THR . . . 89.61 -7.89 80.95 Favored Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 -179.64 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 15.6 m-85 -115.19 167.91 10.41 Favored 'General case' 0 CA--C 1.522 -0.129 0 CA-C-O 121.131 0.491 . . . . 0.0 110.5 179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -139.04 134.08 32.52 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.171 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.456 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 9.3 t80 -50.87 135.39 24.31 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.692 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.456 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.5 t-20 -119.12 95.52 49.4 Favored Pre-proline 0 CA--C 1.545 0.777 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.927 -179.573 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -75.04 0.71 8.6 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.857 2.371 . . . . 0.0 112.35 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 36.3 t -103.0 -17.82 6.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.995 -179.762 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.788 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -110.32 -43.18 3.96 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.598 179.411 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.05 2.29 11.16 Favored Glycine 0 CA--C 1.535 1.333 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.882 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.446 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.2 pt -153.65 -174.21 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.232 0 CA-C-N 117.314 0.557 . . . . 0.0 110.121 179.67 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 3.9 m -88.29 139.99 29.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.04 0.447 . . . . 0.0 110.535 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.8 p -126.21 152.95 45.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.521 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.5 tt -58.0 133.59 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.433 -179.73 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.587 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -85.19 152.24 23.5 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.788 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 8.0 mp . . . . . 0 C--N 1.327 -0.37 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.601 179.965 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.492 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.148 0 CA-C-O 118.224 -0.893 . . . . 0.0 111.044 . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.2 t90 -67.28 133.07 48.98 Favored 'General case' 0 C--N 1.329 -0.317 0 O-C-N 124.262 0.976 . . . . 0.0 110.335 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.9 m -119.7 151.56 38.54 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.471 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.51 169.75 14.29 Favored Pre-proline 0 N--CA 1.452 -0.369 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.742 -179.519 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_exo -58.94 139.24 90.0 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 122.109 1.873 . . . . 0.0 111.795 179.68 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.534 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.52 -0.02 88.53 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 179.296 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -122.21 165.64 15.84 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.139 0.495 . . . . 0.0 110.542 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -146.01 138.44 25.45 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.078 179.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.492 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 18.3 t80 -50.09 137.36 17.64 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.557 -179.452 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.43 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.7 t-20 -118.83 88.84 36.7 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.455 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -66.82 -0.06 4.21 Favored 'Trans proline' 0 N--CA 1.496 1.623 0 C-N-CA 122.732 2.288 . . . . 0.0 112.103 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 19.3 t -103.05 -19.01 6.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.874 0.369 . . . . 0.0 110.471 -179.225 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.803 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -110.03 -41.36 4.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.902 179.416 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.79 -2.92 11.96 Favored Glycine 0 CA--C 1.535 1.288 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.42 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.43 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.2 pt -147.21 -169.55 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 117.5 0.65 . . . . 0.0 110.342 179.599 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 23.6 m -91.76 142.08 27.98 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 121.197 0.523 . . . . 0.0 109.85 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.8 p -129.24 154.73 46.52 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.573 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.522 HD11 ' HD2' ' A' ' 22' ' ' ARG . 12.6 tt -57.81 132.1 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-O 121.189 0.519 . . . . 0.0 110.572 -179.681 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.534 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -85.04 152.9 23.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.574 -179.803 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.513 ' O ' ' CE1' ' A' ' 25' ' ' HIS . 11.2 mp -61.34 -25.83 67.41 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.878 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 88.4 p -56.62 -34.37 67.17 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.508 -179.39 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.522 ' HD2' HD11 ' A' ' 18' ' ' ILE . 21.5 ttm180 -62.45 -40.25 96.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.52 -0.309 . . . . 0.0 111.051 179.489 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.555 HG22 ' N ' ' A' ' 24' ' ' GLU . 92.6 mt -46.27 -99.19 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.963 -179.269 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.555 ' N ' HG22 ' A' ' 23' ' ' ILE . 99.4 mt-10 -127.04 89.72 3.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.77 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.513 ' CE1' ' O ' ' A' ' 20' ' ' LEU . 44.4 m80 -149.44 69.44 9.55 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.452 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.557 ' O ' ' N ' ' A' ' 30' ' ' ASP . 52.2 Cg_exo -53.98 -37.38 86.1 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.423 2.082 . . . . 0.0 111.82 -179.439 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.66 -40.38 98.67 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.959 -0.856 . . . . 0.0 110.959 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 37.7 t-20 -62.1 -44.34 96.86 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.72 0.295 . . . . 0.0 110.988 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.573 ' CD2' ' O ' ' A' ' 29' ' ' TYR . 24.7 p90 -126.17 47.17 2.3 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.934 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.557 ' N ' ' O ' ' A' ' 26' ' ' PRO . 67.7 t0 -59.3 -43.0 92.65 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.717 -179.57 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 66.9 t80 . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.661 179.916 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.47 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.392 -5.127 0 CA-C-O 118.133 -0.937 . . . . 0.0 111.076 . . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 -66.15 131.88 47.19 Favored 'General case' 0 C--N 1.329 -0.324 0 O-C-N 124.286 0.991 . . . . 0.0 110.6 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 77.0 m -120.88 151.58 39.48 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.841 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -88.04 167.04 21.15 Favored Pre-proline 0 N--CA 1.45 -0.474 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.635 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -58.04 139.13 89.31 Favored 'Trans proline' 0 N--CA 1.493 1.482 0 C-N-CA 122.573 2.182 . . . . 0.0 111.87 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.479 ' O ' HG22 ' A' ' 19' ' ' THR . . . 85.66 -4.38 85.85 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -119.63 164.53 15.74 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.067 0.461 . . . . 0.0 110.632 179.734 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -140.51 132.83 28.29 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.298 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.48 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -48.38 134.5 14.95 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.707 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.48 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.5 t-20 -118.01 94.57 46.73 Favored Pre-proline 0 CA--C 1.545 0.752 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.951 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -74.39 0.45 8.56 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.963 2.442 . . . . 0.0 112.33 -179.613 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.8 t -102.74 -19.05 6.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.924 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.8 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -108.65 -43.9 4.17 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.511 179.435 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.77 1.8 9.67 Favored Glycine 0 CA--C 1.534 1.269 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.719 179.328 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.465 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -153.81 -173.49 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.235 0 CA-C-N 117.061 0.431 . . . . 0.0 110.408 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.5 m -89.43 140.97 28.99 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-O 120.884 0.373 . . . . 0.0 110.287 179.613 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.2 p -127.91 152.45 47.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.531 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.524 HD11 ' HD3' ' A' ' 22' ' ' ARG . 12.6 tt -58.42 133.06 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.262 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.479 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -84.04 142.88 30.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.63 -179.935 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 6.8 mp -57.44 -27.96 62.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.89 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.0 t -57.37 -38.48 74.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.417 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.524 ' HD3' HD11 ' A' ' 18' ' ' ILE . 75.7 ttt180 -58.84 -38.85 79.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.399 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 34.4 mm -63.72 -102.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.818 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -149.93 74.06 1.19 Allowed 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.692 0.282 . . . . 0.0 111.05 -179.554 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -144.71 67.51 14.06 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.816 179.356 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -61.79 -37.07 69.98 Favored 'Trans proline' 0 N--CA 1.494 1.554 0 C-N-CA 122.767 2.311 . . . . 0.0 112.19 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.38 -44.81 97.56 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -64.3 -39.97 94.99 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.806 0.336 . . . . 0.0 110.654 179.836 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -132.84 71.52 1.47 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.612 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -61.32 -43.63 98.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.542 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.598 179.975 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.391 -5.152 0 CA-C-O 118.271 -0.871 . . . . 0.0 111.067 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.1 t90 -65.1 132.14 48.4 Favored 'General case' 0 C--N 1.33 -0.261 0 O-C-N 124.167 0.917 . . . . 0.0 110.454 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.42 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 74.1 m -122.28 153.58 38.72 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.245 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -89.05 168.3 15.84 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.902 -179.488 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -57.64 138.11 84.52 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.678 2.252 . . . . 0.0 111.654 179.697 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.479 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.13 1.47 90.35 Favored Glycine 0 CA--C 1.528 0.857 0 N-CA-C 111.206 -0.758 . . . . 0.0 111.206 179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.8 m-85 -125.22 163.23 22.94 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.13 0.49 . . . . 0.0 110.602 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -143.17 135.82 27.56 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.134 179.528 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.42 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 16.1 t80 -48.36 136.96 11.79 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.601 -179.594 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.457 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.7 t-20 -118.58 89.25 36.56 Favored Pre-proline 0 CA--C 1.54 0.568 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.637 -179.605 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -67.02 -0.02 4.3 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 122.907 2.405 . . . . 0.0 112.051 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.0 t -103.49 -17.94 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 CA-C-O 120.94 0.4 . . . . 0.0 110.317 -179.316 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.808 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -111.09 -42.65 3.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.4 179.566 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.57 -2.1 10.26 Favored Glycine 0 CA--C 1.534 1.224 0 CA-C-N 116.113 -0.494 . . . . 0.0 112.432 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.457 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.0 pt -149.92 -173.07 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.917 0.358 . . . . 0.0 110.592 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.9 m -89.27 142.34 27.74 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 120.946 0.403 . . . . 0.0 110.332 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 65.0 p -129.6 150.9 50.73 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.515 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 tt -51.83 137.72 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.149 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.479 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -101.06 169.66 8.79 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.062 -179.328 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.414 ' N ' ' OG1' ' A' ' 19' ' ' THR . 4.8 tt -60.43 -32.53 71.45 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.17 179.444 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 42.0 t -43.78 -29.73 0.57 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.458 -179.584 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 9.8 ttp-105 -53.37 -33.16 52.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.261 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.604 HG22 ' N ' ' A' ' 24' ' ' GLU . 36.4 mm -50.38 -95.34 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.47 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.604 ' N ' HG22 ' A' ' 23' ' ' ILE . 99.4 mt-10 -141.15 30.99 1.76 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.641 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 91.3 m-70 -132.0 59.5 44.9 Favored Pre-proline 0 C--N 1.332 -0.182 0 C-N-CA 120.814 -0.354 . . . . 0.0 110.075 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.65 -23.5 74.68 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.876 2.384 . . . . 0.0 111.97 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.7 -37.24 93.93 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.533 ' ND2' ' OXT' ' A' ' 31' ' ' TYR . 11.2 t30 54.84 43.11 30.51 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.844 0.354 . . . . 0.0 110.514 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 12.1 m-85 56.1 23.23 6.68 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.513 179.439 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 50.8 t0 52.79 41.02 31.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.426 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.533 ' OXT' ' ND2' ' A' ' 28' ' ' ASN . 85.8 t80 . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.557 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.51 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.158 0 CA-C-O 118.242 -0.885 . . . . 0.0 111.114 . . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.6 t90 -66.22 130.2 42.43 Favored 'General case' 0 C--N 1.329 -0.318 0 O-C-N 124.21 0.944 . . . . 0.0 110.452 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.414 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 73.4 m -119.44 151.12 39.07 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.566 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.34 169.02 16.36 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.822 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.93 138.92 88.45 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.539 2.159 . . . . 0.0 111.879 179.554 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.437 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.98 0.06 89.09 Favored Glycine 0 CA--C 1.529 0.912 0 N-CA-C 111.359 -0.697 . . . . 0.0 111.359 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -123.9 164.36 19.43 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.073 0.463 . . . . 0.0 110.601 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.89 136.25 25.22 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.235 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.51 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 17.7 t80 -48.6 136.91 12.56 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.553 -179.6 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.421 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.6 t-20 -119.1 89.22 38.81 Favored Pre-proline 0 CA--C 1.54 0.59 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.539 -179.541 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -66.67 -0.08 4.12 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 122.915 2.41 . . . . 0.0 112.08 -179.616 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.4 t -103.53 -19.89 5.99 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 120.895 0.379 . . . . 0.0 110.303 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.791 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -108.4 -42.04 4.69 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.624 179.413 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.92 -1.72 11.87 Favored Glycine 0 CA--C 1.534 1.28 0 CA-C-N 116.035 -0.529 . . . . 0.0 112.543 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.421 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 4.7 pt -149.66 -172.9 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 117.094 0.447 . . . . 0.0 110.556 179.797 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.5 m -88.94 141.77 28.21 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.061 0.458 . . . . 0.0 110.404 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.6 p -128.69 152.69 48.11 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.542 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.532 ' CD1' ' HE ' ' A' ' 22' ' ' ARG . 10.7 tt -55.25 132.3 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.348 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.437 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -94.01 166.76 11.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.903 -179.667 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.0 mt -65.04 -26.09 68.11 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-O 121.192 0.52 . . . . 0.0 110.861 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 89.1 p -61.28 -17.55 54.08 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.197 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.532 ' HE ' ' CD1' ' A' ' 18' ' ' ILE . 0.1 OUTLIER -53.79 -21.15 6.8 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.576 -179.882 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.533 HG22 ' N ' ' A' ' 24' ' ' GLU . 95.8 mt -58.34 -95.03 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.617 -179.802 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.533 ' N ' HG22 ' A' ' 23' ' ' ILE . 75.1 mm-40 -133.31 41.68 3.08 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.864 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 81.5 m-70 -132.23 59.35 43.42 Favored Pre-proline 0 C--N 1.331 -0.197 0 C-N-CA 120.792 -0.363 . . . . 0.0 110.866 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -76.15 -11.85 19.39 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.865 2.377 . . . . 0.0 112.238 178.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.07 -40.0 96.49 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.236 -0.745 . . . . 0.0 111.236 -179.551 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -62.99 -37.31 86.67 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.846 0.355 . . . . 0.0 110.983 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -103.45 17.53 23.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.361 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -81.86 74.73 8.83 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.238 179.858 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.462 ' CD2' ' O ' ' A' ' 31' ' ' TYR . 74.9 t80 . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.563 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.411 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.138 0 CA-C-O 118.21 -0.9 . . . . 0.0 111.107 . . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.8 t90 -67.03 131.47 45.91 Favored 'General case' 0 C--N 1.329 -0.297 0 O-C-N 124.332 1.02 . . . . 0.0 110.555 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 93.3 m -123.45 148.93 45.69 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.986 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -69.95 161.97 71.61 Favored Pre-proline 0 N--CA 1.446 -0.67 0 CA-C-N 115.549 -0.751 . . . . 0.0 109.979 179.77 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -64.42 139.63 65.89 Favored 'Trans proline' 0 C--N 1.3 -2.001 0 C-N-CA 122.212 1.941 . . . . 0.0 111.904 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.461 ' O ' HG22 ' A' ' 19' ' ' THR . . . 84.88 -2.83 87.98 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 -179.301 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -119.29 166.71 12.66 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 121.006 0.432 . . . . 0.0 110.497 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.69 137.45 31.74 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.097 179.485 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.411 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 19.2 t80 -52.04 137.04 28.19 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.412 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.403 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.7 t-20 -118.57 89.44 37.03 Favored Pre-proline 0 CA--C 1.539 0.53 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.38 -179.165 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -67.57 -0.02 4.69 Favored 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 122.721 2.28 . . . . 0.0 112.039 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 23.0 t -102.68 -18.69 6.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.507 -179.125 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.805 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -110.65 -41.37 4.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.79 179.67 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 119.97 -1.57 13.32 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-N 116.085 -0.507 . . . . 0.0 112.403 179.226 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.403 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -148.17 -172.72 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 117.484 0.642 . . . . 0.0 110.252 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.9 m -90.5 140.56 29.62 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.106 0.479 . . . . 0.0 109.956 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.0 p -127.36 152.53 47.36 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.315 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.536 HD11 ' HD3' ' A' ' 22' ' ' ARG . 11.2 tt -57.65 135.05 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 CA-C-O 121.139 0.495 . . . . 0.0 110.539 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.461 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -86.93 141.75 28.49 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.319 -179.788 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.795 HD23 ' O ' ' A' ' 20' ' ' LEU . 3.3 tt -59.51 -28.9 67.47 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.248 -179.755 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 89.0 p -59.06 -30.47 68.07 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.841 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.536 ' HD3' HD11 ' A' ' 18' ' ' ILE . 75.5 ttt180 -57.87 -39.36 77.62 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.261 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.421 ' O ' ' O ' ' A' ' 22' ' ' ARG . 50.7 mm -45.98 -94.96 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.359 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -143.62 35.0 1.29 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.569 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -132.32 61.14 55.63 Favored Pre-proline 0 C--O 1.232 0.142 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.295 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.401 ' O ' ' ND2' ' A' ' 28' ' ' ASN . 36.7 Cg_endo -65.96 -17.7 55.96 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 C-N-CA 122.574 2.183 . . . . 0.0 112.174 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.94 -29.43 70.65 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.401 ' ND2' ' O ' ' A' ' 26' ' ' PRO . 71.9 m-80 54.8 37.38 28.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.804 0.335 . . . . 0.0 110.654 -179.722 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 46.3 m-85 56.51 23.01 7.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.58 179.502 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 52.6 t0 53.81 41.44 32.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.477 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.965 -1.017 . . . . 0.0 110.527 179.964 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.392 -5.114 0 CA-C-O 118.21 -0.9 . . . . 0.0 111.025 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.8 t90 -65.04 133.07 50.87 Favored 'General case' 0 C--N 1.33 -0.252 0 O-C-N 124.216 0.947 . . . . 0.0 110.527 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.4 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 76.1 m -118.92 153.08 35.16 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 121.184 0.516 . . . . 0.0 110.926 -179.716 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.79 168.51 15.56 Favored Pre-proline 0 N--CA 1.452 -0.364 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.995 179.158 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -58.8 138.55 86.35 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 C-N-CA 122.675 2.25 . . . . 0.0 111.78 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.559 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.02 -0.81 88.16 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.451 -0.66 . . . . 0.0 111.451 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -121.2 166.07 14.51 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-O 120.916 0.388 . . . . 0.0 110.679 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.21 136.59 26.64 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.899 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.486 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 8.4 t80 -49.46 135.48 17.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.755 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.486 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.6 t-20 -119.38 94.92 48.93 Favored Pre-proline 0 CA--C 1.547 0.83 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.882 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -73.63 0.02 8.72 Favored 'Trans proline' 0 N--CA 1.492 1.441 0 C-N-CA 123.182 2.588 . . . . 0.0 112.427 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.5 t -103.29 -17.75 6.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.449 . . . . 0.0 109.985 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.771 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.97 -42.47 4.21 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 179.769 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.44 -0.18 11.3 Favored Glycine 0 CA--C 1.536 1.383 0 CA-C-N 116.253 -0.431 . . . . 0.0 113.185 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.474 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.8 pt -152.4 -170.77 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 O-C-N 122.493 -0.416 . . . . 0.0 110.387 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.9 m -90.89 142.67 27.52 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 120.979 0.418 . . . . 0.0 110.322 179.57 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.4 p -128.0 157.37 40.8 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.654 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.43 ' O ' HG23 ' A' ' 18' ' ' ILE . 14.1 tt -59.75 131.68 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.362 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.559 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -87.48 156.15 19.68 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.562 179.983 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.446 HD22 ' N ' ' A' ' 20' ' ' LEU . 4.3 mm? -63.39 -24.4 67.82 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.641 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 95.8 p -62.42 -22.78 66.44 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.555 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.447 ' HE ' ' HA2' ' A' ' 6' ' ' GLY . 2.2 tpm_? -56.67 -33.59 66.55 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.276 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.435 HG22 ' HG3' ' A' ' 24' ' ' GLU . 95.2 mt -40.11 -82.86 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.045 0.45 . . . . 0.0 110.915 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.435 ' HG3' HG22 ' A' ' 23' ' ' ILE . 98.9 mt-10 -141.5 -106.11 0.14 Allowed 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.97 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 82.3 m-70 55.6 66.17 3.95 Favored Pre-proline 0 C--O 1.237 0.399 0 CA-C-O 120.968 0.414 . . . . 0.0 110.758 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.85 -36.21 82.14 Favored 'Trans proline' 0 N--CA 1.493 1.5 0 C-N-CA 122.783 2.322 . . . . 0.0 111.875 -179.767 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.73 -39.24 97.18 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.829 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -61.34 -40.31 93.75 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.88 0.371 . . . . 0.0 110.488 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.425 ' CE2' ' NH2' ' A' ' 22' ' ' ARG . 96.9 m-85 -96.07 -0.24 50.59 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.616 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 51.5 t0 50.56 49.98 19.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.604 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.442 ' O ' ' CG ' ' A' ' 31' ' ' TYR . 15.5 p90 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.655 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.39 -5.184 0 CA-C-O 118.342 -0.837 . . . . 0.0 111.127 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.1 t90 -70.47 131.67 44.4 Favored 'General case' 0 C--N 1.33 -0.273 0 O-C-N 124.204 0.94 . . . . 0.0 110.418 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.6 m -120.28 154.4 35.01 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.899 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.3 168.94 13.15 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.78 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -59.14 139.05 88.69 Favored 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 122.521 2.147 . . . . 0.0 111.73 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.499 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.07 0.07 89.2 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.427 -0.669 . . . . 0.0 111.427 179.426 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -122.17 165.11 16.65 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-O 121.168 0.508 . . . . 0.0 110.662 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -142.74 135.29 27.77 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.113 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.462 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 9.1 t80 -49.0 135.04 16.41 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.744 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.485 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.6 t-20 -118.38 94.79 47.74 Favored Pre-proline 0 CA--C 1.544 0.747 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.995 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -74.42 0.3 8.77 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 C-N-CA 122.807 2.338 . . . . 0.0 112.41 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.4 t -102.19 -18.43 6.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.838 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.818 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.72 -43.77 3.97 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.73 179.478 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 123.23 0.96 9.5 Favored Glycine 0 CA--C 1.535 1.309 0 CA-C-N 116.081 -0.509 . . . . 0.0 112.61 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.485 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -152.92 -170.61 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.274 0 CA-C-N 117.113 0.457 . . . . 0.0 110.298 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 15.2 m -91.03 141.53 28.74 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 120.916 0.389 . . . . 0.0 110.196 179.6 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 79.7 p -127.71 152.68 47.41 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.679 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.519 HD11 ' HD2' ' A' ' 22' ' ' ARG . 12.2 tt -56.76 133.83 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.582 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.349 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.499 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -87.88 147.56 25.04 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.683 -179.83 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.863 HD23 ' O ' ' A' ' 20' ' ' LEU . 5.3 tt -58.9 -27.0 64.82 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.468 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 72.7 m -56.34 -36.94 69.32 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.901 -179.121 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.519 ' HD2' HD11 ' A' ' 18' ' ' ILE . 24.3 ttm180 -56.5 -39.42 73.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.721 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.401 ' C ' ' O ' ' A' ' 22' ' ' ARG . 47.8 mm -38.25 -86.41 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.899 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -142.86 58.59 1.42 Allowed 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.065 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 54.6 m-70 -135.08 72.36 67.33 Favored Pre-proline 0 N--CA 1.463 0.176 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.531 179.719 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.522 ' O ' ' ND2' ' A' ' 28' ' ' ASN . 45.6 Cg_exo -54.82 -36.05 90.07 Favored 'Trans proline' 0 N--CA 1.498 1.78 0 C-N-CA 122.869 2.379 . . . . 0.0 112.238 -179.754 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.49 -39.66 96.65 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.522 ' ND2' ' O ' ' A' ' 26' ' ' PRO . 60.6 m-80 54.55 36.6 26.21 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.734 0.302 . . . . 0.0 110.528 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 51.9 m-85 57.72 21.77 7.71 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.565 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 51.9 t0 50.4 42.25 25.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.447 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 78.6 t80 . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.06 -0.972 . . . . 0.0 110.516 -179.986 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.485 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.392 -5.106 0 CA-C-O 118.224 -0.893 . . . . 0.0 111.076 . . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.6 t90 -67.33 131.65 46.15 Favored 'General case' 0 C--N 1.332 -0.177 0 O-C-N 124.3 1.0 . . . . 0.0 110.406 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.404 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 73.5 m -120.3 150.59 40.47 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.479 0.657 . . . . 0.0 110.805 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.66 168.1 23.0 Favored Pre-proline 0 CA--C 1.533 0.3 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.601 -179.504 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -59.03 137.87 82.18 Favored 'Trans proline' 0 N--CA 1.492 1.422 0 C-N-CA 122.513 2.142 . . . . 0.0 111.828 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.575 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.51 1.31 90.07 Favored Glycine 0 CA--C 1.528 0.879 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 179.413 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -121.58 165.78 15.18 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-O 121.111 0.481 . . . . 0.0 110.546 179.694 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -143.66 135.64 26.58 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.149 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.485 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 8.4 t80 -48.22 134.69 14.22 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.752 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.491 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.6 t-20 -118.48 94.84 47.99 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.906 -179.667 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -74.25 -0.61 9.85 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.849 2.366 . . . . 0.0 112.348 -179.65 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.6 t -101.43 -18.0 6.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.946 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.796 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.85 -43.31 4.04 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.384 179.515 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.98 0.19 9.78 Favored Glycine 0 CA--C 1.533 1.172 0 CA-C-N 116.109 -0.496 . . . . 0.0 112.725 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.491 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.6 pt -152.67 -169.86 0.1 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.263 0 CA-C-N 117.096 0.448 . . . . 0.0 110.234 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 21.6 m -91.55 142.16 27.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.891 0.377 . . . . 0.0 110.219 179.597 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.6 p -127.2 154.48 44.76 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.63 -179.778 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt -56.84 132.66 21.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.379 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.575 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.1 OUTLIER -92.51 160.18 15.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.692 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 38.7 tp -61.84 -26.83 68.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.418 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.607 ' O ' ' NE2' ' A' ' 25' ' ' HIS . 37.9 t -53.6 -36.74 62.29 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.458 -179.343 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.422 HH11 ' HA3' ' A' ' 6' ' ' GLY . 15.4 tpt180 -38.4 -30.17 0.04 OUTLIER 'General case' 0 C--O 1.231 0.11 0 O-C-N 123.287 0.367 . . . . 0.0 110.386 -179.707 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.449 ' N ' ' O ' ' A' ' 21' ' ' SER . 36.2 mt -129.53 66.75 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.783 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -148.15 44.02 1.05 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.602 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.607 ' NE2' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -171.37 54.59 0.21 Allowed Pre-proline 0 C--N 1.325 -0.477 0 CA-C-O 121.454 0.645 . . . . 0.0 110.325 -179.726 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.432 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 32.1 Cg_endo -65.38 -31.71 51.63 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.498 2.132 . . . . 0.0 111.871 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -62.74 -43.48 98.9 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.939 -0.865 . . . . 0.0 110.939 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -69.05 -38.29 79.03 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.704 0.288 . . . . 0.0 110.801 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 84.6 m-85 -114.63 63.04 0.67 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.756 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' A' ' 26' ' ' PRO . 98.6 m-20 -61.27 -39.96 92.34 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.517 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.511 ' CD2' ' OXT' ' A' ' 31' ' ' TYR . 69.1 t80 . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.581 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.392 -5.098 0 CA-C-O 118.233 -0.889 . . . . 0.0 111.155 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.0 t90 -65.53 133.46 51.27 Favored 'General case' 0 C--N 1.33 -0.262 0 O-C-N 124.256 0.973 . . . . 0.0 110.431 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.408 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.3 m -120.27 153.35 36.5 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.972 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -89.66 168.1 15.77 Favored Pre-proline 0 C--N 1.327 -0.4 0 O-C-N 123.107 0.255 . . . . 0.0 110.874 -179.529 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_exo -57.75 139.06 89.02 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.47 2.113 . . . . 0.0 111.722 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.463 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.76 0.32 89.21 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 179.579 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -124.06 165.24 17.84 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.107 0.479 . . . . 0.0 110.66 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.63 137.07 26.42 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.231 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.408 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 17.7 t80 -49.82 137.57 16.18 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.657 -179.543 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.445 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.6 t-20 -119.42 89.01 39.57 Favored Pre-proline 0 CA--C 1.541 0.634 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.414 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_exo -66.37 -0.56 4.41 Favored 'Trans proline' 0 N--CA 1.496 1.623 0 C-N-CA 122.932 2.421 . . . . 0.0 112.132 -179.715 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.0 t -103.08 -19.71 6.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.952 0.406 . . . . 0.0 110.416 -179.339 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.808 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -108.53 -41.68 4.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.664 179.349 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.62 -3.2 11.07 Favored Glycine 0 CA--C 1.533 1.216 0 CA-C-N 116.029 -0.532 . . . . 0.0 112.415 179.344 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.445 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -148.35 -171.28 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-N 117.042 0.421 . . . . 0.0 110.556 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 15.7 m -90.88 143.12 27.05 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.109 0.481 . . . . 0.0 110.392 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -129.69 152.96 48.62 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.583 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.5 tt -55.17 134.26 18.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.187 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.481 HG23 ' OG ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -90.22 167.96 12.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.068 -179.494 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.522 HD22 ' N ' ' A' ' 20' ' ' LEU . 4.1 mm? -68.22 -11.66 59.69 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.521 -179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.481 ' OG ' HG23 ' A' ' 19' ' ' THR . 89.8 p -61.97 -25.74 67.8 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.051 0.453 . . . . 0.0 110.399 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 39.8 tpt85 -60.62 -39.11 87.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.134 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 51.1 mm -40.96 -86.81 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.845 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -143.23 60.61 1.4 Allowed 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.941 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 38.7 m80 -130.82 63.59 70.62 Favored Pre-proline 0 CA--C 1.529 0.169 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.633 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -61.59 -18.74 61.66 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.886 2.391 . . . . 0.0 112.164 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.97 -40.05 97.89 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -64.08 -39.33 93.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.96 0.41 . . . . 0.0 110.71 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -78.73 -11.88 60.0 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.519 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 53.1 t0 57.84 44.29 20.34 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.357 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 92.4 t80 . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.037 -0.983 . . . . 0.0 110.578 179.896 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.499 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.392 -5.122 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.991 . . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.6 t90 -68.08 130.39 42.81 Favored 'General case' 0 C--N 1.328 -0.331 0 O-C-N 124.273 0.983 . . . . 0.0 110.492 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.402 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.2 m -120.03 148.83 43.08 Favored 'General case' 0 CA--C 1.516 -0.329 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.708 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.44 168.0 26.4 Favored Pre-proline 0 N--CA 1.452 -0.327 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.901 179.809 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo -58.65 138.89 88.28 Favored 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 122.485 2.124 . . . . 0.0 111.739 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.534 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.44 0.61 89.36 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.398 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -122.57 166.28 15.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.097 0.475 . . . . 0.0 110.484 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.65 138.39 25.89 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.172 179.662 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.499 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 17.4 t80 -50.43 136.76 20.04 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.508 -179.619 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.43 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.6 t-20 -118.76 89.24 37.37 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.592 -179.473 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -66.44 -0.04 3.93 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 C-N-CA 122.83 2.353 . . . . 0.0 112.375 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 t -103.8 -19.1 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.02 0.438 . . . . 0.0 110.363 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.816 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -109.54 -40.71 4.78 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.697 179.531 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.41 -3.38 12.41 Favored Glycine 0 CA--C 1.534 1.26 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.424 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.43 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -147.54 -171.25 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-N 117.149 0.474 . . . . 0.0 110.42 179.799 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 23.7 m -90.38 142.3 27.87 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-O 121.179 0.514 . . . . 0.0 110.136 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -129.17 155.21 45.87 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.588 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.415 ' O ' HG23 ' A' ' 18' ' ' ILE . 10.9 tt -56.82 132.35 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.726 0 CA-C-O 121.076 0.465 . . . . 0.0 110.681 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.534 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -87.06 160.56 18.55 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.724 -179.932 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.576 ' HA ' HD12 ' A' ' 23' ' ' ILE . 5.3 tt -56.66 -29.98 62.88 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.821 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 89.0 p -56.32 -23.12 34.95 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.441 -178.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.414 HH11 HD11 ' A' ' 18' ' ' ILE . 57.7 ttt-85 -109.4 30.29 6.76 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.905 0.384 . . . . 0.0 110.365 179.524 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.584 ' N ' ' NE2' ' A' ' 25' ' ' HIS . 57.0 mt -131.88 -32.36 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.338 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.642 ' C ' ' CG ' ' A' ' 25' ' ' HIS . 98.6 mt-10 -115.74 112.28 21.81 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.148 -178.78 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.642 ' CG ' ' C ' ' A' ' 24' ' ' GLU . 0.0 OUTLIER -167.43 51.96 0.23 Allowed Pre-proline 0 N--CA 1.466 0.357 0 CA-C-O 121.656 0.741 . . . . 0.0 110.571 -179.533 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.478 ' CD ' ' N ' ' A' ' 25' ' ' HIS . 33.7 Cg_endo -64.89 -28.34 58.58 Favored 'Trans proline' 0 C--N 1.301 -1.966 0 C-N-CA 122.19 1.927 . . . . 0.0 112.339 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -65.43 -12.55 56.27 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 63.4 t30 -58.8 -38.39 78.49 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.499 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.7 p90 -115.6 38.68 3.2 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.927 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.543 ' OD1' ' N ' ' A' ' 31' ' ' TYR . 56.7 p-10 -60.8 -24.8 66.09 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.772 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.543 ' N ' ' OD1' ' A' ' 30' ' ' ASP . 64.8 t80 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.956 -1.021 . . . . 0.0 110.535 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.391 -5.168 0 CA-C-O 118.302 -0.856 . . . . 0.0 111.084 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.3 t90 -64.65 131.32 46.63 Favored 'General case' 0 C--N 1.329 -0.306 0 O-C-N 124.236 0.96 . . . . 0.0 110.508 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.42 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 78.0 m -123.31 153.52 40.15 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.671 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.68 168.12 16.81 Favored Pre-proline 0 N--CA 1.452 -0.344 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.788 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_exo -56.64 138.86 86.57 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.075 1.85 . . . . 0.0 111.792 179.539 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.459 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.35 0.01 89.41 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 179.328 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -123.95 163.84 20.51 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.297 0.57 . . . . 0.0 110.56 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.39 136.94 26.7 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.086 179.438 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.42 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.6 t80 -50.29 137.22 18.7 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.615 -179.281 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.401 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.7 t-20 -118.74 88.41 35.13 Favored Pre-proline 0 CA--C 1.539 0.545 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.555 -179.199 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -66.39 0.15 3.7 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 122.753 2.302 . . . . 0.0 112.252 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.3 t -103.49 -18.78 6.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.976 0.417 . . . . 0.0 110.281 -179.349 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.799 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -109.82 -41.44 4.51 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.794 179.488 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.47 -3.03 12.4 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-N 116.118 -0.492 . . . . 0.0 112.525 179.156 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.401 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.1 pt -147.69 -172.82 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 117.52 0.66 . . . . 0.0 110.327 179.634 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 25.4 m -90.23 141.14 29.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-O 121.135 0.493 . . . . 0.0 109.922 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.7 p -127.97 153.95 46.14 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.635 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.418 ' O ' HG23 ' A' ' 18' ' ' ILE . 9.9 tt -57.31 131.93 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.504 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.459 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -90.58 164.76 14.08 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.726 -179.691 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.415 ' HA ' HD23 ' A' ' 20' ' ' LEU . 94.1 mt -66.82 -20.56 65.96 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 121.071 0.462 . . . . 0.0 111.106 179.793 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 72.8 m -57.01 -25.57 58.78 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.54 -0.754 . . . . 0.0 110.541 -179.633 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.417 ' O ' ' O ' ' A' ' 23' ' ' ILE . 0.0 OUTLIER -58.0 -35.78 71.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.44 179.679 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.598 HG22 ' N ' ' A' ' 24' ' ' GLU . 97.3 mt -37.54 -92.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.191 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.942 -179.53 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.598 ' N ' HG22 ' A' ' 23' ' ' ILE . 99.9 mt-10 -137.04 33.3 2.61 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.908 179.797 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -130.02 59.13 43.03 Favored Pre-proline 0 C--N 1.33 -0.242 0 CA-C-O 120.8 0.333 . . . . 0.0 110.244 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -64.03 -19.36 66.29 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.806 2.337 . . . . 0.0 112.04 179.68 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.09 -35.48 87.66 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 32.9 m120 55.25 38.11 29.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.774 0.321 . . . . 0.0 110.651 -179.629 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 53.3 m-85 58.05 18.25 5.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.655 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 52.7 t0 49.98 44.03 25.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.486 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 41.9 p90 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.902 -1.047 . . . . 0.0 110.64 179.984 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.391 -5.138 0 CA-C-O 118.251 -0.881 . . . . 0.0 111.069 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.8 t90 -62.3 131.28 48.81 Favored 'General case' 0 C--N 1.328 -0.34 0 O-C-N 124.268 0.98 . . . . 0.0 110.507 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.438 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 71.7 m -121.88 153.14 38.82 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.141 0.496 . . . . 0.0 110.568 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.13 167.77 22.23 Favored Pre-proline 0 N--CA 1.451 -0.405 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.85 179.45 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -58.15 138.61 86.83 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.513 2.142 . . . . 0.0 111.85 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.536 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.18 -0.99 88.2 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.468 -0.653 . . . . 0.0 111.468 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.1 m-85 -121.91 165.32 16.12 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.024 0.44 . . . . 0.0 110.54 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.84 135.91 24.95 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.214 179.615 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.438 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.0 t80 -48.96 137.28 13.09 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.518 -179.668 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.425 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.7 t-20 -119.04 88.79 37.58 Favored Pre-proline 0 CA--C 1.543 0.7 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.468 -179.484 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_exo -66.11 -0.16 3.83 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.835 2.357 . . . . 0.0 112.213 -179.646 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.7 t -103.78 -19.72 6.1 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.318 0 CA-C-O 120.908 0.385 . . . . 0.0 110.246 -179.101 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.777 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -108.53 -41.99 4.67 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.371 179.458 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.0 -3.05 11.65 Favored Glycine 0 CA--C 1.537 1.412 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.779 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.425 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -148.34 -173.5 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 117.126 0.463 . . . . 0.0 110.588 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 21.2 m -89.46 141.28 28.71 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.002 0.429 . . . . 0.0 110.35 179.722 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -128.64 153.89 46.81 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.574 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.55 ' CD1' ' HE ' ' A' ' 22' ' ' ARG . 9.3 tt -56.38 132.61 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.345 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.536 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -88.76 153.75 20.83 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.18 -179.782 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.4 tt -61.31 -34.08 74.66 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.34 179.549 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 50.6 p -59.02 -20.47 53.4 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.144 -179.088 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.55 ' HE ' ' CD1' ' A' ' 18' ' ' ILE . 8.2 tmm_? -52.37 -29.92 26.3 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.769 179.459 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.488 HG22 ' N ' ' A' ' 24' ' ' GLU . 96.9 mt -55.16 -88.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.753 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.488 ' N ' HG22 ' A' ' 23' ' ' ILE . 99.3 mt-10 -141.27 -15.86 0.85 Allowed 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.968 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.413 ' ND1' ' N ' ' A' ' 25' ' ' HIS . 0.0 OUTLIER -169.92 151.4 4.07 Favored Pre-proline 0 N--CA 1.446 -0.662 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.143 -179.718 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -72.79 -43.24 0.89 Allowed 'Trans proline' 0 N--CA 1.494 1.549 0 C-N-CA 122.834 2.356 . . . . 0.0 112.272 179.342 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -63.48 -41.04 99.39 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 179.846 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 33.7 t30 59.27 65.23 1.21 Allowed 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.956 0.408 . . . . 0.0 110.865 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.679 ' N ' ' CD1' ' A' ' 29' ' ' TYR . 0.1 OUTLIER -106.25 62.58 0.65 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.22 0.533 . . . . 0.0 110.603 -179.423 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 54.5 p-10 -78.69 -0.11 28.83 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.4 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.491 ' CD2' ' O ' ' A' ' 31' ' ' TYR . 64.1 t80 . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.632 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.391 -5.154 0 CA-C-O 118.222 -0.894 . . . . 0.0 111.212 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.4 t90 -66.35 132.12 47.62 Favored 'General case' 0 C--N 1.33 -0.281 0 O-C-N 124.257 0.973 . . . . 0.0 110.38 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 79.7 m -120.15 150.73 40.15 Favored 'General case' 0 CA--C 1.519 -0.224 0 CA-C-O 121.216 0.531 . . . . 0.0 110.805 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.23 166.35 28.94 Favored Pre-proline 0 N--CA 1.448 -0.557 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.574 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -58.96 139.73 92.17 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 122.478 2.118 . . . . 0.0 111.841 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.574 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.47 0.01 89.53 Favored Glycine 0 CA--C 1.53 0.997 0 N-CA-C 111.697 -0.561 . . . . 0.0 111.697 179.4 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -121.71 166.47 14.25 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.97 0.414 . . . . 0.0 110.38 179.639 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.5 135.15 29.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.215 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.49 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -50.2 134.73 22.21 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.657 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.49 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.5 t-20 -118.05 94.98 47.59 Favored Pre-proline 0 CA--C 1.546 0.813 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.923 -179.621 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -74.6 0.63 8.45 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 C-N-CA 122.911 2.407 . . . . 0.0 112.443 -179.716 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 26.9 t -102.85 -18.87 6.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.926 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.794 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -108.75 -43.54 4.23 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.469 179.452 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.98 -0.0 9.79 Favored Glycine 0 CA--C 1.535 1.342 0 CA-C-N 116.065 -0.516 . . . . 0.0 112.853 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.477 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -152.38 -170.53 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.165 0 CA-C-N 117.069 0.435 . . . . 0.0 110.339 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.6 m -91.03 142.13 28.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.954 0.406 . . . . 0.0 110.28 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.4 p -128.88 151.99 49.01 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.605 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.552 HD11 HH11 ' A' ' 22' ' ' ARG . 11.7 tt -52.83 139.42 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.477 -179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.574 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -95.5 169.66 9.89 Favored 'General case' 0 C--O 1.241 0.635 0 CA-C-O 121.246 0.546 . . . . 0.0 111.036 -179.944 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.569 HD22 HD12 ' A' ' 23' ' ' ILE . 0.5 OUTLIER -71.7 11.91 0.44 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.841 179.965 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.53 ' C ' ' CE1' ' A' ' 25' ' ' HIS . 68.6 m -107.47 11.13 29.15 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.726 179.568 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.606 ' N ' ' CE1' ' A' ' 25' ' ' HIS . 75.6 ttt-85 -139.16 -30.13 0.74 Allowed 'General case' 0 CA--C 1.533 0.325 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.109 179.606 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.569 HD12 HD22 ' A' ' 20' ' ' LEU . 92.6 mt -57.23 -45.18 84.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-O 120.928 0.394 . . . . 0.0 111.337 -179.244 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.645 ' C ' ' CG ' ' A' ' 25' ' ' HIS . 99.6 mt-10 -103.36 42.24 1.19 Allowed 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.222 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.645 ' CG ' ' C ' ' A' ' 24' ' ' GLU . 0.0 OUTLIER -165.79 74.66 1.29 Allowed Pre-proline 0 CA--C 1.538 0.485 0 CA-C-O 121.35 0.595 . . . . 0.0 110.66 -178.934 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_exo -55.43 -36.97 95.13 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 122.579 2.186 . . . . 0.0 112.14 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.04 -38.5 95.65 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.419 ' O ' ' ND2' ' A' ' 28' ' ' ASN . 0.7 OUTLIER 59.85 59.79 2.36 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-O 121.073 0.463 . . . . 0.0 111.036 -179.827 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.682 ' CD1' ' N ' ' A' ' 29' ' ' TYR . 0.1 OUTLIER -99.59 45.66 0.99 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.559 -179.606 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.439 ' O ' ' OXT' ' A' ' 31' ' ' TYR . 67.0 t0 -59.85 -43.38 94.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.32 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.439 ' OXT' ' O ' ' A' ' 30' ' ' ASP . 69.0 t80 . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 117.956 -1.021 . . . . 0.0 110.577 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.392 -5.112 0 CA-C-O 118.43 -0.795 . . . . 0.0 111.115 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.1 t90 -67.98 131.36 45.32 Favored 'General case' 0 C--N 1.329 -0.313 0 O-C-N 124.065 0.853 . . . . 0.0 110.21 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.44 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.5 m -119.01 150.56 39.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.671 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.4 168.55 18.33 Favored Pre-proline 0 N--CA 1.451 -0.381 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.668 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -57.94 138.56 86.63 Favored 'Trans proline' 0 N--CA 1.496 1.643 0 C-N-CA 122.115 1.877 . . . . 0.0 111.8 179.665 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.529 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.87 1.31 90.21 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 179.195 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 20.0 m-85 -123.75 165.54 17.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.272 0.558 . . . . 0.0 110.568 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.29 138.2 26.23 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.076 179.325 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.44 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.8 t80 -50.81 137.31 20.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.509 -179.339 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.415 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.7 t-20 -118.77 88.3 34.99 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.311 -179.134 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_exo -66.2 0.27 3.46 Favored 'Trans proline' 0 N--CA 1.495 1.562 0 C-N-CA 122.771 2.314 . . . . 0.0 112.305 -179.626 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.8 t -103.08 -19.84 5.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.917 0.389 . . . . 0.0 110.441 -179.478 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.816 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.24 -41.23 4.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.136 179.464 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.04 -3.0 11.62 Favored Glycine 0 CA--C 1.533 1.188 0 CA-C-N 116.208 -0.451 . . . . 0.0 112.228 178.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.415 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -147.61 -171.95 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 117.469 0.634 . . . . 0.0 110.262 179.7 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 24.0 m -90.85 142.41 27.79 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.259 0.552 . . . . 0.0 109.845 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.7 p -128.68 154.35 46.38 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.692 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.443 ' O ' HG23 ' A' ' 18' ' ' ILE . 10.4 tt -57.31 131.11 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.805 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.529 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -88.27 154.45 20.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.85 -179.938 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -62.4 -17.7 59.8 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.407 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 73.6 m -62.41 -25.38 67.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.401 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 4.0 tmt_? -60.65 -39.25 87.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.537 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.65 HG22 ' HG2' ' A' ' 24' ' ' GLU . 34.1 mm -52.5 -87.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.991 -179.039 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.65 ' HG2' HG22 ' A' ' 23' ' ' ILE . 77.9 mm-40 -129.13 -118.83 0.24 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.507 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.442 ' CD2' ' C ' ' A' ' 24' ' ' GLU . 12.4 m-70 68.99 153.2 0.14 Allowed Pre-proline 0 CA--C 1.536 0.418 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.995 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -44.22 -35.8 8.36 Favored 'Trans proline' 0 N--CA 1.5 1.903 0 C-N-CA 122.574 2.183 . . . . 0.0 112.777 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.438 ' O ' ' OD1' ' A' ' 30' ' ' ASP . . . -56.46 -34.48 63.77 Favored Glycine 0 CA--C 1.529 0.965 0 N-CA-C 111.074 -0.811 . . . . 0.0 111.074 -179.576 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -87.21 -34.2 19.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.074 0.464 . . . . 0.0 110.791 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 67.5 m-85 -73.83 -9.46 58.67 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.586 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' A' ' 27' ' ' GLY . 50.9 p-10 -77.8 -0.52 27.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.211 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 1.5 p90 . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 117.917 -1.04 . . . . 0.0 110.539 179.85 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.52 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.16 0 CA-C-O 118.235 -0.888 . . . . 0.0 111.203 . . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.1 t90 -68.88 131.05 44.49 Favored 'General case' 0 C--N 1.33 -0.28 0 O-C-N 124.25 0.969 . . . . 0.0 110.435 179.809 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.414 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 75.4 m -120.34 153.08 36.96 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.363 -179.815 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -87.55 170.67 11.3 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.487 -179.681 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_exo -59.18 139.25 89.45 Favored 'Trans proline' 0 C--N 1.311 -1.406 0 C-N-CA 121.946 1.764 . . . . 0.0 111.855 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.516 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.43 -0.05 88.39 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 179.098 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -122.3 164.88 17.13 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.008 0.432 . . . . 0.0 110.448 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.54 139.5 28.23 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.648 179.385 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.52 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 20.3 t80 -52.24 137.99 27.29 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.973 0.416 . . . . 0.0 110.575 -179.422 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.412 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.8 t-20 -119.16 87.91 35.91 Favored Pre-proline 0 CA--C 1.54 0.578 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.357 -179.035 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -66.28 0.71 3.06 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.892 2.395 . . . . 0.0 112.105 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.1 t -103.36 -19.27 6.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.069 0.462 . . . . 0.0 110.35 -179.263 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.811 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -110.52 -41.35 4.36 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.949 179.647 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.04 -3.38 11.56 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 121.302 -0.475 . . . . 0.0 112.45 179.01 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.412 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.1 pt -146.02 -170.9 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-N 117.14 0.47 . . . . 0.0 110.617 179.597 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 28.0 m -92.14 142.09 27.88 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 120.959 0.409 . . . . 0.0 110.078 179.755 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.1 p -128.33 154.41 45.98 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.109 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.641 HD11 ' HG2' ' A' ' 22' ' ' ARG . 15.7 tt -57.34 133.06 22.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.668 -179.596 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.516 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -92.84 163.93 13.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.727 -179.455 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.0 mt -64.46 -26.05 68.27 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.843 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.596 ' O ' ' NE2' ' A' ' 25' ' ' HIS . 73.6 m -56.38 -35.71 68.02 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.394 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.641 ' HG2' HD11 ' A' ' 18' ' ' ILE . 6.3 tpm_? -36.94 -30.24 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.603 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.494 ' N ' ' O ' ' A' ' 21' ' ' SER . 33.8 mt -131.15 67.09 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.814 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -146.12 27.77 1.15 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.784 179.807 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.596 ' NE2' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -155.25 58.46 1.93 Allowed Pre-proline 0 C--N 1.324 -0.51 0 CA-C-O 121.229 0.538 . . . . 0.0 110.528 -179.369 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.62 -25.31 47.26 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.449 2.1 . . . . 0.0 111.987 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.91 -22.11 61.97 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -60.12 -40.99 91.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.659 0.266 . . . . 0.0 110.547 179.801 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.405 ' HD2' ' H ' ' A' ' 30' ' ' ASP . 0.5 OUTLIER -118.5 -107.98 0.37 Allowed 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.439 179.734 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.405 ' H ' ' HD2' ' A' ' 29' ' ' TYR . 68.0 t0 -143.66 107.26 4.61 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.496 ' CD2' ' OXT' ' A' ' 31' ' ' TYR . 74.2 t80 . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.47 -179.811 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.514 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.157 0 CA-C-O 118.31 -0.853 . . . . 0.0 111.046 . . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.3 t90 -63.68 132.75 52.04 Favored 'General case' 0 C--N 1.33 -0.282 0 O-C-N 124.24 0.962 . . . . 0.0 110.451 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.6 m -120.31 152.25 38.08 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.817 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -88.27 168.33 16.73 Favored Pre-proline 0 N--CA 1.45 -0.455 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.733 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -58.15 138.79 87.78 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 C-N-CA 122.526 2.151 . . . . 0.0 111.755 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.466 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.38 0.27 89.68 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.7 m-85 -123.27 164.43 18.79 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 121.168 0.508 . . . . 0.0 110.745 179.744 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -142.93 135.43 27.57 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.249 179.394 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.514 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 9.0 t80 -48.34 135.47 13.69 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.848 -179.634 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.483 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.6 t-20 -119.13 94.81 48.76 Favored Pre-proline 0 CA--C 1.545 0.753 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.054 -179.597 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -74.22 -0.12 9.2 Favored 'Trans proline' 0 N--CA 1.493 1.452 0 C-N-CA 122.715 2.277 . . . . 0.0 112.503 -179.554 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 t -101.58 -18.62 6.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.885 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.818 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.34 -43.35 4.14 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.006 179.421 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.78 0.21 9.96 Favored Glycine 0 CA--C 1.535 1.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 112.56 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.483 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.7 pt -152.38 -170.48 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.281 0 CA-C-N 117.215 0.507 . . . . 0.0 110.258 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 18.7 m -91.13 141.93 28.28 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 120.999 0.428 . . . . 0.0 110.13 179.435 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.7 p -127.36 153.78 45.79 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.529 -0.76 . . . . 0.0 110.858 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.411 ' O ' HG23 ' A' ' 18' ' ' ILE . 10.5 tt -57.23 131.81 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.422 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.466 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -90.39 160.99 15.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.722 -179.903 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.514 HD22 ' N ' ' A' ' 20' ' ' LEU . 4.2 mm? -67.26 -19.71 65.55 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.702 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 99.0 p -62.62 -21.52 65.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.424 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 4.1 tmt_? -59.23 -36.45 75.47 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.368 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.659 HG22 ' N ' ' A' ' 24' ' ' GLU . 78.1 mt -61.77 -111.78 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.019 -179.327 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.659 ' N ' HG22 ' A' ' 23' ' ' ILE . 98.7 mt-10 -120.79 108.31 13.8 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.971 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.568 ' CG ' ' O ' ' A' ' 24' ' ' GLU . 52.6 m80 -158.77 145.66 12.92 Favored Pre-proline 0 C--O 1.245 0.848 0 CA-C-O 120.915 0.388 . . . . 0.0 110.324 -179.647 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -68.37 -33.26 23.94 Favored 'Trans proline' 0 N--CA 1.492 1.386 0 C-N-CA 122.638 2.225 . . . . 0.0 112.379 179.532 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.53 -14.35 77.52 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.798 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.431 HD21 ' HA ' ' A' ' 28' ' ' ASN . 2.1 t-20 -87.37 -48.37 8.03 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.751 0.31 . . . . 0.0 110.863 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -160.57 -33.14 0.05 Allowed 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.714 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 16.2 t0 63.38 72.37 0.48 Allowed 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.029 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.466 ' CD2' ' OXT' ' A' ' 31' ' ' TYR . 89.6 t80 . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.436 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.511 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.171 0 CA-C-O 118.216 -0.897 . . . . 0.0 110.98 . . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 -68.35 131.21 44.93 Favored 'General case' 0 C--N 1.328 -0.367 0 O-C-N 124.237 0.961 . . . . 0.0 110.515 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.441 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.3 m -119.94 151.98 38.12 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.586 -179.855 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.43 168.81 17.14 Favored Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.845 179.302 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -58.45 138.92 88.43 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 122.624 2.216 . . . . 0.0 111.833 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.537 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.48 -0.24 88.18 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 179.602 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -122.33 166.33 14.86 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.043 0.449 . . . . 0.0 110.503 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.88 137.5 25.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.0 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.511 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 16.1 t80 -50.36 136.79 19.73 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.64 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.419 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.6 t-20 -119.16 89.27 39.15 Favored Pre-proline 0 CA--C 1.543 0.699 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.524 -179.655 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -66.66 -0.14 4.19 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 122.964 2.443 . . . . 0.0 112.135 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.8 t -103.95 -18.89 6.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.9 0.381 . . . . 0.0 110.383 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.775 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.08 -42.12 4.51 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.629 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.25 -2.35 11.47 Favored Glycine 0 CA--C 1.536 1.367 0 CA-C-N 116.214 -0.448 . . . . 0.0 112.914 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.419 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.7 pt -149.33 -171.5 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 122.641 -0.329 . . . . 0.0 110.543 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.2 m -91.62 142.84 27.19 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-O 121.091 0.472 . . . . 0.0 110.297 179.782 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 66.4 p -129.1 154.84 46.3 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.444 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.591 HD11 ' HG2' ' A' ' 22' ' ' ARG . 14.3 tt -57.08 131.1 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.586 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.537 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -87.47 159.74 18.54 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.793 -179.994 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.4 mt -63.11 -27.14 69.18 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-O 121.111 0.482 . . . . 0.0 110.998 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 40.5 t -57.38 -36.96 71.92 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.261 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.591 ' HG2' HD11 ' A' ' 18' ' ' ILE . 11.7 tpt180 -43.19 -31.6 0.62 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.407 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.622 HG22 ' N ' ' A' ' 24' ' ' GLU . 96.7 mt -89.56 -98.21 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.742 179.786 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.622 ' N ' HG22 ' A' ' 23' ' ' ILE . 94.2 mt-10 -151.47 70.78 0.97 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.146 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -143.03 69.34 18.3 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.779 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.411 ' O ' ' N ' ' A' ' 30' ' ' ASP . 22.9 Cg_exo -63.28 -28.54 72.48 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 123.054 2.503 . . . . 0.0 112.129 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.88 -27.49 68.65 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 8.4 m120 -60.5 -39.43 87.7 Favored 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 121.049 -0.261 . . . . 0.0 110.988 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 79.1 m-85 -115.52 4.72 14.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.653 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.411 ' N ' ' O ' ' A' ' 26' ' ' PRO . 65.7 m-20 49.4 40.19 18.13 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.374 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 57.8 t80 . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.627 -179.888 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.391 -5.151 0 CA-C-O 118.267 -0.873 . . . . 0.0 111.223 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.0 t90 -62.18 132.36 52.5 Favored 'General case' 0 C--N 1.329 -0.326 0 O-C-N 124.311 1.007 . . . . 0.0 110.445 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.9 m -123.04 155.16 37.42 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.292 0.568 . . . . 0.0 111.107 -179.694 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.69 166.59 18.77 Favored Pre-proline 0 N--CA 1.449 -0.516 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.797 179.208 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -57.79 139.16 89.38 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 122.494 2.129 . . . . 0.0 111.911 179.573 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.548 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.78 1.67 90.29 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.748 -0.541 . . . . 0.0 111.748 179.481 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 18.9 m-85 -123.61 165.63 16.85 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.062 0.458 . . . . 0.0 110.415 179.731 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.68 134.59 28.84 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.225 179.614 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.498 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -49.1 135.31 16.5 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.639 -179.764 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.498 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.5 t-20 -118.93 94.64 48.38 Favored Pre-proline 0 CA--C 1.546 0.794 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.807 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -74.25 -0.33 9.49 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.851 2.367 . . . . 0.0 112.249 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.7 t -101.99 -18.14 6.61 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.965 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.799 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.61 -43.65 4.02 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.376 179.455 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.69 1.12 9.94 Favored Glycine 0 CA--C 1.535 1.322 0 CA-C-N 116.049 -0.523 . . . . 0.0 112.908 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.476 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -153.07 -170.85 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.163 0 CA-C-N 117.055 0.427 . . . . 0.0 110.354 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 16.7 m -91.86 141.34 28.77 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-O 120.945 0.402 . . . . 0.0 110.24 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.0 p -127.99 153.0 47.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.615 -179.799 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.8 tt -53.66 141.03 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.799 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.346 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.548 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -97.16 163.22 13.01 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.847 -179.78 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -59.2 -19.03 41.85 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.52 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.416 ' O ' ' O ' ' A' ' 24' ' ' GLU . 75.1 m -60.33 -44.26 95.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.434 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 37.7 mtp180 -75.98 -30.91 58.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.623 179.304 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.549 HG22 ' HG3' ' A' ' 24' ' ' GLU . 47.5 mm -59.61 -46.94 92.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.539 -179.438 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.549 ' HG3' HG22 ' A' ' 23' ' ' ILE . 98.2 mt-10 -143.58 173.19 11.86 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.9 180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.481 ' CG ' ' C ' ' A' ' 24' ' ' GLU . 2.5 p80 35.49 57.08 2.63 Favored Pre-proline 0 CA--C 1.531 0.248 0 CA-C-O 120.992 0.425 . . . . 0.0 110.489 179.798 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -59.92 -28.09 86.37 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 C-N-CA 122.668 2.245 . . . . 0.0 111.885 -178.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -62.28 -39.22 97.43 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 179.67 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 67.0 m-80 51.65 39.81 25.93 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.784 0.326 . . . . 0.0 110.691 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 55.64 24.95 7.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.594 179.737 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.524 ' O ' ' CD2' ' A' ' 31' ' ' TYR . 67.2 m-20 48.11 37.33 7.8 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.724 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.524 ' CD2' ' O ' ' A' ' 30' ' ' ASP . 9.9 m-85 . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.545 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.491 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.15 0 CA-C-O 118.248 -0.882 . . . . 0.0 111.02 . . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 -65.86 132.87 49.7 Favored 'General case' 0 C--N 1.329 -0.318 0 O-C-N 124.275 0.984 . . . . 0.0 110.394 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.8 m -118.08 152.26 35.92 Favored 'General case' 0 CA--C 1.52 -0.202 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.568 -179.776 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -89.53 169.27 13.07 Favored Pre-proline 0 N--CA 1.451 -0.404 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 -179.436 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -57.79 139.23 89.6 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 121.939 1.759 . . . . 0.0 111.779 179.53 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.513 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.88 1.18 90.18 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.416 -0.674 . . . . 0.0 111.416 179.267 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.8 m-85 -124.23 164.28 19.85 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.273 0.559 . . . . 0.0 110.525 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.68 137.37 26.55 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.164 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.491 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 18.8 t80 -50.8 137.86 19.66 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 120.478 -0.489 . . . . 0.0 110.681 -179.321 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.405 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.7 t-20 -119.37 88.39 37.98 Favored Pre-proline 0 CA--C 1.538 0.511 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.504 -179.209 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -66.62 0.52 3.45 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.705 2.27 . . . . 0.0 112.189 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.0 t -103.3 -19.24 6.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.952 0.406 . . . . 0.0 110.282 -179.294 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.801 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.56 -41.66 4.52 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.143 179.491 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.49 -2.38 12.44 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-N 116.068 -0.515 . . . . 0.0 112.312 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.405 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -147.87 -172.45 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 117.707 0.753 . . . . 0.0 110.25 179.58 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.5 m -90.63 142.48 27.71 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.254 0.549 . . . . 0.0 109.592 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.7 p -128.96 154.1 46.91 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.641 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.418 ' O ' HG23 ' A' ' 18' ' ' ILE . 8.9 tt -57.22 131.82 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-O 120.991 0.424 . . . . 0.0 110.547 -179.489 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.513 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -89.55 160.98 16.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.78 -179.613 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 8.8 mp -62.45 -23.97 67.18 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.892 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 43.5 t -53.07 -37.17 61.43 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.575 -179.419 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.409 ' O ' ' O ' ' A' ' 23' ' ' ILE . 0.0 OUTLIER -56.07 -39.99 72.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.257 -179.831 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.409 ' O ' ' O ' ' A' ' 22' ' ' ARG . 50.2 mm -45.67 -94.46 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.617 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -145.71 38.87 1.13 Allowed 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.551 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 90.7 m-70 -133.57 59.99 44.01 Favored Pre-proline 0 N--CA 1.461 0.121 0 C-N-CA 120.486 -0.486 . . . . 0.0 110.713 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -75.29 -18.37 18.18 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.745 2.296 . . . . 0.0 112.541 179.662 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -58.41 -38.53 90.98 Favored Glycine 0 CA--C 1.52 0.395 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.176 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -60.41 -36.93 79.3 Favored 'General case' 0 C--N 1.321 -0.666 0 C-N-CA 121.158 -0.217 . . . . 0.0 110.631 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -113.82 31.4 6.55 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.269 -179.016 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 59.0 p30 -92.88 7.5 43.61 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.936 -0.305 . . . . 0.0 110.575 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.476 ' CD2' ' OXT' ' A' ' 31' ' ' TYR . 55.6 t80 . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.676 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.393 -5.094 0 CA-C-O 118.161 -0.923 . . . . 0.0 111.026 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.2 t90 -65.89 129.98 41.68 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 124.29 0.994 . . . . 0.0 110.453 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 97.5 m -123.56 149.39 45.34 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-O 121.403 0.62 . . . . 0.0 111.109 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.78 160.73 81.33 Favored Pre-proline 0 N--CA 1.442 -0.846 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.252 179.306 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -64.46 138.51 60.33 Favored 'Trans proline' 0 C--N 1.302 -1.883 0 C-N-CA 122.429 2.086 . . . . 0.0 111.929 -179.665 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.587 ' O ' HG22 ' A' ' 19' ' ' THR . . . 89.61 -7.89 80.95 Favored Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 -179.64 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 15.6 m-85 -115.19 167.91 10.41 Favored 'General case' 0 CA--C 1.522 -0.129 0 CA-C-O 121.131 0.491 . . . . 0.0 110.5 179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -139.04 134.08 32.52 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.171 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.456 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 9.3 t80 -50.87 135.39 24.31 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.692 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.456 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.5 t-20 -119.12 95.52 49.4 Favored Pre-proline 0 CA--C 1.545 0.777 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.927 -179.573 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -75.04 0.71 8.6 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.857 2.371 . . . . 0.0 112.35 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 36.3 t -103.0 -17.82 6.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.995 -179.762 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.788 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -110.32 -43.18 3.96 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.598 179.411 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.05 2.29 11.16 Favored Glycine 0 CA--C 1.535 1.333 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.882 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.446 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.2 pt -153.65 -174.21 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.232 0 CA-C-N 117.314 0.557 . . . . 0.0 110.121 179.67 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 3.9 m -88.29 139.99 29.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.04 0.447 . . . . 0.0 110.535 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.8 p -126.21 152.95 45.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.521 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.5 tt -58.0 133.59 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.433 -179.73 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.587 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -85.19 152.24 23.5 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.788 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 8.0 mp -57.43 -27.55 62.51 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.601 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.502 ' OG ' ' CE2' ' A' ' 29' ' ' TYR . 70.5 m -58.49 -44.09 89.25 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.189 -179.385 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 73.3 ttt180 -70.59 -35.85 73.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.057 0.455 . . . . 0.0 110.149 179.168 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.57 HG22 ' HG3' ' A' ' 24' ' ' GLU . 40.0 mm -59.66 -49.55 83.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.053 -178.865 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.57 ' HG3' HG22 ' A' ' 23' ' ' ILE . 35.9 mt-10 -157.22 -167.64 2.38 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.701 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.504 ' N ' ' HD3' ' A' ' 26' ' ' PRO . 0.1 OUTLIER 58.87 55.65 5.52 Favored Pre-proline 0 CA--C 1.542 0.659 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.831 -179.756 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.547 ' O ' ' N ' ' A' ' 30' ' ' ASP . 31.3 Cg_exo -58.94 -40.15 74.36 Favored 'Trans proline' 0 N--CA 1.497 1.698 0 C-N-CA 122.272 1.981 . . . . 0.0 112.166 -179.551 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.33 -39.66 91.83 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 111.774 -0.53 . . . . 0.0 111.774 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -61.05 -40.06 92.22 Favored 'General case' 0 CA--C 1.52 -0.195 0 C-N-CA 121.007 -0.277 . . . . 0.0 111.009 -179.264 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.502 ' CE2' ' OG ' ' A' ' 21' ' ' SER . 82.7 m-85 -112.55 11.33 19.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.829 -179.864 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.547 ' N ' ' O ' ' A' ' 26' ' ' PRO . 54.2 t0 49.37 44.51 23.73 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.552 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.527 ' CD2' ' O ' ' A' ' 31' ' ' TYR . 90.7 t80 . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.577 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.2 t90 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.632 0.253 . . . . 0.0 110.335 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.9 m -119.7 151.56 38.54 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.471 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.51 169.75 14.29 Favored Pre-proline 0 N--CA 1.452 -0.369 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.742 -179.519 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_exo -58.94 139.24 90.0 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 122.109 1.873 . . . . 0.0 111.795 179.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.534 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.52 -0.02 88.53 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 179.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -122.21 165.64 15.84 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.139 0.495 . . . . 0.0 110.542 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -146.01 138.44 25.45 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.078 179.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.3 t80 -50.09 137.36 17.64 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.557 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.43 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -118.83 88.84 36.7 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.455 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -66.82 -0.06 4.21 Favored 'Trans proline' 0 N--CA 1.496 1.623 0 C-N-CA 122.732 2.288 . . . . 0.0 112.103 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 19.3 t -103.05 -19.01 6.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.874 0.369 . . . . 0.0 110.471 -179.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.803 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -110.03 -41.36 4.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.902 179.416 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.79 -2.92 11.96 Favored Glycine 0 CA--C 1.535 1.288 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.42 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.43 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.2 pt -147.21 -169.55 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 117.5 0.65 . . . . 0.0 110.342 179.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 23.6 m -91.76 142.08 27.98 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 121.197 0.523 . . . . 0.0 109.85 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.8 p -129.24 154.73 46.52 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.573 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.413 ' O ' HG23 ' A' ' 18' ' ' ILE . 12.6 tt -57.81 132.1 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-O 121.189 0.519 . . . . 0.0 110.572 -179.681 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.534 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -85.04 152.9 23.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.574 -179.803 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.475 ' N ' HD12 ' A' ' 20' ' ' LEU . 11.2 mp . . . . . 0 N--CA 1.452 -0.338 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.645 0.26 . . . . 0.0 110.6 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 77.0 m -120.88 151.58 39.48 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.841 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -88.04 167.04 21.15 Favored Pre-proline 0 N--CA 1.45 -0.474 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.635 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -58.04 139.13 89.31 Favored 'Trans proline' 0 N--CA 1.493 1.482 0 C-N-CA 122.573 2.182 . . . . 0.0 111.87 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.479 ' O ' HG22 ' A' ' 19' ' ' THR . . . 85.66 -4.38 85.85 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -119.63 164.53 15.74 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.067 0.461 . . . . 0.0 110.632 179.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -140.51 132.83 28.29 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.298 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.48 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -48.38 134.5 14.95 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.707 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.48 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.8 t30 -118.01 94.57 46.73 Favored Pre-proline 0 CA--C 1.545 0.752 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.951 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -74.39 0.45 8.56 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.963 2.442 . . . . 0.0 112.33 -179.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.8 t -102.74 -19.05 6.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.924 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.8 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -108.65 -43.9 4.17 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.511 179.435 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.77 1.8 9.67 Favored Glycine 0 CA--C 1.534 1.269 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.719 179.328 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.465 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -153.81 -173.49 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.235 0 CA-C-N 117.061 0.431 . . . . 0.0 110.408 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.5 m -89.43 140.97 28.99 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-O 120.884 0.373 . . . . 0.0 110.287 179.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.2 p -127.91 152.45 47.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.531 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 tt -58.42 133.06 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.262 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.479 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -84.04 142.88 30.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.63 -179.935 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 6.8 mp . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.89 180.0 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.1 t90 . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.674 0.274 . . . . 0.0 110.454 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.42 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 74.1 m -122.28 153.58 38.72 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.245 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -89.05 168.3 15.84 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.902 -179.488 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -57.64 138.11 84.52 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.678 2.252 . . . . 0.0 111.654 179.697 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.479 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.13 1.47 90.35 Favored Glycine 0 CA--C 1.528 0.857 0 N-CA-C 111.206 -0.758 . . . . 0.0 111.206 179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.8 m-85 -125.22 163.23 22.94 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.13 0.49 . . . . 0.0 110.602 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -143.17 135.82 27.56 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.134 179.528 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.42 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 16.1 t80 -48.36 136.96 11.79 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.601 -179.594 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.457 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -118.58 89.25 36.56 Favored Pre-proline 0 CA--C 1.54 0.568 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.637 -179.605 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -67.02 -0.02 4.3 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 122.907 2.405 . . . . 0.0 112.051 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.0 t -103.49 -17.94 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 CA-C-O 120.94 0.4 . . . . 0.0 110.317 -179.316 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.808 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -111.09 -42.65 3.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.4 179.566 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.57 -2.1 10.26 Favored Glycine 0 CA--C 1.534 1.224 0 CA-C-N 116.113 -0.494 . . . . 0.0 112.432 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.457 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.0 pt -149.92 -173.07 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.917 0.358 . . . . 0.0 110.592 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.9 m -89.27 142.34 27.74 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 120.946 0.403 . . . . 0.0 110.332 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 65.0 p -129.6 150.9 50.73 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.515 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 tt -51.83 137.72 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.149 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.479 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -101.06 169.66 8.79 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.062 -179.328 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.414 ' N ' ' OG1' ' A' ' 19' ' ' THR . 4.8 tt . . . . . 0 N--CA 1.451 -0.396 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.17 179.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.6 t90 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.645 0.26 . . . . 0.0 110.452 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.414 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 73.4 m -119.44 151.12 39.07 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.566 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.34 169.02 16.36 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.822 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.93 138.92 88.45 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.539 2.159 . . . . 0.0 111.879 179.554 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.437 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.98 0.06 89.09 Favored Glycine 0 CA--C 1.529 0.912 0 N-CA-C 111.359 -0.697 . . . . 0.0 111.359 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -123.9 164.36 19.43 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.073 0.463 . . . . 0.0 110.601 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.89 136.25 25.22 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.235 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.414 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 17.7 t80 -48.6 136.91 12.56 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.553 -179.6 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.421 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -119.1 89.22 38.81 Favored Pre-proline 0 CA--C 1.54 0.59 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.539 -179.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -66.67 -0.08 4.12 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 122.915 2.41 . . . . 0.0 112.08 -179.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.4 t -103.53 -19.89 5.99 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 120.895 0.379 . . . . 0.0 110.303 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.791 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -108.4 -42.04 4.69 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.624 179.413 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.92 -1.72 11.87 Favored Glycine 0 CA--C 1.534 1.28 0 CA-C-N 116.035 -0.529 . . . . 0.0 112.543 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.421 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 4.7 pt -149.66 -172.9 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 117.094 0.447 . . . . 0.0 110.556 179.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.5 m -88.94 141.77 28.21 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.061 0.458 . . . . 0.0 110.404 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.6 p -128.69 152.69 48.11 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.542 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.407 ' O ' HG23 ' A' ' 18' ' ' ILE . 10.7 tt -55.25 132.3 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.348 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.437 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -94.01 166.76 11.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.903 -179.667 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.0 mt . . . . . 0 N--CA 1.449 -0.516 0 CA-C-O 121.192 0.52 . . . . 0.0 110.861 179.708 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.8 t90 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.694 0.283 . . . . 0.0 110.555 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 93.3 m -123.45 148.93 45.69 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.986 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -69.95 161.97 71.61 Favored Pre-proline 0 N--CA 1.446 -0.67 0 CA-C-N 115.549 -0.751 . . . . 0.0 109.979 179.77 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -64.42 139.63 65.89 Favored 'Trans proline' 0 C--N 1.3 -2.001 0 C-N-CA 122.212 1.941 . . . . 0.0 111.904 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.461 ' O ' HG22 ' A' ' 19' ' ' THR . . . 84.88 -2.83 87.98 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 -179.301 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -119.29 166.71 12.66 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 121.006 0.432 . . . . 0.0 110.497 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.69 137.45 31.74 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.097 179.485 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 19.2 t80 -52.04 137.04 28.19 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.412 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.403 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -118.57 89.44 37.03 Favored Pre-proline 0 CA--C 1.539 0.53 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.38 -179.165 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -67.57 -0.02 4.69 Favored 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 122.721 2.28 . . . . 0.0 112.039 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 23.0 t -102.68 -18.69 6.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.507 -179.125 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.805 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -110.65 -41.37 4.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.79 179.67 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 119.97 -1.57 13.32 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-N 116.085 -0.507 . . . . 0.0 112.403 179.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.403 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -148.17 -172.72 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 117.484 0.642 . . . . 0.0 110.252 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.9 m -90.5 140.56 29.62 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.106 0.479 . . . . 0.0 109.956 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.0 p -127.36 152.53 47.36 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.315 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.2 tt -57.65 135.05 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 CA-C-O 121.139 0.495 . . . . 0.0 110.539 -179.646 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.461 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -86.93 141.75 28.49 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.319 -179.788 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.795 HD23 ' O ' ' A' ' 20' ' ' LEU . 3.3 tt . . . . . 0 N--CA 1.448 -0.526 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.248 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.8 t90 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.596 0.236 . . . . 0.0 110.527 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.4 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 76.1 m -118.92 153.08 35.16 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 121.184 0.516 . . . . 0.0 110.926 -179.716 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.79 168.51 15.56 Favored Pre-proline 0 N--CA 1.452 -0.364 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.995 179.158 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -58.8 138.55 86.35 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 C-N-CA 122.675 2.25 . . . . 0.0 111.78 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.559 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.02 -0.81 88.16 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.451 -0.66 . . . . 0.0 111.451 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -121.2 166.07 14.51 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-O 120.916 0.388 . . . . 0.0 110.679 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.21 136.59 26.64 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.899 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.486 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 8.4 t80 -49.46 135.48 17.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.755 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.486 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -119.38 94.92 48.93 Favored Pre-proline 0 CA--C 1.547 0.83 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.882 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -73.63 0.02 8.72 Favored 'Trans proline' 0 N--CA 1.492 1.441 0 C-N-CA 123.182 2.588 . . . . 0.0 112.427 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.5 t -103.29 -17.75 6.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.449 . . . . 0.0 109.985 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.771 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.97 -42.47 4.21 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 179.769 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.44 -0.18 11.3 Favored Glycine 0 CA--C 1.536 1.383 0 CA-C-N 116.253 -0.431 . . . . 0.0 113.185 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.474 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.8 pt -152.4 -170.77 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 O-C-N 122.493 -0.416 . . . . 0.0 110.387 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.9 m -90.89 142.67 27.52 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 120.979 0.418 . . . . 0.0 110.322 179.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.4 p -128.0 157.37 40.8 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.654 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.43 ' O ' HG23 ' A' ' 18' ' ' ILE . 14.1 tt -59.75 131.68 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.362 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.559 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -87.48 156.15 19.68 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.562 179.983 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.446 HD22 ' N ' ' A' ' 20' ' ' LEU . 4.3 mm? . . . . . 0 C--N 1.326 -0.439 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.641 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.1 t90 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.6 0.238 . . . . 0.0 110.418 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.6 m -120.28 154.4 35.01 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.899 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.3 168.94 13.15 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.78 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -59.14 139.05 88.69 Favored 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 122.521 2.147 . . . . 0.0 111.73 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.499 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.07 0.07 89.2 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.427 -0.669 . . . . 0.0 111.427 179.426 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -122.17 165.11 16.65 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-O 121.168 0.508 . . . . 0.0 110.662 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -142.74 135.29 27.77 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.113 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.462 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 9.1 t80 -49.0 135.04 16.41 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.744 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.485 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.9 t30 -118.38 94.79 47.74 Favored Pre-proline 0 CA--C 1.544 0.747 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.995 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -74.42 0.3 8.77 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 C-N-CA 122.807 2.338 . . . . 0.0 112.41 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.4 t -102.19 -18.43 6.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.838 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.818 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.72 -43.77 3.97 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.73 179.478 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 123.23 0.96 9.5 Favored Glycine 0 CA--C 1.535 1.309 0 CA-C-N 116.081 -0.509 . . . . 0.0 112.61 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.485 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -152.92 -170.61 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.274 0 CA-C-N 117.113 0.457 . . . . 0.0 110.298 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 15.2 m -91.03 141.53 28.74 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 120.916 0.389 . . . . 0.0 110.196 179.6 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 79.7 p -127.71 152.68 47.41 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.679 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.2 tt -56.76 133.83 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.582 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.349 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.499 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -87.88 147.56 25.04 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.683 -179.83 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.863 HD23 ' O ' ' A' ' 20' ' ' LEU . 5.3 tt . . . . . 0 N--CA 1.45 -0.437 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.468 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.6 t90 . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.607 0.241 . . . . 0.0 110.406 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.404 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 73.5 m -120.3 150.59 40.47 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.479 0.657 . . . . 0.0 110.805 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.66 168.1 23.0 Favored Pre-proline 0 CA--C 1.533 0.3 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.601 -179.504 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -59.03 137.87 82.18 Favored 'Trans proline' 0 N--CA 1.492 1.422 0 C-N-CA 122.513 2.142 . . . . 0.0 111.828 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.575 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.51 1.31 90.07 Favored Glycine 0 CA--C 1.528 0.879 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 179.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -121.58 165.78 15.18 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-O 121.111 0.481 . . . . 0.0 110.546 179.694 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -143.66 135.64 26.58 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.149 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.476 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 8.4 t80 -48.22 134.69 14.22 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.752 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.491 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.9 t30 -118.48 94.84 47.99 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.906 -179.667 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -74.25 -0.61 9.85 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.849 2.366 . . . . 0.0 112.348 -179.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.6 t -101.43 -18.0 6.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.946 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.796 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.85 -43.31 4.04 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.384 179.515 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.98 0.19 9.78 Favored Glycine 0 CA--C 1.533 1.172 0 CA-C-N 116.109 -0.496 . . . . 0.0 112.725 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.491 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.6 pt -152.67 -169.86 0.1 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.263 0 CA-C-N 117.096 0.448 . . . . 0.0 110.234 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 21.6 m -91.55 142.16 27.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.891 0.377 . . . . 0.0 110.219 179.597 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.6 p -127.2 154.48 44.76 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.63 -179.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt -56.84 132.66 21.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.379 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.575 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.1 OUTLIER -92.51 160.18 15.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.692 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 38.7 tp . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.418 179.81 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.0 t90 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.586 0.231 . . . . 0.0 110.431 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.408 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.3 m -120.27 153.35 36.5 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.972 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -89.66 168.1 15.77 Favored Pre-proline 0 C--N 1.327 -0.4 0 O-C-N 123.107 0.255 . . . . 0.0 110.874 -179.529 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_exo -57.75 139.06 89.02 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.47 2.113 . . . . 0.0 111.722 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.463 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.76 0.32 89.21 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 179.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -124.06 165.24 17.84 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.107 0.479 . . . . 0.0 110.66 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.63 137.07 26.42 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.231 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.408 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 17.7 t80 -49.82 137.57 16.18 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.657 -179.543 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.445 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -119.42 89.01 39.57 Favored Pre-proline 0 CA--C 1.541 0.634 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.414 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_exo -66.37 -0.56 4.41 Favored 'Trans proline' 0 N--CA 1.496 1.623 0 C-N-CA 122.932 2.421 . . . . 0.0 112.132 -179.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.0 t -103.08 -19.71 6.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.952 0.406 . . . . 0.0 110.416 -179.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.808 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -108.53 -41.68 4.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.664 179.349 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.62 -3.2 11.07 Favored Glycine 0 CA--C 1.533 1.216 0 CA-C-N 116.029 -0.532 . . . . 0.0 112.415 179.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.445 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -148.35 -171.28 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-N 117.042 0.421 . . . . 0.0 110.556 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 15.7 m -90.88 143.12 27.05 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.109 0.481 . . . . 0.0 110.392 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -129.69 152.96 48.62 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.583 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.5 tt -55.17 134.26 18.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.187 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.463 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -90.22 167.96 12.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.068 -179.494 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.522 HD22 ' N ' ' A' ' 20' ' ' LEU . 4.1 mm? . . . . . 0 N--CA 1.451 -0.393 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.521 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.6 t90 . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.717 0.294 . . . . 0.0 110.492 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.402 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.2 m -120.03 148.83 43.08 Favored 'General case' 0 CA--C 1.516 -0.329 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.708 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.44 168.0 26.4 Favored Pre-proline 0 N--CA 1.452 -0.327 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.901 179.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo -58.65 138.89 88.28 Favored 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 122.485 2.124 . . . . 0.0 111.739 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.534 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.44 0.61 89.36 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.398 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -122.57 166.28 15.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.097 0.475 . . . . 0.0 110.484 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.65 138.39 25.89 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.172 179.662 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.402 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 17.4 t80 -50.43 136.76 20.04 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.508 -179.619 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.43 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -118.76 89.24 37.37 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.592 -179.473 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -66.44 -0.04 3.93 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 C-N-CA 122.83 2.353 . . . . 0.0 112.375 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 t -103.8 -19.1 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.02 0.438 . . . . 0.0 110.363 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.816 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -109.54 -40.71 4.78 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.697 179.531 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.41 -3.38 12.41 Favored Glycine 0 CA--C 1.534 1.26 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.424 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.43 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -147.54 -171.25 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-N 117.149 0.474 . . . . 0.0 110.42 179.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 23.7 m -90.38 142.3 27.87 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-O 121.179 0.514 . . . . 0.0 110.136 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -129.17 155.21 45.87 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.588 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.415 ' O ' HG23 ' A' ' 18' ' ' ILE . 10.9 tt -56.82 132.35 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.726 0 CA-C-O 121.076 0.465 . . . . 0.0 110.681 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.534 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -87.06 160.56 18.55 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.724 -179.932 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.3 tt . . . . . 0 C--N 1.327 -0.404 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.821 179.779 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.3 t90 . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.71 0.29 . . . . 0.0 110.508 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.42 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 78.0 m -123.31 153.52 40.15 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.671 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.68 168.12 16.81 Favored Pre-proline 0 N--CA 1.452 -0.344 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.788 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_exo -56.64 138.86 86.57 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.075 1.85 . . . . 0.0 111.792 179.539 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.459 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.35 0.01 89.41 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 179.328 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -123.95 163.84 20.51 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.297 0.57 . . . . 0.0 110.56 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.39 136.94 26.7 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.086 179.438 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.42 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.6 t80 -50.29 137.22 18.7 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.615 -179.281 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.401 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -118.74 88.41 35.13 Favored Pre-proline 0 CA--C 1.539 0.545 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.555 -179.199 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -66.39 0.15 3.7 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 122.753 2.302 . . . . 0.0 112.252 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.3 t -103.49 -18.78 6.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.976 0.417 . . . . 0.0 110.281 -179.349 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.799 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -109.82 -41.44 4.51 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.794 179.488 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.47 -3.03 12.4 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-N 116.118 -0.492 . . . . 0.0 112.525 179.156 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.401 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.1 pt -147.69 -172.82 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 117.52 0.66 . . . . 0.0 110.327 179.634 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 25.4 m -90.23 141.14 29.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-O 121.135 0.493 . . . . 0.0 109.922 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.7 p -127.97 153.95 46.14 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.635 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.418 ' O ' HG23 ' A' ' 18' ' ' ILE . 9.9 tt -57.31 131.93 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.504 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.459 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -90.58 164.76 14.08 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.726 -179.691 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.415 ' HA ' HD23 ' A' ' 20' ' ' LEU . 94.1 mt . . . . . 0 N--CA 1.449 -0.492 0 CA-C-O 121.071 0.462 . . . . 0.0 111.106 179.793 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.8 t90 . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.648 0.261 . . . . 0.0 110.507 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.438 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 71.7 m -121.88 153.14 38.82 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.141 0.496 . . . . 0.0 110.568 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.13 167.77 22.23 Favored Pre-proline 0 N--CA 1.451 -0.405 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.85 179.45 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -58.15 138.61 86.83 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.513 2.142 . . . . 0.0 111.85 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.536 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.18 -0.99 88.2 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.468 -0.653 . . . . 0.0 111.468 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.1 m-85 -121.91 165.32 16.12 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.024 0.44 . . . . 0.0 110.54 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.84 135.91 24.95 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.214 179.615 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.438 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.0 t80 -48.96 137.28 13.09 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.518 -179.668 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.425 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -119.04 88.79 37.58 Favored Pre-proline 0 CA--C 1.543 0.7 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.468 -179.484 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_exo -66.11 -0.16 3.83 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.835 2.357 . . . . 0.0 112.213 -179.646 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.7 t -103.78 -19.72 6.1 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.318 0 CA-C-O 120.908 0.385 . . . . 0.0 110.246 -179.101 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.777 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -108.53 -41.99 4.67 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.371 179.458 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.0 -3.05 11.65 Favored Glycine 0 CA--C 1.537 1.412 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.779 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.425 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -148.34 -173.5 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 117.126 0.463 . . . . 0.0 110.588 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 21.2 m -89.46 141.28 28.71 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.002 0.429 . . . . 0.0 110.35 179.722 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -128.64 153.89 46.81 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.574 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.3 tt -56.38 132.61 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.345 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.536 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -88.76 153.75 20.83 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.18 -179.782 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.4 tt . . . . . 0 C--N 1.325 -0.458 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.34 179.549 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.4 t90 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.594 0.235 . . . . 0.0 110.38 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 79.7 m -120.15 150.73 40.15 Favored 'General case' 0 CA--C 1.519 -0.224 0 CA-C-O 121.216 0.531 . . . . 0.0 110.805 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.23 166.35 28.94 Favored Pre-proline 0 N--CA 1.448 -0.557 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.574 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -58.96 139.73 92.17 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 122.478 2.118 . . . . 0.0 111.841 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.574 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.47 0.01 89.53 Favored Glycine 0 CA--C 1.53 0.997 0 N-CA-C 111.697 -0.561 . . . . 0.0 111.697 179.4 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -121.71 166.47 14.25 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.97 0.414 . . . . 0.0 110.38 179.639 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.5 135.15 29.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.215 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.49 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -50.2 134.73 22.21 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.657 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.49 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -118.05 94.98 47.59 Favored Pre-proline 0 CA--C 1.546 0.813 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.923 -179.621 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -74.6 0.63 8.45 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 C-N-CA 122.911 2.407 . . . . 0.0 112.443 -179.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 26.9 t -102.85 -18.87 6.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.926 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.794 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -108.75 -43.54 4.23 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.469 179.452 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.98 -0.0 9.79 Favored Glycine 0 CA--C 1.535 1.342 0 CA-C-N 116.065 -0.516 . . . . 0.0 112.853 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.477 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -152.38 -170.53 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.165 0 CA-C-N 117.069 0.435 . . . . 0.0 110.339 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.6 m -91.03 142.13 28.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.954 0.406 . . . . 0.0 110.28 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.4 p -128.88 151.99 49.01 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.605 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.7 tt -52.83 139.42 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.477 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.574 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -95.5 169.66 9.89 Favored 'General case' 0 C--O 1.241 0.635 0 CA-C-O 121.246 0.546 . . . . 0.0 111.036 -179.944 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.416 HD13 ' HA ' ' A' ' 20' ' ' LEU . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.841 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.1 t90 . . . . . 0 C--O 1.231 0.091 0 N-CA-C 110.21 -0.293 . . . . 0.0 110.21 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.44 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.5 m -119.01 150.56 39.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.671 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.4 168.55 18.33 Favored Pre-proline 0 N--CA 1.451 -0.381 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.668 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -57.94 138.56 86.63 Favored 'Trans proline' 0 N--CA 1.496 1.643 0 C-N-CA 122.115 1.877 . . . . 0.0 111.8 179.665 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.529 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.87 1.31 90.21 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 179.195 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 20.0 m-85 -123.75 165.54 17.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.272 0.558 . . . . 0.0 110.568 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.29 138.2 26.23 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.076 179.325 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.44 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.8 t80 -50.81 137.31 20.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.509 -179.339 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.415 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -118.77 88.3 34.99 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.311 -179.134 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_exo -66.2 0.27 3.46 Favored 'Trans proline' 0 N--CA 1.495 1.562 0 C-N-CA 122.771 2.314 . . . . 0.0 112.305 -179.626 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.8 t -103.08 -19.84 5.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.917 0.389 . . . . 0.0 110.441 -179.478 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.816 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.24 -41.23 4.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.136 179.464 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.04 -3.0 11.62 Favored Glycine 0 CA--C 1.533 1.188 0 CA-C-N 116.208 -0.451 . . . . 0.0 112.228 178.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.415 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -147.61 -171.95 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 117.469 0.634 . . . . 0.0 110.262 179.7 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 24.0 m -90.85 142.41 27.79 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.259 0.552 . . . . 0.0 109.845 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.7 p -128.68 154.35 46.38 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.692 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.443 ' O ' HG23 ' A' ' 18' ' ' ILE . 10.4 tt -57.31 131.11 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.805 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.529 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -88.27 154.45 20.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.85 -179.938 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 2.7 mm? . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.407 179.868 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.1 t90 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.651 0.262 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.414 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 75.4 m -120.34 153.08 36.96 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.363 -179.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -87.55 170.67 11.3 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.487 -179.681 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_exo -59.18 139.25 89.45 Favored 'Trans proline' 0 C--N 1.311 -1.406 0 C-N-CA 121.946 1.764 . . . . 0.0 111.855 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.516 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.43 -0.05 88.39 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 179.098 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -122.3 164.88 17.13 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.008 0.432 . . . . 0.0 110.448 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.54 139.5 28.23 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.648 179.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.414 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 20.3 t80 -52.24 137.99 27.29 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.973 0.416 . . . . 0.0 110.575 -179.422 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.412 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -119.16 87.91 35.91 Favored Pre-proline 0 CA--C 1.54 0.578 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.357 -179.035 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -66.28 0.71 3.06 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.892 2.395 . . . . 0.0 112.105 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.1 t -103.36 -19.27 6.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.069 0.462 . . . . 0.0 110.35 -179.263 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.811 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -110.52 -41.35 4.36 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.949 179.647 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.04 -3.38 11.56 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 121.302 -0.475 . . . . 0.0 112.45 179.01 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.412 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.1 pt -146.02 -170.9 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-N 117.14 0.47 . . . . 0.0 110.617 179.597 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 28.0 m -92.14 142.09 27.88 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 120.959 0.409 . . . . 0.0 110.078 179.755 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.1 p -128.33 154.41 45.98 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.109 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 15.7 tt -57.34 133.06 22.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.668 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.516 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -92.84 163.93 13.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.727 -179.455 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.0 mt . . . . . 0 N--CA 1.449 -0.51 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.843 179.894 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.3 t90 . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.568 0.223 . . . . 0.0 110.451 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.6 m -120.31 152.25 38.08 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.817 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -88.27 168.33 16.73 Favored Pre-proline 0 N--CA 1.45 -0.455 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.733 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -58.15 138.79 87.78 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 C-N-CA 122.526 2.151 . . . . 0.0 111.755 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.466 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.38 0.27 89.68 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.7 m-85 -123.27 164.43 18.79 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 121.168 0.508 . . . . 0.0 110.745 179.744 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -142.93 135.43 27.57 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.249 179.394 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.483 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 9.0 t80 -48.34 135.47 13.69 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.848 -179.634 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.483 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -119.13 94.81 48.76 Favored Pre-proline 0 CA--C 1.545 0.753 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.054 -179.597 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -74.22 -0.12 9.2 Favored 'Trans proline' 0 N--CA 1.493 1.452 0 C-N-CA 122.715 2.277 . . . . 0.0 112.503 -179.554 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 t -101.58 -18.62 6.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.885 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.818 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.34 -43.35 4.14 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.006 179.421 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.78 0.21 9.96 Favored Glycine 0 CA--C 1.535 1.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 112.56 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.483 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.7 pt -152.38 -170.48 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.281 0 CA-C-N 117.215 0.507 . . . . 0.0 110.258 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 18.7 m -91.13 141.93 28.28 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 120.999 0.428 . . . . 0.0 110.13 179.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.7 p -127.36 153.78 45.79 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.529 -0.76 . . . . 0.0 110.858 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.411 ' O ' HG23 ' A' ' 18' ' ' ILE . 10.5 tt -57.23 131.81 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.422 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.466 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -90.39 160.99 15.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.722 -179.903 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.514 HD22 ' N ' ' A' ' 20' ' ' LEU . 4.2 mm? . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.702 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.607 0.241 . . . . 0.0 110.515 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.441 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.3 m -119.94 151.98 38.12 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.586 -179.855 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.43 168.81 17.14 Favored Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.845 179.302 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -58.45 138.92 88.43 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 122.624 2.216 . . . . 0.0 111.833 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.537 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.48 -0.24 88.18 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 179.602 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -122.33 166.33 14.86 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.043 0.449 . . . . 0.0 110.503 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.88 137.5 25.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.0 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.441 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 16.1 t80 -50.36 136.79 19.73 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.64 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.419 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -119.16 89.27 39.15 Favored Pre-proline 0 CA--C 1.543 0.699 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.524 -179.655 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -66.66 -0.14 4.19 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 122.964 2.443 . . . . 0.0 112.135 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.8 t -103.95 -18.89 6.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.9 0.381 . . . . 0.0 110.383 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.775 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.08 -42.12 4.51 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.629 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.25 -2.35 11.47 Favored Glycine 0 CA--C 1.536 1.367 0 CA-C-N 116.214 -0.448 . . . . 0.0 112.914 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.419 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.7 pt -149.33 -171.5 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 122.641 -0.329 . . . . 0.0 110.543 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.2 m -91.62 142.84 27.19 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-O 121.091 0.472 . . . . 0.0 110.297 179.782 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 66.4 p -129.1 154.84 46.3 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.444 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.449 ' O ' HG23 ' A' ' 18' ' ' ILE . 14.3 tt -57.08 131.1 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.586 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.537 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -87.47 159.74 18.54 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.793 -179.994 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.4 mt . . . . . 0 N--CA 1.447 -0.607 0 CA-C-O 121.111 0.482 . . . . 0.0 110.998 179.651 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.0 t90 . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.595 0.236 . . . . 0.0 110.445 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.9 m -123.04 155.16 37.42 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.292 0.568 . . . . 0.0 111.107 -179.694 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.69 166.59 18.77 Favored Pre-proline 0 N--CA 1.449 -0.516 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.797 179.208 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -57.79 139.16 89.38 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 122.494 2.129 . . . . 0.0 111.911 179.573 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.548 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.78 1.67 90.29 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.748 -0.541 . . . . 0.0 111.748 179.481 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 18.9 m-85 -123.61 165.63 16.85 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.062 0.458 . . . . 0.0 110.415 179.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.68 134.59 28.84 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.225 179.614 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.498 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -49.1 135.31 16.5 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.639 -179.764 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.498 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -118.93 94.64 48.38 Favored Pre-proline 0 CA--C 1.546 0.794 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.807 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -74.25 -0.33 9.49 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.851 2.367 . . . . 0.0 112.249 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.7 t -101.99 -18.14 6.61 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.965 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.799 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.61 -43.65 4.02 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.376 179.455 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.69 1.12 9.94 Favored Glycine 0 CA--C 1.535 1.322 0 CA-C-N 116.049 -0.523 . . . . 0.0 112.908 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.476 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -153.07 -170.85 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.163 0 CA-C-N 117.055 0.427 . . . . 0.0 110.354 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 16.7 m -91.86 141.34 28.77 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-O 120.945 0.402 . . . . 0.0 110.24 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.0 p -127.99 153.0 47.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.615 -179.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.8 tt -53.66 141.03 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.799 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.346 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.548 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -97.16 163.22 13.01 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.847 -179.78 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 3.8 mm? . . . . . 0 N--CA 1.454 -0.271 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.52 -179.707 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.68 0.276 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.8 m -118.08 152.26 35.92 Favored 'General case' 0 CA--C 1.52 -0.202 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.568 -179.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -89.53 169.27 13.07 Favored Pre-proline 0 N--CA 1.451 -0.404 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 -179.436 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -57.79 139.23 89.6 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 121.939 1.759 . . . . 0.0 111.779 179.53 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.513 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.88 1.18 90.18 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.416 -0.674 . . . . 0.0 111.416 179.267 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.8 m-85 -124.23 164.28 19.85 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.273 0.559 . . . . 0.0 110.525 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.68 137.37 26.55 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.164 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.8 t80 -50.8 137.86 19.66 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 120.478 -0.489 . . . . 0.0 110.681 -179.321 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.405 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -119.37 88.39 37.98 Favored Pre-proline 0 CA--C 1.538 0.511 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.504 -179.209 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -66.62 0.52 3.45 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.705 2.27 . . . . 0.0 112.189 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.0 t -103.3 -19.24 6.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.952 0.406 . . . . 0.0 110.282 -179.294 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.801 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.56 -41.66 4.52 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.143 179.491 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.49 -2.38 12.44 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-N 116.068 -0.515 . . . . 0.0 112.312 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.405 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -147.87 -172.45 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 117.707 0.753 . . . . 0.0 110.25 179.58 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.5 m -90.63 142.48 27.71 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.254 0.549 . . . . 0.0 109.592 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.7 p -128.96 154.1 46.91 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.641 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.418 ' O ' HG23 ' A' ' 18' ' ' ILE . 8.9 tt -57.22 131.82 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-O 120.991 0.424 . . . . 0.0 110.547 -179.489 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.513 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -89.55 160.98 16.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.78 -179.613 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 8.8 mp . . . . . 0 C--N 1.331 -0.233 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.892 179.751 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.2 t90 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.647 0.26 . . . . 0.0 110.453 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 97.5 m -123.56 149.39 45.34 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-O 121.403 0.62 . . . . 0.0 111.109 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.78 160.73 81.33 Favored Pre-proline 0 N--CA 1.442 -0.846 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.252 179.306 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -64.46 138.51 60.33 Favored 'Trans proline' 0 C--N 1.302 -1.883 0 C-N-CA 122.429 2.086 . . . . 0.0 111.929 -179.665 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.587 ' O ' HG22 ' A' ' 19' ' ' THR . . . 89.61 -7.89 80.95 Favored Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 -179.64 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 15.6 m-85 -115.19 167.91 10.41 Favored 'General case' 0 CA--C 1.522 -0.129 0 CA-C-O 121.131 0.491 . . . . 0.0 110.5 179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -139.04 134.08 32.52 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.171 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.456 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 9.3 t80 -50.87 135.39 24.31 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.692 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.456 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -119.12 95.52 49.4 Favored Pre-proline 0 CA--C 1.545 0.777 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.927 -179.573 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -75.04 0.71 8.6 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.857 2.371 . . . . 0.0 112.35 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 36.3 t -103.0 -17.82 6.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.995 -179.762 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.788 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -110.32 -43.18 3.96 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.598 179.411 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.05 2.29 11.16 Favored Glycine 0 CA--C 1.535 1.333 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.882 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.446 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.2 pt -153.65 -174.21 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.232 0 CA-C-N 117.314 0.557 . . . . 0.0 110.121 179.67 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 3.9 m -88.29 139.99 29.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.04 0.447 . . . . 0.0 110.535 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.8 p -126.21 152.95 45.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.521 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.5 tt -58.0 133.59 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.433 -179.73 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.587 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -85.19 152.24 23.5 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.788 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 8.0 mp . . . . . 0 C--N 1.327 -0.37 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.601 179.965 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.492 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.148 0 CA-C-O 118.224 -0.893 . . . . 0.0 111.044 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.2 t90 -67.28 133.07 48.98 Favored 'General case' 0 C--N 1.329 -0.317 0 O-C-N 124.262 0.976 . . . . 0.0 110.335 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.9 m -119.7 151.56 38.54 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.471 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.51 169.75 14.29 Favored Pre-proline 0 N--CA 1.452 -0.369 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.742 -179.519 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_exo -58.94 139.24 90.0 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 122.109 1.873 . . . . 0.0 111.795 179.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.534 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.52 -0.02 88.53 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 179.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -122.21 165.64 15.84 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.139 0.495 . . . . 0.0 110.542 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -146.01 138.44 25.45 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.078 179.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.492 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 18.3 t80 -50.09 137.36 17.64 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.557 -179.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.43 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -118.83 88.84 36.7 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.455 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -66.82 -0.06 4.21 Favored 'Trans proline' 0 N--CA 1.496 1.623 0 C-N-CA 122.732 2.288 . . . . 0.0 112.103 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 19.3 t -103.05 -19.01 6.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.874 0.369 . . . . 0.0 110.471 -179.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.803 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -110.03 -41.36 4.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.902 179.416 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.79 -2.92 11.96 Favored Glycine 0 CA--C 1.535 1.288 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.42 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.43 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.2 pt -147.21 -169.55 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 117.5 0.65 . . . . 0.0 110.342 179.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 23.6 m -91.76 142.08 27.98 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 121.197 0.523 . . . . 0.0 109.85 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.8 p -129.24 154.73 46.52 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.573 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.522 HD11 ' HD2' ' A' ' 22' ' ' ARG . 12.6 tt -57.81 132.1 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-O 121.189 0.519 . . . . 0.0 110.572 -179.681 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.534 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -85.04 152.9 23.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.574 -179.803 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.491 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 11.2 mp -61.34 -25.83 67.41 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.878 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 88.4 p -56.62 -34.37 67.17 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.508 -179.39 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.522 ' HD2' HD11 ' A' ' 18' ' ' ILE . 21.5 ttm180 -62.45 -40.25 96.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.52 -0.309 . . . . 0.0 111.051 179.489 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.555 HG22 ' N ' ' A' ' 24' ' ' GLU . 92.6 mt -46.27 -99.19 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.963 -179.269 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.555 ' N ' HG22 ' A' ' 23' ' ' ILE . 99.4 mt-10 -127.04 89.72 3.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.77 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.491 ' CD2' ' O ' ' A' ' 20' ' ' LEU . 49.1 m-70 -149.44 69.44 9.55 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.452 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.557 ' O ' ' N ' ' A' ' 30' ' ' ASP . 52.2 Cg_exo -53.98 -37.38 86.1 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.423 2.082 . . . . 0.0 111.82 -179.439 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.66 -40.38 98.67 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.959 -0.856 . . . . 0.0 110.959 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 37.7 t-20 -62.1 -44.34 96.86 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.72 0.295 . . . . 0.0 110.988 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.573 ' CD2' ' O ' ' A' ' 29' ' ' TYR . 24.7 p90 -126.17 47.17 2.3 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.934 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.557 ' N ' ' O ' ' A' ' 26' ' ' PRO . 67.7 t0 -59.3 -43.0 92.65 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.717 -179.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 66.9 t80 . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.661 179.916 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.47 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.392 -5.127 0 CA-C-O 118.133 -0.937 . . . . 0.0 111.076 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 -66.15 131.88 47.19 Favored 'General case' 0 C--N 1.329 -0.324 0 O-C-N 124.286 0.991 . . . . 0.0 110.6 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 77.0 m -120.88 151.58 39.48 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.841 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -88.04 167.04 21.15 Favored Pre-proline 0 N--CA 1.45 -0.474 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.635 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -58.04 139.13 89.31 Favored 'Trans proline' 0 N--CA 1.493 1.482 0 C-N-CA 122.573 2.182 . . . . 0.0 111.87 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.479 ' O ' HG22 ' A' ' 19' ' ' THR . . . 85.66 -4.38 85.85 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -119.63 164.53 15.74 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.067 0.461 . . . . 0.0 110.632 179.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -140.51 132.83 28.29 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.298 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.48 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -48.38 134.5 14.95 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.707 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.48 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.8 t30 -118.01 94.57 46.73 Favored Pre-proline 0 CA--C 1.545 0.752 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.951 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -74.39 0.45 8.56 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.963 2.442 . . . . 0.0 112.33 -179.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.8 t -102.74 -19.05 6.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.924 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.8 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -108.65 -43.9 4.17 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.511 179.435 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.77 1.8 9.67 Favored Glycine 0 CA--C 1.534 1.269 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.719 179.328 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.465 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -153.81 -173.49 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.235 0 CA-C-N 117.061 0.431 . . . . 0.0 110.408 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.5 m -89.43 140.97 28.99 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-O 120.884 0.373 . . . . 0.0 110.287 179.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.2 p -127.91 152.45 47.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.531 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.524 HD11 ' HD3' ' A' ' 22' ' ' ARG . 12.6 tt -58.42 133.06 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.262 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.479 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -84.04 142.88 30.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.63 -179.935 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 6.8 mp -57.44 -27.96 62.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.89 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.0 t -57.37 -38.48 74.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.417 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.524 ' HD3' HD11 ' A' ' 18' ' ' ILE . 75.7 ttt180 -58.84 -38.85 79.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.399 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 34.4 mm -63.72 -102.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.818 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -149.93 74.06 1.19 Allowed 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.692 0.282 . . . . 0.0 111.05 -179.554 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -144.71 67.51 14.06 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.816 179.356 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -61.79 -37.07 69.98 Favored 'Trans proline' 0 N--CA 1.494 1.554 0 C-N-CA 122.767 2.311 . . . . 0.0 112.19 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.38 -44.81 97.56 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -64.3 -39.97 94.99 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.806 0.336 . . . . 0.0 110.654 179.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -132.84 71.52 1.47 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.612 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -61.32 -43.63 98.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.542 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.598 179.975 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.391 -5.152 0 CA-C-O 118.271 -0.871 . . . . 0.0 111.067 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.1 t90 -65.1 132.14 48.4 Favored 'General case' 0 C--N 1.33 -0.261 0 O-C-N 124.167 0.917 . . . . 0.0 110.454 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.42 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 74.1 m -122.28 153.58 38.72 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.245 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -89.05 168.3 15.84 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.902 -179.488 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -57.64 138.11 84.52 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.678 2.252 . . . . 0.0 111.654 179.697 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.479 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.13 1.47 90.35 Favored Glycine 0 CA--C 1.528 0.857 0 N-CA-C 111.206 -0.758 . . . . 0.0 111.206 179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.8 m-85 -125.22 163.23 22.94 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.13 0.49 . . . . 0.0 110.602 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -143.17 135.82 27.56 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.134 179.528 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.42 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 16.1 t80 -48.36 136.96 11.79 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.601 -179.594 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.457 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -118.58 89.25 36.56 Favored Pre-proline 0 CA--C 1.54 0.568 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.637 -179.605 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -67.02 -0.02 4.3 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 122.907 2.405 . . . . 0.0 112.051 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.0 t -103.49 -17.94 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 CA-C-O 120.94 0.4 . . . . 0.0 110.317 -179.316 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.808 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -111.09 -42.65 3.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.4 179.566 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.57 -2.1 10.26 Favored Glycine 0 CA--C 1.534 1.224 0 CA-C-N 116.113 -0.494 . . . . 0.0 112.432 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.457 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.0 pt -149.92 -173.07 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.917 0.358 . . . . 0.0 110.592 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.9 m -89.27 142.34 27.74 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 120.946 0.403 . . . . 0.0 110.332 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 65.0 p -129.6 150.9 50.73 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.515 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 tt -51.83 137.72 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.149 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.479 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -101.06 169.66 8.79 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.062 -179.328 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.414 ' N ' ' OG1' ' A' ' 19' ' ' THR . 4.8 tt -60.43 -32.53 71.45 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.17 179.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 42.0 t -43.78 -29.73 0.57 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.458 -179.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 9.8 ttp-105 -53.37 -33.16 52.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.261 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.604 HG22 ' N ' ' A' ' 24' ' ' GLU . 36.4 mm -50.38 -95.34 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.47 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.604 ' N ' HG22 ' A' ' 23' ' ' ILE . 99.4 mt-10 -141.15 30.99 1.76 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.641 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 91.3 m-70 -132.0 59.5 44.9 Favored Pre-proline 0 C--N 1.332 -0.182 0 C-N-CA 120.814 -0.354 . . . . 0.0 110.075 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.65 -23.5 74.68 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.876 2.384 . . . . 0.0 111.97 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.7 -37.24 93.93 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 11.8 t-20 54.84 43.11 30.51 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.844 0.354 . . . . 0.0 110.514 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 12.1 m-85 56.1 23.23 6.68 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.513 179.439 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 50.8 t0 52.79 41.02 31.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.426 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 85.8 t80 . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.557 179.972 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.51 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.158 0 CA-C-O 118.242 -0.885 . . . . 0.0 111.114 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.6 t90 -66.22 130.2 42.43 Favored 'General case' 0 C--N 1.329 -0.318 0 O-C-N 124.21 0.944 . . . . 0.0 110.452 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.414 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 73.4 m -119.44 151.12 39.07 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.566 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.34 169.02 16.36 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.822 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.93 138.92 88.45 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.539 2.159 . . . . 0.0 111.879 179.554 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.437 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.98 0.06 89.09 Favored Glycine 0 CA--C 1.529 0.912 0 N-CA-C 111.359 -0.697 . . . . 0.0 111.359 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -123.9 164.36 19.43 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.073 0.463 . . . . 0.0 110.601 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.89 136.25 25.22 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.235 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.51 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 17.7 t80 -48.6 136.91 12.56 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.553 -179.6 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.421 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -119.1 89.22 38.81 Favored Pre-proline 0 CA--C 1.54 0.59 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.539 -179.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -66.67 -0.08 4.12 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 122.915 2.41 . . . . 0.0 112.08 -179.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.4 t -103.53 -19.89 5.99 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 120.895 0.379 . . . . 0.0 110.303 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.791 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -108.4 -42.04 4.69 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.624 179.413 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.92 -1.72 11.87 Favored Glycine 0 CA--C 1.534 1.28 0 CA-C-N 116.035 -0.529 . . . . 0.0 112.543 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.421 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 4.7 pt -149.66 -172.9 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 117.094 0.447 . . . . 0.0 110.556 179.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.5 m -88.94 141.77 28.21 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.061 0.458 . . . . 0.0 110.404 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.6 p -128.69 152.69 48.11 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.542 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.532 ' CD1' ' HE ' ' A' ' 22' ' ' ARG . 10.7 tt -55.25 132.3 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.348 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.437 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -94.01 166.76 11.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.903 -179.667 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 89.0 mt -65.04 -26.09 68.11 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-O 121.192 0.52 . . . . 0.0 110.861 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 89.1 p -61.28 -17.55 54.08 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.197 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.532 ' HE ' ' CD1' ' A' ' 18' ' ' ILE . 0.1 OUTLIER -53.79 -21.15 6.8 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.576 -179.882 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.533 HG22 ' N ' ' A' ' 24' ' ' GLU . 95.8 mt -58.34 -95.03 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.617 -179.802 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.533 ' N ' HG22 ' A' ' 23' ' ' ILE . 75.1 mm-40 -133.31 41.68 3.08 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.864 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 81.5 m-70 -132.23 59.35 43.42 Favored Pre-proline 0 C--N 1.331 -0.197 0 C-N-CA 120.792 -0.363 . . . . 0.0 110.866 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -76.15 -11.85 19.39 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.865 2.377 . . . . 0.0 112.238 178.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.07 -40.0 96.49 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.236 -0.745 . . . . 0.0 111.236 -179.551 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -62.99 -37.31 86.67 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.846 0.355 . . . . 0.0 110.983 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -103.45 17.53 23.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.361 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -81.86 74.73 8.83 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.238 179.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.462 ' CD2' ' O ' ' A' ' 31' ' ' TYR . 74.9 t80 . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.563 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.411 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.138 0 CA-C-O 118.21 -0.9 . . . . 0.0 111.107 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.8 t90 -67.03 131.47 45.91 Favored 'General case' 0 C--N 1.329 -0.297 0 O-C-N 124.332 1.02 . . . . 0.0 110.555 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 93.3 m -123.45 148.93 45.69 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.986 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -69.95 161.97 71.61 Favored Pre-proline 0 N--CA 1.446 -0.67 0 CA-C-N 115.549 -0.751 . . . . 0.0 109.979 179.77 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -64.42 139.63 65.89 Favored 'Trans proline' 0 C--N 1.3 -2.001 0 C-N-CA 122.212 1.941 . . . . 0.0 111.904 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.461 ' O ' HG22 ' A' ' 19' ' ' THR . . . 84.88 -2.83 87.98 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 -179.301 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -119.29 166.71 12.66 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 121.006 0.432 . . . . 0.0 110.497 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.69 137.45 31.74 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.097 179.485 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.411 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 19.2 t80 -52.04 137.04 28.19 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.412 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.403 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -118.57 89.44 37.03 Favored Pre-proline 0 CA--C 1.539 0.53 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.38 -179.165 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -67.57 -0.02 4.69 Favored 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 122.721 2.28 . . . . 0.0 112.039 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 23.0 t -102.68 -18.69 6.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.507 -179.125 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.805 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -110.65 -41.37 4.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.79 179.67 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 119.97 -1.57 13.32 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-N 116.085 -0.507 . . . . 0.0 112.403 179.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.403 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -148.17 -172.72 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 117.484 0.642 . . . . 0.0 110.252 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.9 m -90.5 140.56 29.62 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.106 0.479 . . . . 0.0 109.956 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.0 p -127.36 152.53 47.36 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.315 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.536 HD11 ' HD3' ' A' ' 22' ' ' ARG . 11.2 tt -57.65 135.05 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 CA-C-O 121.139 0.495 . . . . 0.0 110.539 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.461 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -86.93 141.75 28.49 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.319 -179.788 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.795 HD23 ' O ' ' A' ' 20' ' ' LEU . 3.3 tt -59.51 -28.9 67.47 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.248 -179.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.431 ' CB ' HD21 ' A' ' 28' ' ' ASN . 89.0 p -59.06 -30.47 68.07 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.841 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.536 ' HD3' HD11 ' A' ' 18' ' ' ILE . 75.5 ttt180 -57.87 -39.36 77.62 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.261 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.421 ' O ' ' O ' ' A' ' 22' ' ' ARG . 50.7 mm -45.98 -94.96 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.359 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -143.62 35.0 1.29 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.569 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -132.32 61.14 55.63 Favored Pre-proline 0 C--O 1.232 0.142 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.295 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.96 -17.7 55.96 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 C-N-CA 122.574 2.183 . . . . 0.0 112.174 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.94 -29.43 70.65 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.431 HD21 ' CB ' ' A' ' 21' ' ' SER . 33.5 m120 54.8 37.38 28.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.804 0.335 . . . . 0.0 110.654 -179.722 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 46.3 m-85 56.51 23.01 7.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.58 179.502 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 52.6 t0 53.81 41.44 32.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.477 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.965 -1.017 . . . . 0.0 110.527 179.964 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.392 -5.114 0 CA-C-O 118.21 -0.9 . . . . 0.0 111.025 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.8 t90 -65.04 133.07 50.87 Favored 'General case' 0 C--N 1.33 -0.252 0 O-C-N 124.216 0.947 . . . . 0.0 110.527 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.4 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 76.1 m -118.92 153.08 35.16 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 121.184 0.516 . . . . 0.0 110.926 -179.716 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.79 168.51 15.56 Favored Pre-proline 0 N--CA 1.452 -0.364 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.995 179.158 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -58.8 138.55 86.35 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 C-N-CA 122.675 2.25 . . . . 0.0 111.78 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.559 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.02 -0.81 88.16 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.451 -0.66 . . . . 0.0 111.451 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -121.2 166.07 14.51 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-O 120.916 0.388 . . . . 0.0 110.679 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.21 136.59 26.64 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.899 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.486 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 8.4 t80 -49.46 135.48 17.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.755 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.486 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -119.38 94.92 48.93 Favored Pre-proline 0 CA--C 1.547 0.83 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.882 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -73.63 0.02 8.72 Favored 'Trans proline' 0 N--CA 1.492 1.441 0 C-N-CA 123.182 2.588 . . . . 0.0 112.427 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.5 t -103.29 -17.75 6.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.449 . . . . 0.0 109.985 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.771 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.97 -42.47 4.21 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 179.769 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.44 -0.18 11.3 Favored Glycine 0 CA--C 1.536 1.383 0 CA-C-N 116.253 -0.431 . . . . 0.0 113.185 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.474 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.8 pt -152.4 -170.77 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 O-C-N 122.493 -0.416 . . . . 0.0 110.387 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.9 m -90.89 142.67 27.52 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 120.979 0.418 . . . . 0.0 110.322 179.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.4 p -128.0 157.37 40.8 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.654 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.43 ' O ' HG23 ' A' ' 18' ' ' ILE . 14.1 tt -59.75 131.68 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.362 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.559 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -87.48 156.15 19.68 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.562 179.983 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.446 HD22 ' N ' ' A' ' 20' ' ' LEU . 4.3 mm? -63.39 -24.4 67.82 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.641 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 95.8 p -62.42 -22.78 66.44 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.555 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.447 ' HE ' ' HA2' ' A' ' 6' ' ' GLY . 2.2 tpm_? -56.67 -33.59 66.55 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.276 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.435 HG22 ' HG3' ' A' ' 24' ' ' GLU . 95.2 mt -40.11 -82.86 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.045 0.45 . . . . 0.0 110.915 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.435 ' HG3' HG22 ' A' ' 23' ' ' ILE . 98.9 mt-10 -141.5 -106.11 0.14 Allowed 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.97 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 82.3 m-70 55.6 66.17 3.95 Favored Pre-proline 0 C--O 1.237 0.399 0 CA-C-O 120.968 0.414 . . . . 0.0 110.758 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.85 -36.21 82.14 Favored 'Trans proline' 0 N--CA 1.493 1.5 0 C-N-CA 122.783 2.322 . . . . 0.0 111.875 -179.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.73 -39.24 97.18 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -61.34 -40.31 93.75 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.88 0.371 . . . . 0.0 110.488 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.425 ' CE2' ' NH2' ' A' ' 22' ' ' ARG . 96.9 m-85 -96.07 -0.24 50.59 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.616 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 51.5 t0 50.56 49.98 19.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.604 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.442 ' O ' ' CG ' ' A' ' 31' ' ' TYR . 15.5 p90 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.655 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.39 -5.184 0 CA-C-O 118.342 -0.837 . . . . 0.0 111.127 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.1 t90 -70.47 131.67 44.4 Favored 'General case' 0 C--N 1.33 -0.273 0 O-C-N 124.204 0.94 . . . . 0.0 110.418 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.6 m -120.28 154.4 35.01 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.899 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.3 168.94 13.15 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.78 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -59.14 139.05 88.69 Favored 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 122.521 2.147 . . . . 0.0 111.73 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.499 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.07 0.07 89.2 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.427 -0.669 . . . . 0.0 111.427 179.426 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -122.17 165.11 16.65 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-O 121.168 0.508 . . . . 0.0 110.662 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -142.74 135.29 27.77 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.113 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.462 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 9.1 t80 -49.0 135.04 16.41 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.744 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.485 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.9 t30 -118.38 94.79 47.74 Favored Pre-proline 0 CA--C 1.544 0.747 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.995 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -74.42 0.3 8.77 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 C-N-CA 122.807 2.338 . . . . 0.0 112.41 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.4 t -102.19 -18.43 6.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.838 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.818 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.72 -43.77 3.97 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.73 179.478 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 123.23 0.96 9.5 Favored Glycine 0 CA--C 1.535 1.309 0 CA-C-N 116.081 -0.509 . . . . 0.0 112.61 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.485 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -152.92 -170.61 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.274 0 CA-C-N 117.113 0.457 . . . . 0.0 110.298 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 15.2 m -91.03 141.53 28.74 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 120.916 0.389 . . . . 0.0 110.196 179.6 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 79.7 p -127.71 152.68 47.41 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.679 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.519 HD11 ' HD2' ' A' ' 22' ' ' ARG . 12.2 tt -56.76 133.83 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.582 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.349 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.499 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -87.88 147.56 25.04 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.683 -179.83 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.863 HD23 ' O ' ' A' ' 20' ' ' LEU . 5.3 tt -58.9 -27.0 64.82 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.468 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.403 ' HB3' HD22 ' A' ' 28' ' ' ASN . 72.7 m -56.34 -36.94 69.32 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.901 -179.121 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.519 ' HD2' HD11 ' A' ' 18' ' ' ILE . 24.3 ttm180 -56.5 -39.42 73.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.721 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.401 ' C ' ' O ' ' A' ' 22' ' ' ARG . 47.8 mm -38.25 -86.41 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.899 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -142.86 58.59 1.42 Allowed 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.065 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 54.6 m-70 -135.08 72.36 67.33 Favored Pre-proline 0 N--CA 1.463 0.176 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.531 179.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -54.82 -36.05 90.07 Favored 'Trans proline' 0 N--CA 1.498 1.78 0 C-N-CA 122.869 2.379 . . . . 0.0 112.238 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.49 -39.66 96.65 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.403 HD22 ' HB3' ' A' ' 21' ' ' SER . 32.6 m120 54.55 36.6 26.21 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.734 0.302 . . . . 0.0 110.528 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 51.9 m-85 57.72 21.77 7.71 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.565 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 51.9 t0 50.4 42.25 25.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.447 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 78.6 t80 . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.06 -0.972 . . . . 0.0 110.516 -179.986 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.485 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.392 -5.106 0 CA-C-O 118.224 -0.893 . . . . 0.0 111.076 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.6 t90 -67.33 131.65 46.15 Favored 'General case' 0 C--N 1.332 -0.177 0 O-C-N 124.3 1.0 . . . . 0.0 110.406 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.404 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 73.5 m -120.3 150.59 40.47 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.479 0.657 . . . . 0.0 110.805 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.66 168.1 23.0 Favored Pre-proline 0 CA--C 1.533 0.3 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.601 -179.504 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -59.03 137.87 82.18 Favored 'Trans proline' 0 N--CA 1.492 1.422 0 C-N-CA 122.513 2.142 . . . . 0.0 111.828 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.575 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.51 1.31 90.07 Favored Glycine 0 CA--C 1.528 0.879 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 179.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -121.58 165.78 15.18 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-O 121.111 0.481 . . . . 0.0 110.546 179.694 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -143.66 135.64 26.58 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.149 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.485 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 8.4 t80 -48.22 134.69 14.22 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.752 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.491 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 1.9 t30 -118.48 94.84 47.99 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.906 -179.667 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -74.25 -0.61 9.85 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.849 2.366 . . . . 0.0 112.348 -179.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.6 t -101.43 -18.0 6.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.946 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.796 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.85 -43.31 4.04 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.384 179.515 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.98 0.19 9.78 Favored Glycine 0 CA--C 1.533 1.172 0 CA-C-N 116.109 -0.496 . . . . 0.0 112.725 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.491 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.6 pt -152.67 -169.86 0.1 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.263 0 CA-C-N 117.096 0.448 . . . . 0.0 110.234 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 21.6 m -91.55 142.16 27.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.891 0.377 . . . . 0.0 110.219 179.597 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.6 p -127.2 154.48 44.76 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.63 -179.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt -56.84 132.66 21.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.379 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.575 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.1 OUTLIER -92.51 160.18 15.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.692 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 38.7 tp -61.84 -26.83 68.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.418 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.607 ' O ' ' NE2' ' A' ' 25' ' ' HIS . 37.9 t -53.6 -36.74 62.29 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.458 -179.343 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.422 HH11 ' HA3' ' A' ' 6' ' ' GLY . 15.4 tpt180 -38.4 -30.17 0.04 OUTLIER 'General case' 0 C--O 1.231 0.11 0 O-C-N 123.287 0.367 . . . . 0.0 110.386 -179.707 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.449 ' N ' ' O ' ' A' ' 21' ' ' SER . 36.2 mt -129.53 66.75 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.783 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -148.15 44.02 1.05 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.602 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.607 ' NE2' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -171.37 54.59 0.21 Allowed Pre-proline 0 C--N 1.325 -0.477 0 CA-C-O 121.454 0.645 . . . . 0.0 110.325 -179.726 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.432 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 32.1 Cg_endo -65.38 -31.71 51.63 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.498 2.132 . . . . 0.0 111.871 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -62.74 -43.48 98.9 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.939 -0.865 . . . . 0.0 110.939 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -69.05 -38.29 79.03 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.704 0.288 . . . . 0.0 110.801 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 84.6 m-85 -114.63 63.04 0.67 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.756 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' A' ' 26' ' ' PRO . 98.6 m-20 -61.27 -39.96 92.34 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.517 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.511 ' CD2' ' OXT' ' A' ' 31' ' ' TYR . 69.1 t80 . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.581 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.392 -5.098 0 CA-C-O 118.233 -0.889 . . . . 0.0 111.155 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.0 t90 -65.53 133.46 51.27 Favored 'General case' 0 C--N 1.33 -0.262 0 O-C-N 124.256 0.973 . . . . 0.0 110.431 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.408 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.3 m -120.27 153.35 36.5 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.972 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -89.66 168.1 15.77 Favored Pre-proline 0 C--N 1.327 -0.4 0 O-C-N 123.107 0.255 . . . . 0.0 110.874 -179.529 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_exo -57.75 139.06 89.02 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.47 2.113 . . . . 0.0 111.722 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.463 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.76 0.32 89.21 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 179.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -124.06 165.24 17.84 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.107 0.479 . . . . 0.0 110.66 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.63 137.07 26.42 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.231 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.408 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 17.7 t80 -49.82 137.57 16.18 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.657 -179.543 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.445 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -119.42 89.01 39.57 Favored Pre-proline 0 CA--C 1.541 0.634 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.414 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_exo -66.37 -0.56 4.41 Favored 'Trans proline' 0 N--CA 1.496 1.623 0 C-N-CA 122.932 2.421 . . . . 0.0 112.132 -179.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.0 t -103.08 -19.71 6.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.952 0.406 . . . . 0.0 110.416 -179.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.808 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -108.53 -41.68 4.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.664 179.349 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.62 -3.2 11.07 Favored Glycine 0 CA--C 1.533 1.216 0 CA-C-N 116.029 -0.532 . . . . 0.0 112.415 179.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.445 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -148.35 -171.28 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-N 117.042 0.421 . . . . 0.0 110.556 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 15.7 m -90.88 143.12 27.05 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.109 0.481 . . . . 0.0 110.392 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -129.69 152.96 48.62 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.583 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.5 tt -55.17 134.26 18.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.187 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.481 HG23 ' OG ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -90.22 167.96 12.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.068 -179.494 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.522 HD22 ' N ' ' A' ' 20' ' ' LEU . 4.1 mm? -68.22 -11.66 59.69 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.521 -179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.481 ' OG ' HG23 ' A' ' 19' ' ' THR . 89.8 p -61.97 -25.74 67.8 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.051 0.453 . . . . 0.0 110.399 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 39.8 tpt85 -60.62 -39.11 87.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.134 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 51.1 mm -40.96 -86.81 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.845 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -143.23 60.61 1.4 Allowed 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.941 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 42.8 m-70 -130.82 63.59 70.62 Favored Pre-proline 0 CA--C 1.529 0.169 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.633 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -61.59 -18.74 61.66 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.886 2.391 . . . . 0.0 112.164 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.97 -40.05 97.89 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -64.08 -39.33 93.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.96 0.41 . . . . 0.0 110.71 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -78.73 -11.88 60.0 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.519 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 53.1 t0 57.84 44.29 20.34 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.357 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 92.4 t80 . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.037 -0.983 . . . . 0.0 110.578 179.896 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.499 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.392 -5.122 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.991 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.6 t90 -68.08 130.39 42.81 Favored 'General case' 0 C--N 1.328 -0.331 0 O-C-N 124.273 0.983 . . . . 0.0 110.492 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.402 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.2 m -120.03 148.83 43.08 Favored 'General case' 0 CA--C 1.516 -0.329 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.708 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.44 168.0 26.4 Favored Pre-proline 0 N--CA 1.452 -0.327 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.901 179.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo -58.65 138.89 88.28 Favored 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 122.485 2.124 . . . . 0.0 111.739 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.534 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.44 0.61 89.36 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.398 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -122.57 166.28 15.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.097 0.475 . . . . 0.0 110.484 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.65 138.39 25.89 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.172 179.662 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.499 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 17.4 t80 -50.43 136.76 20.04 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.508 -179.619 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.43 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -118.76 89.24 37.37 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.592 -179.473 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -66.44 -0.04 3.93 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 C-N-CA 122.83 2.353 . . . . 0.0 112.375 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 t -103.8 -19.1 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.02 0.438 . . . . 0.0 110.363 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.816 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -109.54 -40.71 4.78 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.697 179.531 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.41 -3.38 12.41 Favored Glycine 0 CA--C 1.534 1.26 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.424 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.43 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -147.54 -171.25 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-N 117.149 0.474 . . . . 0.0 110.42 179.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 23.7 m -90.38 142.3 27.87 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-O 121.179 0.514 . . . . 0.0 110.136 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -129.17 155.21 45.87 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.588 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.415 ' O ' HG23 ' A' ' 18' ' ' ILE . 10.9 tt -56.82 132.35 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.726 0 CA-C-O 121.076 0.465 . . . . 0.0 110.681 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.534 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -87.06 160.56 18.55 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.724 -179.932 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.576 ' HA ' HD12 ' A' ' 23' ' ' ILE . 5.3 tt -56.66 -29.98 62.88 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.821 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 89.0 p -56.32 -23.12 34.95 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.441 -178.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.414 HH11 HD11 ' A' ' 18' ' ' ILE . 57.7 ttt-85 -109.4 30.29 6.76 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.905 0.384 . . . . 0.0 110.365 179.524 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.584 ' N ' ' NE2' ' A' ' 25' ' ' HIS . 57.0 mt -131.88 -32.36 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.338 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.642 ' C ' ' CG ' ' A' ' 25' ' ' HIS . 98.6 mt-10 -115.74 112.28 21.81 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.148 -178.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.642 ' CG ' ' C ' ' A' ' 24' ' ' GLU . 0.0 OUTLIER -167.43 51.96 0.23 Allowed Pre-proline 0 N--CA 1.466 0.357 0 CA-C-O 121.656 0.741 . . . . 0.0 110.571 -179.533 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.478 ' CD ' ' N ' ' A' ' 25' ' ' HIS . 33.7 Cg_endo -64.89 -28.34 58.58 Favored 'Trans proline' 0 C--N 1.301 -1.966 0 C-N-CA 122.19 1.927 . . . . 0.0 112.339 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -65.43 -12.55 56.27 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 63.4 t30 -58.8 -38.39 78.49 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.499 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.7 p90 -115.6 38.68 3.2 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.927 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.543 ' OD1' ' N ' ' A' ' 31' ' ' TYR . 56.7 p-10 -60.8 -24.8 66.09 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.772 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.543 ' N ' ' OD1' ' A' ' 30' ' ' ASP . 64.8 t80 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.956 -1.021 . . . . 0.0 110.535 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.391 -5.168 0 CA-C-O 118.302 -0.856 . . . . 0.0 111.084 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.3 t90 -64.65 131.32 46.63 Favored 'General case' 0 C--N 1.329 -0.306 0 O-C-N 124.236 0.96 . . . . 0.0 110.508 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.42 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 78.0 m -123.31 153.52 40.15 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.671 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.68 168.12 16.81 Favored Pre-proline 0 N--CA 1.452 -0.344 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.788 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_exo -56.64 138.86 86.57 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.075 1.85 . . . . 0.0 111.792 179.539 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.459 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.35 0.01 89.41 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 179.328 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -123.95 163.84 20.51 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.297 0.57 . . . . 0.0 110.56 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.39 136.94 26.7 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.086 179.438 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.42 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.6 t80 -50.29 137.22 18.7 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.615 -179.281 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.401 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -118.74 88.41 35.13 Favored Pre-proline 0 CA--C 1.539 0.545 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.555 -179.199 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -66.39 0.15 3.7 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 122.753 2.302 . . . . 0.0 112.252 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.3 t -103.49 -18.78 6.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.976 0.417 . . . . 0.0 110.281 -179.349 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.799 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -109.82 -41.44 4.51 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.794 179.488 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.47 -3.03 12.4 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-N 116.118 -0.492 . . . . 0.0 112.525 179.156 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.401 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.1 pt -147.69 -172.82 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 117.52 0.66 . . . . 0.0 110.327 179.634 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 25.4 m -90.23 141.14 29.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-O 121.135 0.493 . . . . 0.0 109.922 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.7 p -127.97 153.95 46.14 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.635 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.418 ' O ' HG23 ' A' ' 18' ' ' ILE . 9.9 tt -57.31 131.93 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.504 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.459 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -90.58 164.76 14.08 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.726 -179.691 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.415 ' HA ' HD23 ' A' ' 20' ' ' LEU . 94.1 mt -66.82 -20.56 65.96 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 121.071 0.462 . . . . 0.0 111.106 179.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 72.8 m -57.01 -25.57 58.78 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.54 -0.754 . . . . 0.0 110.541 -179.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.417 ' O ' ' O ' ' A' ' 23' ' ' ILE . 0.0 OUTLIER -58.0 -35.78 71.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.44 179.679 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.598 HG22 ' N ' ' A' ' 24' ' ' GLU . 97.3 mt -37.54 -92.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.191 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.942 -179.53 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.598 ' N ' HG22 ' A' ' 23' ' ' ILE . 99.9 mt-10 -137.04 33.3 2.61 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.908 179.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -130.02 59.13 43.03 Favored Pre-proline 0 C--N 1.33 -0.242 0 CA-C-O 120.8 0.333 . . . . 0.0 110.244 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -64.03 -19.36 66.29 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.806 2.337 . . . . 0.0 112.04 179.68 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.09 -35.48 87.66 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 32.9 m120 55.25 38.11 29.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.774 0.321 . . . . 0.0 110.651 -179.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 53.3 m-85 58.05 18.25 5.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.655 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 52.7 t0 49.98 44.03 25.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.486 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 41.9 p90 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.902 -1.047 . . . . 0.0 110.64 179.984 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.391 -5.138 0 CA-C-O 118.251 -0.881 . . . . 0.0 111.069 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.8 t90 -62.3 131.28 48.81 Favored 'General case' 0 C--N 1.328 -0.34 0 O-C-N 124.268 0.98 . . . . 0.0 110.507 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.438 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 71.7 m -121.88 153.14 38.82 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.141 0.496 . . . . 0.0 110.568 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.13 167.77 22.23 Favored Pre-proline 0 N--CA 1.451 -0.405 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.85 179.45 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -58.15 138.61 86.83 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.513 2.142 . . . . 0.0 111.85 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.536 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.18 -0.99 88.2 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.468 -0.653 . . . . 0.0 111.468 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.1 m-85 -121.91 165.32 16.12 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.024 0.44 . . . . 0.0 110.54 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.84 135.91 24.95 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.214 179.615 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.438 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.0 t80 -48.96 137.28 13.09 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.518 -179.668 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.425 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -119.04 88.79 37.58 Favored Pre-proline 0 CA--C 1.543 0.7 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.468 -179.484 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_exo -66.11 -0.16 3.83 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.835 2.357 . . . . 0.0 112.213 -179.646 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.7 t -103.78 -19.72 6.1 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.318 0 CA-C-O 120.908 0.385 . . . . 0.0 110.246 -179.101 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.777 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -108.53 -41.99 4.67 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.371 179.458 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.0 -3.05 11.65 Favored Glycine 0 CA--C 1.537 1.412 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.779 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.425 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -148.34 -173.5 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 117.126 0.463 . . . . 0.0 110.588 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 21.2 m -89.46 141.28 28.71 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.002 0.429 . . . . 0.0 110.35 179.722 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -128.64 153.89 46.81 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.574 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.55 ' CD1' ' HE ' ' A' ' 22' ' ' ARG . 9.3 tt -56.38 132.61 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.345 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.536 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -88.76 153.75 20.83 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.18 -179.782 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.4 tt -61.31 -34.08 74.66 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.34 179.549 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 50.6 p -59.02 -20.47 53.4 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.144 -179.088 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.55 ' HE ' ' CD1' ' A' ' 18' ' ' ILE . 8.2 tmm_? -52.37 -29.92 26.3 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.769 179.459 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.488 HG22 ' N ' ' A' ' 24' ' ' GLU . 96.9 mt -55.16 -88.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.753 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.488 ' N ' HG22 ' A' ' 23' ' ' ILE . 99.3 mt-10 -141.27 -15.86 0.85 Allowed 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.968 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.6 ' CD2' ' N ' ' A' ' 25' ' ' HIS . 0.1 OUTLIER -169.92 151.4 4.07 Favored Pre-proline 0 N--CA 1.446 -0.662 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.143 -179.718 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -72.79 -43.24 0.89 Allowed 'Trans proline' 0 N--CA 1.494 1.549 0 C-N-CA 122.834 2.356 . . . . 0.0 112.272 179.342 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -63.48 -41.04 99.39 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 179.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 59.27 65.23 1.21 Allowed 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.956 0.408 . . . . 0.0 110.865 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.679 ' N ' ' CD1' ' A' ' 29' ' ' TYR . 0.1 OUTLIER -106.25 62.58 0.65 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.22 0.533 . . . . 0.0 110.603 -179.423 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 54.5 p-10 -78.69 -0.11 28.83 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.4 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.491 ' CD2' ' O ' ' A' ' 31' ' ' TYR . 64.1 t80 . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.632 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.391 -5.154 0 CA-C-O 118.222 -0.894 . . . . 0.0 111.212 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.4 t90 -66.35 132.12 47.62 Favored 'General case' 0 C--N 1.33 -0.281 0 O-C-N 124.257 0.973 . . . . 0.0 110.38 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 79.7 m -120.15 150.73 40.15 Favored 'General case' 0 CA--C 1.519 -0.224 0 CA-C-O 121.216 0.531 . . . . 0.0 110.805 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.23 166.35 28.94 Favored Pre-proline 0 N--CA 1.448 -0.557 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.574 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -58.96 139.73 92.17 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 122.478 2.118 . . . . 0.0 111.841 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.574 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.47 0.01 89.53 Favored Glycine 0 CA--C 1.53 0.997 0 N-CA-C 111.697 -0.561 . . . . 0.0 111.697 179.4 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -121.71 166.47 14.25 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.97 0.414 . . . . 0.0 110.38 179.639 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.5 135.15 29.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.215 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.49 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -50.2 134.73 22.21 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.657 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.49 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -118.05 94.98 47.59 Favored Pre-proline 0 CA--C 1.546 0.813 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.923 -179.621 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -74.6 0.63 8.45 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 C-N-CA 122.911 2.407 . . . . 0.0 112.443 -179.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 26.9 t -102.85 -18.87 6.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.926 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.794 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -108.75 -43.54 4.23 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.469 179.452 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.98 -0.0 9.79 Favored Glycine 0 CA--C 1.535 1.342 0 CA-C-N 116.065 -0.516 . . . . 0.0 112.853 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.477 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -152.38 -170.53 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.165 0 CA-C-N 117.069 0.435 . . . . 0.0 110.339 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.6 m -91.03 142.13 28.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.954 0.406 . . . . 0.0 110.28 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.4 p -128.88 151.99 49.01 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.605 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.552 HD11 HH11 ' A' ' 22' ' ' ARG . 11.7 tt -52.83 139.42 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.477 -179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.574 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -95.5 169.66 9.89 Favored 'General case' 0 C--O 1.241 0.635 0 CA-C-O 121.246 0.546 . . . . 0.0 111.036 -179.944 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.569 HD22 HD12 ' A' ' 23' ' ' ILE . 0.5 OUTLIER -71.7 11.91 0.44 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.841 179.965 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.53 ' C ' ' CE1' ' A' ' 25' ' ' HIS . 68.6 m -107.47 11.13 29.15 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.726 179.568 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.606 ' N ' ' CE1' ' A' ' 25' ' ' HIS . 75.6 ttt-85 -139.16 -30.13 0.74 Allowed 'General case' 0 CA--C 1.533 0.325 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.109 179.606 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.569 HD12 HD22 ' A' ' 20' ' ' LEU . 92.6 mt -57.23 -45.18 84.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-O 120.928 0.394 . . . . 0.0 111.337 -179.244 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.645 ' C ' ' CG ' ' A' ' 25' ' ' HIS . 99.6 mt-10 -103.36 42.24 1.19 Allowed 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.222 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.645 ' CG ' ' C ' ' A' ' 24' ' ' GLU . 0.0 OUTLIER -165.79 74.66 1.29 Allowed Pre-proline 0 CA--C 1.538 0.485 0 CA-C-O 121.35 0.595 . . . . 0.0 110.66 -178.934 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_exo -55.43 -36.97 95.13 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 122.579 2.186 . . . . 0.0 112.14 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.04 -38.5 95.65 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.418 HD22 ' HG3' ' A' ' 22' ' ' ARG . 16.9 t-20 59.85 59.79 2.36 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-O 121.073 0.463 . . . . 0.0 111.036 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.682 ' CD1' ' N ' ' A' ' 29' ' ' TYR . 0.1 OUTLIER -99.59 45.66 0.99 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.559 -179.606 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.439 ' O ' ' OXT' ' A' ' 31' ' ' TYR . 67.0 t0 -59.85 -43.38 94.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.32 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.439 ' OXT' ' O ' ' A' ' 30' ' ' ASP . 69.0 t80 . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 117.956 -1.021 . . . . 0.0 110.577 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.392 -5.112 0 CA-C-O 118.43 -0.795 . . . . 0.0 111.115 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.1 t90 -67.98 131.36 45.32 Favored 'General case' 0 C--N 1.329 -0.313 0 O-C-N 124.065 0.853 . . . . 0.0 110.21 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.44 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.5 m -119.01 150.56 39.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.671 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.4 168.55 18.33 Favored Pre-proline 0 N--CA 1.451 -0.381 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.668 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -57.94 138.56 86.63 Favored 'Trans proline' 0 N--CA 1.496 1.643 0 C-N-CA 122.115 1.877 . . . . 0.0 111.8 179.665 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.529 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.87 1.31 90.21 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 179.195 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 20.0 m-85 -123.75 165.54 17.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.272 0.558 . . . . 0.0 110.568 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.29 138.2 26.23 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.076 179.325 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.44 ' N ' ' SG ' ' A' ' 3' ' ' CYS . 18.8 t80 -50.81 137.31 20.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.509 -179.339 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.415 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -118.77 88.3 34.99 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.311 -179.134 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_exo -66.2 0.27 3.46 Favored 'Trans proline' 0 N--CA 1.495 1.562 0 C-N-CA 122.771 2.314 . . . . 0.0 112.305 -179.626 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.8 t -103.08 -19.84 5.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.917 0.389 . . . . 0.0 110.441 -179.478 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.816 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.24 -41.23 4.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.136 179.464 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.04 -3.0 11.62 Favored Glycine 0 CA--C 1.533 1.188 0 CA-C-N 116.208 -0.451 . . . . 0.0 112.228 178.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.415 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.4 pt -147.61 -171.95 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 117.469 0.634 . . . . 0.0 110.262 179.7 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 24.0 m -90.85 142.41 27.79 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.259 0.552 . . . . 0.0 109.845 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.7 p -128.68 154.35 46.38 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.692 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.443 ' O ' HG23 ' A' ' 18' ' ' ILE . 10.4 tt -57.31 131.11 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.805 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.529 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -88.27 154.45 20.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.85 -179.938 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -62.4 -17.7 59.8 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.407 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.536 ' O ' ' ND2' ' A' ' 28' ' ' ASN . 73.6 m -62.41 -25.38 67.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.401 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.559 ' C ' HD21 ' A' ' 28' ' ' ASN . 4.0 tmt_? -60.65 -39.25 87.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.537 179.84 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.65 HG22 ' HG2' ' A' ' 24' ' ' GLU . 34.1 mm -52.5 -87.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.991 -179.039 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.65 ' HG2' HG22 ' A' ' 23' ' ' ILE . 77.9 mm-40 -129.13 -118.83 0.24 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.507 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.442 ' CD2' ' C ' ' A' ' 24' ' ' GLU . 12.4 m-70 68.99 153.2 0.14 Allowed Pre-proline 0 CA--C 1.536 0.418 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.995 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -44.22 -35.8 8.36 Favored 'Trans proline' 0 N--CA 1.5 1.903 0 C-N-CA 122.574 2.183 . . . . 0.0 112.777 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.438 ' O ' ' OD1' ' A' ' 30' ' ' ASP . . . -56.46 -34.48 63.77 Favored Glycine 0 CA--C 1.529 0.965 0 N-CA-C 111.074 -0.811 . . . . 0.0 111.074 -179.576 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.587 HD22 ' CA ' ' A' ' 24' ' ' GLU . 98.7 m-20 -87.21 -34.2 19.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.074 0.464 . . . . 0.0 110.791 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 67.5 m-85 -73.83 -9.46 58.67 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.586 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' A' ' 27' ' ' GLY . 50.9 p-10 -77.8 -0.52 27.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.211 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 1.5 p90 . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 117.917 -1.04 . . . . 0.0 110.539 179.85 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.52 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.16 0 CA-C-O 118.235 -0.888 . . . . 0.0 111.203 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.1 t90 -68.88 131.05 44.49 Favored 'General case' 0 C--N 1.33 -0.28 0 O-C-N 124.25 0.969 . . . . 0.0 110.435 179.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.414 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 75.4 m -120.34 153.08 36.96 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.363 -179.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -87.55 170.67 11.3 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.487 -179.681 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_exo -59.18 139.25 89.45 Favored 'Trans proline' 0 C--N 1.311 -1.406 0 C-N-CA 121.946 1.764 . . . . 0.0 111.855 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.516 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.43 -0.05 88.39 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 179.098 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -122.3 164.88 17.13 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.008 0.432 . . . . 0.0 110.448 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.54 139.5 28.23 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.648 179.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.52 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 20.3 t80 -52.24 137.99 27.29 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.973 0.416 . . . . 0.0 110.575 -179.422 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.412 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -119.16 87.91 35.91 Favored Pre-proline 0 CA--C 1.54 0.578 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.357 -179.035 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -66.28 0.71 3.06 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.892 2.395 . . . . 0.0 112.105 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.1 t -103.36 -19.27 6.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.069 0.462 . . . . 0.0 110.35 -179.263 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.811 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -110.52 -41.35 4.36 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.949 179.647 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.04 -3.38 11.56 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 121.302 -0.475 . . . . 0.0 112.45 179.01 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.412 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.1 pt -146.02 -170.9 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-N 117.14 0.47 . . . . 0.0 110.617 179.597 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 28.0 m -92.14 142.09 27.88 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 120.959 0.409 . . . . 0.0 110.078 179.755 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.1 p -128.33 154.41 45.98 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.109 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.641 HD11 ' HG2' ' A' ' 22' ' ' ARG . 15.7 tt -57.34 133.06 22.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.668 -179.596 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.516 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -92.84 163.93 13.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.727 -179.455 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.0 mt -64.46 -26.05 68.27 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.843 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.596 ' O ' ' NE2' ' A' ' 25' ' ' HIS . 73.6 m -56.38 -35.71 68.02 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.394 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.641 ' HG2' HD11 ' A' ' 18' ' ' ILE . 6.3 tpm_? -36.94 -30.24 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.603 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.494 ' N ' ' O ' ' A' ' 21' ' ' SER . 33.8 mt -131.15 67.09 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.814 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -146.12 27.77 1.15 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.784 179.807 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.596 ' NE2' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -155.25 58.46 1.93 Allowed Pre-proline 0 C--N 1.324 -0.51 0 CA-C-O 121.229 0.538 . . . . 0.0 110.528 -179.369 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.62 -25.31 47.26 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.449 2.1 . . . . 0.0 111.987 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.91 -22.11 61.97 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -60.12 -40.99 91.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.659 0.266 . . . . 0.0 110.547 179.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.405 ' HD2' ' H ' ' A' ' 30' ' ' ASP . 0.5 OUTLIER -118.5 -107.98 0.37 Allowed 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.439 179.734 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.405 ' H ' ' HD2' ' A' ' 29' ' ' TYR . 68.0 t0 -143.66 107.26 4.61 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.496 ' CD2' ' OXT' ' A' ' 31' ' ' TYR . 74.2 t80 . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.47 -179.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.514 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.157 0 CA-C-O 118.31 -0.853 . . . . 0.0 111.046 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 87.3 t90 -63.68 132.75 52.04 Favored 'General case' 0 C--N 1.33 -0.282 0 O-C-N 124.24 0.962 . . . . 0.0 110.451 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.6 m -120.31 152.25 38.08 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.817 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -88.27 168.33 16.73 Favored Pre-proline 0 N--CA 1.45 -0.455 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.733 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -58.15 138.79 87.78 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 C-N-CA 122.526 2.151 . . . . 0.0 111.755 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.466 ' O ' HG22 ' A' ' 19' ' ' THR . . . 82.38 0.27 89.68 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.7 m-85 -123.27 164.43 18.79 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 121.168 0.508 . . . . 0.0 110.745 179.744 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -142.93 135.43 27.57 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.249 179.394 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.514 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 9.0 t80 -48.34 135.47 13.69 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.848 -179.634 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.483 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -119.13 94.81 48.76 Favored Pre-proline 0 CA--C 1.545 0.753 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.054 -179.597 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -74.22 -0.12 9.2 Favored 'Trans proline' 0 N--CA 1.493 1.452 0 C-N-CA 122.715 2.277 . . . . 0.0 112.503 -179.554 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 t -101.58 -18.62 6.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.885 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.818 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.34 -43.35 4.14 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.006 179.421 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.78 0.21 9.96 Favored Glycine 0 CA--C 1.535 1.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 112.56 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.483 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.7 pt -152.38 -170.48 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.281 0 CA-C-N 117.215 0.507 . . . . 0.0 110.258 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 18.7 m -91.13 141.93 28.28 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 120.999 0.428 . . . . 0.0 110.13 179.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.7 p -127.36 153.78 45.79 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.529 -0.76 . . . . 0.0 110.858 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.411 HG23 ' O ' ' A' ' 18' ' ' ILE . 10.5 tt -57.23 131.81 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.422 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.466 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -90.39 160.99 15.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.722 -179.903 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.514 HD22 ' N ' ' A' ' 20' ' ' LEU . 4.2 mm? -67.26 -19.71 65.55 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.702 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.497 ' O ' ' ND2' ' A' ' 28' ' ' ASN . 99.0 p -62.62 -21.52 65.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.424 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 4.1 tmt_? -59.23 -36.45 75.47 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.368 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.659 HG22 ' N ' ' A' ' 24' ' ' GLU . 78.1 mt -61.77 -111.78 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.019 -179.327 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.659 ' N ' HG22 ' A' ' 23' ' ' ILE . 98.7 mt-10 -120.79 108.31 13.8 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.971 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.568 ' CG ' ' O ' ' A' ' 24' ' ' GLU . 63.1 m-70 -158.77 145.66 12.92 Favored Pre-proline 0 C--O 1.245 0.848 0 CA-C-O 120.915 0.388 . . . . 0.0 110.324 -179.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -68.37 -33.26 23.94 Favored 'Trans proline' 0 N--CA 1.492 1.386 0 C-N-CA 122.638 2.225 . . . . 0.0 112.379 179.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.53 -14.35 77.52 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.497 ' ND2' ' O ' ' A' ' 21' ' ' SER . 64.2 t30 -87.37 -48.37 8.03 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.751 0.31 . . . . 0.0 110.863 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -160.57 -33.14 0.05 Allowed 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.714 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 16.2 t0 63.38 72.37 0.48 Allowed 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.029 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.466 ' CD2' ' OXT' ' A' ' 31' ' ' TYR . 89.6 t80 . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.436 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.511 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.171 0 CA-C-O 118.216 -0.897 . . . . 0.0 110.98 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 -68.35 131.21 44.93 Favored 'General case' 0 C--N 1.328 -0.367 0 O-C-N 124.237 0.961 . . . . 0.0 110.515 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.441 ' SG ' ' N ' ' A' ' 9' ' ' TYR . 72.3 m -119.94 151.98 38.12 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.586 -179.855 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -86.43 168.81 17.14 Favored Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.845 179.302 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -58.45 138.92 88.43 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 122.624 2.216 . . . . 0.0 111.833 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.537 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.48 -0.24 88.18 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 179.602 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -122.33 166.33 14.86 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.043 0.449 . . . . 0.0 110.503 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -145.88 137.5 25.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.0 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.511 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 16.1 t80 -50.36 136.79 19.73 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.64 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.419 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.3 t30 -119.16 89.27 39.15 Favored Pre-proline 0 CA--C 1.543 0.699 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.524 -179.655 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -66.66 -0.14 4.19 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 122.964 2.443 . . . . 0.0 112.135 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.8 t -103.95 -18.89 6.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.9 0.381 . . . . 0.0 110.383 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.775 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.08 -42.12 4.51 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.629 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.25 -2.35 11.47 Favored Glycine 0 CA--C 1.536 1.367 0 CA-C-N 116.214 -0.448 . . . . 0.0 112.914 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.419 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.7 pt -149.33 -171.5 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 122.641 -0.329 . . . . 0.0 110.543 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.2 m -91.62 142.84 27.19 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-O 121.091 0.472 . . . . 0.0 110.297 179.782 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 66.4 p -129.1 154.84 46.3 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.444 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.591 HD11 ' HG2' ' A' ' 22' ' ' ARG . 14.3 tt -57.08 131.1 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.586 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.537 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -87.47 159.74 18.54 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.793 -179.994 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.4 mt -63.11 -27.14 69.18 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-O 121.111 0.482 . . . . 0.0 110.998 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 40.5 t -57.38 -36.96 71.92 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.261 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.591 ' HG2' HD11 ' A' ' 18' ' ' ILE . 11.7 tpt180 -43.19 -31.6 0.62 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.407 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.622 HG22 ' N ' ' A' ' 24' ' ' GLU . 96.7 mt -89.56 -98.21 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.742 179.786 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.622 ' N ' HG22 ' A' ' 23' ' ' ILE . 94.2 mt-10 -151.47 70.78 0.97 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.146 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -143.03 69.34 18.3 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.779 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.411 ' O ' ' N ' ' A' ' 30' ' ' ASP . 22.9 Cg_exo -63.28 -28.54 72.48 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 123.054 2.503 . . . . 0.0 112.129 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.88 -27.49 68.65 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -60.5 -39.43 87.7 Favored 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 121.049 -0.261 . . . . 0.0 110.988 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 79.1 m-85 -115.52 4.72 14.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.653 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.411 ' N ' ' O ' ' A' ' 26' ' ' PRO . 65.7 m-20 49.4 40.19 18.13 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.374 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 57.8 t80 . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.627 -179.888 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.391 -5.151 0 CA-C-O 118.267 -0.873 . . . . 0.0 111.223 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.0 t90 -62.18 132.36 52.5 Favored 'General case' 0 C--N 1.329 -0.326 0 O-C-N 124.311 1.007 . . . . 0.0 110.445 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.9 m -123.04 155.16 37.42 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.292 0.568 . . . . 0.0 111.107 -179.694 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.69 166.59 18.77 Favored Pre-proline 0 N--CA 1.449 -0.516 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.797 179.208 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -57.79 139.16 89.38 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 122.494 2.129 . . . . 0.0 111.911 179.573 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.548 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.78 1.67 90.29 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.748 -0.541 . . . . 0.0 111.748 179.481 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 18.9 m-85 -123.61 165.63 16.85 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.062 0.458 . . . . 0.0 110.415 179.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -141.68 134.59 28.84 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.225 179.614 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.498 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 7.9 t80 -49.1 135.31 16.5 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.639 -179.764 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.498 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -118.93 94.64 48.38 Favored Pre-proline 0 CA--C 1.546 0.794 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.807 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -74.25 -0.33 9.49 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.851 2.367 . . . . 0.0 112.249 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.7 t -101.99 -18.14 6.61 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.965 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.799 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.61 -43.65 4.02 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.376 179.455 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.69 1.12 9.94 Favored Glycine 0 CA--C 1.535 1.322 0 CA-C-N 116.049 -0.523 . . . . 0.0 112.908 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.476 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.3 pt -153.07 -170.85 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.163 0 CA-C-N 117.055 0.427 . . . . 0.0 110.354 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 16.7 m -91.86 141.34 28.77 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-O 120.945 0.402 . . . . 0.0 110.24 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.0 p -127.99 153.0 47.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.615 -179.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.8 tt -53.66 141.03 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.799 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.346 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.548 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -97.16 163.22 13.01 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.847 -179.78 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -59.2 -19.03 41.85 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.52 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.416 ' O ' ' O ' ' A' ' 24' ' ' GLU . 75.1 m -60.33 -44.26 95.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.434 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 37.7 mtp180 -75.98 -30.91 58.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.623 179.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.549 HG22 ' HG3' ' A' ' 24' ' ' GLU . 47.5 mm -59.61 -46.94 92.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.539 -179.438 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.56 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 98.2 mt-10 -143.58 173.19 11.86 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.9 180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.56 ' CD2' ' O ' ' A' ' 24' ' ' GLU . 1.9 p-80 35.49 57.08 2.63 Favored Pre-proline 0 CA--C 1.531 0.248 0 CA-C-O 120.992 0.425 . . . . 0.0 110.489 179.798 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -59.92 -28.09 86.37 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 C-N-CA 122.668 2.245 . . . . 0.0 111.885 -178.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -62.28 -39.22 97.43 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 179.67 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 67.0 m-80 51.65 39.81 25.93 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.784 0.326 . . . . 0.0 110.691 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 55.64 24.95 7.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.594 179.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.524 ' O ' ' CD2' ' A' ' 31' ' ' TYR . 67.2 m-20 48.11 37.33 7.8 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.724 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.524 ' CD2' ' O ' ' A' ' 30' ' ' ASP . 9.9 m-85 . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.545 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.491 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . . . . . . . . 1 CA--C 1.391 -5.15 0 CA-C-O 118.248 -0.882 . . . . 0.0 111.02 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 88.4 t90 -65.86 132.87 49.7 Favored 'General case' 0 C--N 1.329 -0.318 0 O-C-N 124.275 0.984 . . . . 0.0 110.394 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.8 m -118.08 152.26 35.92 Favored 'General case' 0 CA--C 1.52 -0.202 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.568 -179.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -89.53 169.27 13.07 Favored Pre-proline 0 N--CA 1.451 -0.404 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 -179.436 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -57.79 139.23 89.6 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 121.939 1.759 . . . . 0.0 111.779 179.53 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.513 ' O ' HG22 ' A' ' 19' ' ' THR . . . 81.88 1.18 90.18 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.416 -0.674 . . . . 0.0 111.416 179.267 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.8 m-85 -124.23 164.28 19.85 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.273 0.559 . . . . 0.0 110.525 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.68 137.37 26.55 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.164 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.491 ' CD2' ' HG2' ' A' ' 1' ' ' PCA . 18.8 t80 -50.8 137.86 19.66 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 120.478 -0.489 . . . . 0.0 110.681 -179.321 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.405 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.4 t30 -119.37 88.39 37.98 Favored Pre-proline 0 CA--C 1.538 0.511 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.504 -179.209 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -66.62 0.52 3.45 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.705 2.27 . . . . 0.0 112.189 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.0 t -103.3 -19.24 6.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.952 0.406 . . . . 0.0 110.282 -179.294 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.801 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -109.56 -41.66 4.52 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.143 179.491 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 120.49 -2.38 12.44 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-N 116.068 -0.515 . . . . 0.0 112.312 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.405 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.5 pt -147.87 -172.45 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 117.707 0.753 . . . . 0.0 110.25 179.58 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.5 m -90.63 142.48 27.71 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.254 0.549 . . . . 0.0 109.592 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.7 p -128.96 154.1 46.91 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.641 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.418 ' O ' HG23 ' A' ' 18' ' ' ILE . 8.9 tt -57.22 131.82 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-O 120.991 0.424 . . . . 0.0 110.547 -179.489 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.513 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -89.55 160.98 16.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.78 -179.613 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 8.8 mp -62.45 -23.97 67.18 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.892 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 43.5 t -53.07 -37.17 61.43 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.575 -179.419 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.409 ' O ' ' O ' ' A' ' 23' ' ' ILE . 0.0 OUTLIER -56.07 -39.99 72.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.257 -179.831 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.409 ' O ' ' O ' ' A' ' 22' ' ' ARG . 50.2 mm -45.67 -94.46 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.617 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -145.71 38.87 1.13 Allowed 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.551 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 90.7 m-70 -133.57 59.99 44.01 Favored Pre-proline 0 N--CA 1.461 0.121 0 C-N-CA 120.486 -0.486 . . . . 0.0 110.713 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -75.29 -18.37 18.18 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.745 2.296 . . . . 0.0 112.541 179.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -58.41 -38.53 90.98 Favored Glycine 0 CA--C 1.52 0.395 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.176 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -60.41 -36.93 79.3 Favored 'General case' 0 C--N 1.321 -0.666 0 C-N-CA 121.158 -0.217 . . . . 0.0 110.631 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -113.82 31.4 6.55 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.269 -179.016 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 59.0 p30 -92.88 7.5 43.61 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.936 -0.305 . . . . 0.0 110.575 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.476 ' CD2' ' OXT' ' A' ' 31' ' ' TYR . 55.6 t80 . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.676 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 1 CA--C 1.393 -5.094 0 CA-C-O 118.161 -0.923 . . . . 0.0 111.026 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.2 t90 -65.89 129.98 41.68 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 124.29 0.994 . . . . 0.0 110.453 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 97.5 m -123.56 149.39 45.34 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-O 121.403 0.62 . . . . 0.0 111.109 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.78 160.73 81.33 Favored Pre-proline 0 N--CA 1.442 -0.846 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.252 179.306 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -64.46 138.51 60.33 Favored 'Trans proline' 0 C--N 1.302 -1.883 0 C-N-CA 122.429 2.086 . . . . 0.0 111.929 -179.665 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.587 ' O ' HG22 ' A' ' 19' ' ' THR . . . 89.61 -7.89 80.95 Favored Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 -179.64 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 15.6 m-85 -115.19 167.91 10.41 Favored 'General case' 0 CA--C 1.522 -0.129 0 CA-C-O 121.131 0.491 . . . . 0.0 110.5 179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -139.04 134.08 32.52 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.171 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.456 ' CD1' ' N ' ' A' ' 10' ' ' ASN . 9.3 t80 -50.87 135.39 24.31 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.692 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.456 ' N ' ' CD1' ' A' ' 9' ' ' TYR . 1.9 t30 -119.12 95.52 49.4 Favored Pre-proline 0 CA--C 1.545 0.777 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.927 -179.573 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -75.04 0.71 8.6 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.857 2.371 . . . . 0.0 112.35 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 36.3 t -103.0 -17.82 6.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.995 -179.762 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.788 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -110.32 -43.18 3.96 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.598 179.411 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 121.05 2.29 11.16 Favored Glycine 0 CA--C 1.535 1.333 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.882 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.446 ' O ' ' CB ' ' A' ' 10' ' ' ASN . 5.2 pt -153.65 -174.21 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.232 0 CA-C-N 117.314 0.557 . . . . 0.0 110.121 179.67 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 3.9 m -88.29 139.99 29.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.04 0.447 . . . . 0.0 110.535 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.8 p -126.21 152.95 45.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.521 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.5 tt -58.0 133.59 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.433 -179.73 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.587 HG22 ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -85.19 152.24 23.5 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.788 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 8.0 mp -57.43 -27.55 62.51 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.601 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.502 ' OG ' ' CE2' ' A' ' 29' ' ' TYR . 70.5 m -58.49 -44.09 89.25 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.189 -179.385 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 73.3 ttt180 -70.59 -35.85 73.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.057 0.455 . . . . 0.0 110.149 179.168 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.57 HG22 ' HG3' ' A' ' 24' ' ' GLU . 40.0 mm -59.66 -49.55 83.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.053 -178.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.57 ' HG3' HG22 ' A' ' 23' ' ' ILE . 35.9 mt-10 -157.22 -167.64 2.38 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.701 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.504 ' N ' ' HD3' ' A' ' 26' ' ' PRO . 1.6 m-70 58.87 55.65 5.52 Favored Pre-proline 0 CA--C 1.542 0.659 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.831 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.547 ' O ' ' N ' ' A' ' 30' ' ' ASP . 31.3 Cg_exo -58.94 -40.15 74.36 Favored 'Trans proline' 0 N--CA 1.497 1.698 0 C-N-CA 122.272 1.981 . . . . 0.0 112.166 -179.551 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.33 -39.66 91.83 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 111.774 -0.53 . . . . 0.0 111.774 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -61.05 -40.06 92.22 Favored 'General case' 0 CA--C 1.52 -0.195 0 C-N-CA 121.007 -0.277 . . . . 0.0 111.009 -179.264 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.502 ' CE2' ' OG ' ' A' ' 21' ' ' SER . 82.7 m-85 -112.55 11.33 19.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.829 -179.864 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.547 ' N ' ' O ' ' A' ' 26' ' ' PRO . 54.2 t0 49.37 44.51 23.73 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.552 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.527 ' CD2' ' O ' ' A' ' 31' ' ' TYR . 90.7 t80 . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.577 -179.904 . . . . . . . . 1 1 . 1 stop_ save_